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ABSTRACT
My research focus was to investigate alligator blood using mass spectrometry-based
proteomics methods to understand their innate immune systems. The first goal was to sequence
peptides and proteins from the blood serum and leukocytes using tandem mass spectrometry and
de novo sequencing. The second goal was to determine the function of these biological
molecules and their relationship to the immune system.
One- and two-dimensional gel electrophoresis was used to separate proteins from
alligator leukocytes, which were enzymatically digested. The peptides were measured using
reversed phase nano-high performance liquid chromatography coupled with tandem mass
spectrometry (nano-HPLC-MS/MS) followed with de novo sequencing. The results, as described
in Chapter 3 show that alligator leukocytes contain proteins that are similar to proteins found in
other vertebrates such as mammals and reptiles that are related to immune responses. Isolation of
small molecule interferences and peptides exhibiting antimicrobial activity from alligator
leukocyte extracts are described in Chapters 4 and 5. Reversed-phase HPLC was used to separate
the leukocyte mixture and antimicrobial activity tests were used to determine the active fractions.
Interferants, EDTA and spermine were present and showed activity in early fractions. Two major
peptides measured at 4.7 and 4.9 kDa in an active fraction were further separated on the basis of
their charge, size and shape using ion mobility-mass spectrometry (IM-MS). Due to the limited
fragmentation of the peptides using IM-MS, the peptides were isolated and fragmented using
MALDI TOF/TOF MS for de novo sequencing.
Lectins are a class of carbohydrate selective proteins that are part of the complement
immune system. Chapter 6 presents results for a lectin isolated from alligators that have mannan
and mannose binding activity. In this study, the monomeric lectin was isolated and enzymatically
digested using five different proteases to create small and large peptides which were analyzed by
xvi

LC-MS/MS. The peptides were determined via de novo sequencing and overlapped to generate
the lectin sequence. Lectins may have varying degrees of glycosylation, therefore
deglycosylation procedures suitable for mass spectrometry analysis are described in Chapter 7.
Conclusions and future directions for the work in this dissertation will be summarized in Chapter
8.
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CHAPTER 1. INTRODUCTION
Alligators exhibit strong immune responses when exposed to microorganisms, and are
highly resistant to microbial infections.1-3 Therefore, characterization of biological components
that make up the immune system of alligators is of interest because these compounds may have
therapeutic applications. Antibiotic resistance has become a global public health issue and is
increasing at a rate that exceeds the pace of the development of new drugs. Hence, isolation of
antimicrobial peptides from alligators may lead to a new class of antibiotics.
Another class of molecules that are part of the immune system is the set of proteins
known as lectins, which show promise for their application in cancer therapy, pharmacology and
immunology.5 The study of lectins isolated from Alligator mississippiensis, can provide insight
on its structure-function relationship within the crocodile’s immune system.
The goal of this research was to use mass spectrometry-based proteomics to isolate and
characterize biological molecules in alligator blood and identify specific components that may
have medicinal use.
1.1 Biochemistry of the Immune System
The vertebrate immune system is composed of a network of circulating cells and
molecules7 that recognize and respond to the invasion of foreign pathogens such as viruses,
bacteria, fungi and protists.8 These molecules include antimicrobial molecules such as lysozymes
and defensins, molecules involved in specific recognition of foreign antigens such as
immunoglobulins and T-cell receptors, molecules that carry intracellular signals such as
cytokines, and molecules that receive and transduce these signals such as cytokine receptors.8
Vertebrates have both innate and adaptive immune systems that work together.7 The innate
immune system responds rapidly and is the first line of defense against pathogens and does not
1

require previous exposure to exhibit a full immunological response.7 In contrast to the innate
immune system, the adaptive immune system requires previous exposure to an antigen to exhibit
a full immunological response and can take several days to weeks to become completely active.7
Most studies on vertebrate immune systems have been performed on mammals8 and the
evolutionary development of the immune systems of major group of vertebrates, including
mammals, birds, amphibians and fish is well known compared to other groups of organisms.8 In
contrast, little is known about the reptilian immune systems.8 A better understanding of reptilian
immunology will provide important information on the evolution of both innate and adaptive
immune mechanisms. Crocodilians are of interest because they are the only living reptilian
archosaurs, which include the dinosaurs, pterosaurs, and crocodilians.9
Crocodilians are vertebrates with a complex immune system. The components that make
up the reptilian immune system are antimicrobial peptides, macrophages, heterophils,
neutrophils, basophils, eosinophils, phagocytic B cells, and proteins of the complement system.
Like other vertebrates, crocodilians also have an innate and adaptive immune system.7,

10

Crocodilians thrive in microbe containing environments but exhibit a strong resistance to
infections.
Alligator serum has been shown to have antibacterial,3 antiviral,2 and antiamoebacidal
properties.11 Antibacterial activity has also been observed in crocodile serum, particularly
Crocodylus siamensis.12, 13 In addition, the leukocytes of Alligator mississippiensis have also
shown to produce a broad antimicrobial spectrum.1 The alligator complement system, which is
part of the innate immune system, has also been shown to be effective against gram-positive
bacteria.3,

14

When alligator serum was compared to human serum, the alligator serum was

effective against different strains of Gram-positive bacteria, unlike human serum which had no
antibacterial activity. It was proposed that the complement is also responsible for antiviral
2

activity from the alligator serum. Human T-cells were infected with human immunodeficiency
virus type 1 (HIV-1) and when incubated with alligator serum potent antiviral activity was
observed.2 These studies suggest that crocodilians have a strong innate immune system.
1.1.1 Innate Immune System
The innate immune system comprises different molecules and cells including lysozymes,
proteins of the complement system, non-specific leukocytes, and antimicrobial peptides.7
Lysozymes are enzymes that cause bacteria cells to be lysed by the hydrolysis of their cell wall.15
Lysozymes have been isolated from several reptilian organisms such as, lizards,16 turtles,16
crocodiles,17 and alligators6. The complement system consists of various proteins found in
plasma that kill bacteria via lysis or opsonization.7 Lysis entails the complement proteins
rupturing the bacterial membrane therefore killing the invading bacteria.18 Opsonization is the
process by which opsonin proteins found in blood serum, bind to the bacterial membrane
allowing the bacteria to be recognized by macrophages. The macrophages then engulf the
bacteria through phagocytosis.7
There are three different pathways to the complement immune system: classical,
alternative, and lectin.19 The classical pathway is activated by the immunoglobulins,
immunoglobulin G (IgG) and immunoglobulin M (IgM) to activate an immune response.7, 19 The
alternative pathway does not require antibodies but is activated by molecules such as viruses or
lipopolysaccharide (LPS) that are found on the surface of bacteria.18 Finally, the lectin pathway
is activated by mannose sugars of proteins that are on the surface of bacteria.19 The complement
immune system has been characterized in the American alligator14 and is believed to be
responsible for antiviral activity exhibited by alligator serum.2
There are non-specific leukocytes in reptiles including eosinophils, herterophils,
basophils, monocytes, and macrophages.7 Limited information is known about the function of
3

eosinophils in reptiles; however, in mammals they play a key role in the defense against parasitic
infections.19 Heterophils are involved in the inflammatory response in reptiles and are also
responsible for suppressing microbial invasion.20 Basophils contain immunoglobulins on their
surface and when triggered by an antigen releases histamine.21 Monocytes and macrophages are
phagocytic cells that are responsible for processing and releasing antigens as well as releasing
cytokines.19 Cytokines are regulatory proteins that are released by the cells of the immune
system to generate an immune response.22
An important component of the innate immune system is antimicrobial peptides and
proteins. Antimicrobial peptides are found in the host defense system and exhibit antimicrobial
activity.23 Antimicrobial molecules are typically amphipathic and cationic small peptides less
than10 kDa in mass.24 However, they can also be anionic peptides25 or proteins.26 Antimicrobial
peptides can be linear and α-helical or cysteine containing and β-sheet. The linear peptides
typically consist of 12–25 residues and no cysteines.24 The β-sheet peptides have several
antiparallel β-strands and are stabilized with up to six disulfide bonds.24 There are also
antimicrobial peptides that are rich in specific residues, such as tryptophan,27 proline, and/or
arginine28, 29 and histidine.30
There are two major antimicrobial peptide families found in vertebrates: defensins and
cathelicidins. Defensins are antimicrobial peptides that are rich in arginine residues and have a
characteristic β-sheet fold and six disulfide linked cysteines.23 They are cationic peptides that
bind to microbes via electrostatic interactions.31 Defensins have been found in mammals and
birds32 and recently the first reptilian defensin was discovered in the European pond turtle Emys
orbicularis.33 Defensins are 38-42 residues and found in cells and tissues involved in the host
defense system. In many animals the highest concentration of defensins are found in the
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granules, where the leukocytes are stored.23 Defensins exhibit antibacterial, antifungal, and
antiviral activity.23
Another family of antimicrobial peptides is the cathelicidins. Cathelicidins are linear
molecules that range in size from 12 to 80 amino acids and, unlike the β-defensins, they lack
disulfide bridges.34 Cathelicidins have antifungal35 and antibacterial activity.36 They have been
isolated from fish,37 birds,38 mammals,39 and reptiles.40 Cathelicidins are produced in the myeloid
cells in the bone marrow and stored in the neutrophil granules.41 Cathelicidins have also been
found in monocytes, epithelial cells of the skin, respiratory tract, urogenital tract, as well as T
and B lymphocytes.41
The membranes of microbes and multicellular animals differ in that microbes,
particularly bacteria, have an outer membrane surface that is composed of lipids with negatively
charged phospholipid head groups. The outer membranes of plants and animals are composed of
lipids that do not have a net negative charge (Figure 1-1); the negatively charged head groups are
positioned towards the cytoplasm.42, 43
The primary model that explains the mechanism of antimicrobial peptides is the ShaiMatsuzaki-Huang model.43,

44

The Shai-Matsuzaki-Huang Model postulates that the peptide

interacts with the pathogen membrane, displacing the lipids and disrupting the membrane
structure. In some cases the peptide may also penetrate the cell.44 The membrane of multicellular
animal cells contains cholesterol, which reduces the activity of the antimicrobial peptide via
peptide interaction with the cholesterol or stabilization of the lipid bilayer. In addition to this
proposed mechanism, studies suggest that there are other mechanisms involved. These
mechanisms include 1) depolarization of the bacterial membrane leading to death,45 2) creation
of holes in the cell causing cellular leakage,46 3) activation of processes that cause cell death (e.g.
hydrolases which destroys the cell wall),47 4) disruption of the membrane function by
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rearrangeement of the lipids on the outer cell
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Figure 1-1. Comparison of antimicrobia
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al peptide iinteraction with animaal and baccterial
membran
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Some antimicrobial pepttides have been
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tested for pharmaaceutical usee, primarily as a
topical trreatment. The first antimicrobial peptide
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peptide isolated from
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nin peptide w
was developped as a topical treatmennt and
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peeptide to bee equally ass effective w
when comppared to thee oral
antibioticc ofloxacin.51 A variety
y of antimiicrobial pepttides are cuurrently beinng developeed as
potential antibiotics as
a indicated in Table 1-1
1.
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The broad antimicrobial spectrum of the antimicrobial peptides allows them to be used
for diverse applications. However, a major drawback of antimicrobial peptides for clinical use is
the level of toxicity. The level at which the antimicrobial peptides are effective in vivo are
usually toxic.52 Other factors are stability and immunogenicity.49
Table 1-1. Antimicrobial peptides available for therapeutic use.49, 53
Pharmaceutical
Name

Origin

Magainin 2

Pexiganan

African
clawed frog
skin

Indolicidin

Omiganan
(MBI-226)

Indolicidin

MBI-594AN

Peptide

Histatin

Iseganan
(IB-367)
P113P113D

Heliomycin

Heliomycin

Lactoferricin
Bactericidal
permeability
increasing
protein
histatin

Lactoferricin

Synthetic
analog of
indolicidin
Cow
erythrocytes
Pig
leukocytes
Human
Tobacco
budworm
Human

XMP.629

Human

Protegrin

Mode of
Application

Application

Stage
Completed
Phase III.

Topical

Foot ulcers

Topical

Catheter
infection

Phase III

Topical

Acne

Phase III

Oral

Mucositis

Phase III

Oral

Gingivitis

Phase II

Systemic

Antifungal

Preclinical

Systemic

Antibacterial

Preclinical

Systemic

Meningococcal
meningitis

Phase III

(Not
approved by
FDA)

Another group of molecules that play an important role in vertebrate innate immune
systems is lectins. Lectins have been studied for more than 100 years in plants and have recently
been recognized for their importance in animals.54 Lectins are proteins that can recognize
carbohydrates that are endogenous to the animal or those on microbes.55 They have been
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classified based on their carbohydrate ligands, biological processes, subcellular location, and
dependence on divalent cations.55 They have a wide range of structures, but carbohydratebinding activity is limited to a particular region of the protein known as the carbohydraterecognition domain (CRD).56
Animal lectins are grouped into two structural families: C-type and S-type.56 C-type
lectins are found in serum, extracellular matrix, and plasma membranes. They require calcium
for binding and bind to a variety of sugars. S-type lectins are found intracellularly and require
sulfydryl for binding to β-galactosides.57
Animal lectins possess a wide variety of functions such as cellular growth regulation,
mediation of endocytosis, intracellular routing of glycoconjugates, and urate transport.58
However, the major function of lectins is to behave as recognition molecules within the immune
system.58 These roles within the immune system include: direct defense, cell recognition and
trafficking, immune regulation, and prevention of autoimmunity.58 Different applications of
lectins have been demonstrated such as immobilization onto columns for affinity separation of
glycoproteins, glycopeptides and oligosaccharides,59 selective agglutination,60 and blood
typing.61 Lectins show promise for their application in agriculture, cancer therapy,
pharmacology, and immunology.5
1.1.2 Adaptive Immune System
The adaptive immune system becomes activated following the innate immune response.
There are two adaptive immunity responses: cell-mediated and humoral adaptive immunity.7
Cell-mediated immunity involves T-cells that are responsible for regulating antibody production.
T-cells can differentiate into two types of cells: cytotoxic T-cell (TC) or T helper cell (TH). TC
can rapidly kill bacterial or viral infected cells through apotosis. TC regulates other immune
cells. TH helps control other immune cells. T-cells also release cytokines that affect the humoral
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response (the immune responses mediated by antibodies).7 Humoral adaptive immunity relies on
B-cells that recognize antigens even before being processed.19
1.1.3 Study of the Immune System
To study the immune system of vertebrates, serological assays are typically used, in
which in vitro reactions between antigen and serum antibodies are studied.62 There are many
different types of serological assays including agglutination, precipitation, immunoassays,
immunofluorescence, fluorescence-activated cell sorting analysis, and lymphocyte function.62
These assays help elucidate the immune system’s functional and regulatory properties through
lymphocyte function measurements and the responses of B- and T-cells as well as antibodies.
Another approach to studying the immune system is hematology, which is the study of
blood, including white blood cells, red blood cells, hemoglobin, and platelets.62 Hematological
tests allow for observation of live blood (whole blood that is unaltered and unstained) with
microscopy. Using this test, microbial activity in the blood and its potential effects can be
measured. In addition, the white blood cells can be quantified, which can provide insight on how
the immune system is functioning. There is also the standard blood microscopy technique in
which the blood is stained and fixed; however, staining kills the blood cells.
Another technique for studying the immune system is genomics and proteomics, which is
discussed in Section 1.2. Genomics and proteomics provide a more comprehensive view of the
immune system and its function as compared to serological assays and hematology tests.
1.2 Chemical Analysis Methods for Proteomics
Proteomics is the approach used to understand complex biological systems by analyzing
protein expression, function, modifications, and interactions.63 Proteomics is related to genomics,
which is the study of the genetic make-up of an organism.64 An important step towards
understanding an organism’s biology is to determine its genome sequence. However, the genome
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sequence is not enough to provide information on complex cellular processes; the complement of
proteins associated with a particular genome is essential to this understanding.65
Proteomics is complimentary to genomics and provides an additional component to the
understanding of biological systems. However, there are significant challenges in proteomics
such as limited sample quantity, sample degradation, broad dynamic range (>106 fold for protein
abundance), post-translational modifications, and disease changes.66 Protein concentrations
typically exceed the dynamic range of a single analytical instrument or method necessitating the
use of one or more dimensions of separation.63
Proteomics can be divided into three major branches: structural proteomics,67 expression
proteomics,68 and functional proteomics.68 Structural proteomics involves determining the
structures of proteins, such as its three-dimensional shape (secondary and tertiary structure) and
its amino acid sequence (primary structure).67 A commonly used approach for protein
sequencing is Edman degradation. Edman degradation was developed by Pehr Edman in 1950
and is one of the oldest and most developed techniques for protein sequencing.69 However,
Edman sequencing chemistry has largely been replaced by mass spectrometry for protein
sequencing and identification.70, 71 Protein secondary and tertiary structures can be characterized
by X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy.67
Expression proteomics involves the quantitative and qualitative analysis of proteins under
different conditions.68 This approach allows disease-specific proteins to be identified by
comparing the entire proteome between two samples. Proteins that are over-expressed or underexpressed can be identified and characterized. The techniques commonly used for expression
proteomics are two-dimensional gel electrophoresis,72 multi-dimensional chromatography with
mass spectrometry,73 and micro-array techniques.74 Two-dimensional electrophoresis suffers
from limitations such as the large dynamic range of protein expression in biological systems and
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difficulty in analyzing proteins that are post-translationally modified.68 Limitations of microarray
technology include the sensitivity of the arrays for detection of low abundance genes75 as well as
its inability to measure post-translational modifications.76 Unlike 2-D electrophoresis and microarray techniques, multi-dimensional chromatography with mass spectrometry can measure posttranslational modifications in expression proteomics.77
Functional proteomics is an approach to analyze and understand the properties of
macromolecular networks involved in cells.68 Proteins and their specific roles in metabolic
activities can be identified.
1.2.1 Sample Purification
Blood plasma and serum are commonly used biological fluids for proteomic analysis
because many cells release a portion of their content into the plasma when damaged or upon cell
death. There are approximately 10,000 proteins present in human serum78 and many proteins of
interest are present in low abundance. Plasma comprises ~97% high abundance proteins
including albumin (57–71%) and immunoglobulins (8–26%).79 Hence plasma samples are
difficult to analyze directly and purification is required. In addition, proteomic samples usually
contain a large amount of contaminants such as lipids, nucleic acids, and surfactants.80 The
dynamic range of expressed proteins is greater than six orders of magnitude81 and protein
mixtures can be quite complex and contain proteins with different solubility, hydrophobicity and
hydrophilicity, pI, and molecular masses.82 Therefore, sample purification is necessary before
mass spectrometry analysis.
Separation

methods

such

as

affinity-based

techniques,

chromatography

and

centrifugation have been employed.83 It is important that the proteins of interest are well resolved
with limited sample purification steps to avoid sample loss. Affinity-based techniques have been
established for removal of albumin and IgG using immobilized antibodies that are selective
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against albumin84 and protein A or protein G that selectively capture IgG on the columns.85 The
removal of salts and other contaminants from protein samples has been accomplished using
precipitation with centrifugation.80 Commonly used precipitation methods include acetone,
trichloroacetic acid (TCA), ammonium sulfate, and chloroform/methanol precipitation.
1.2.2 Digestion
Protein digestion can be performed using three common approaches: in-gel,86,

87

in-

solution,88 or solid phase.89, 90 In an in-gel digestion, the proteins are separated on a 1- or 2-D gel
and the gel bands are excised for chemical or proteolytic digestion.87 A major advantage of in-gel
digestion is that it removes detergents and salts that can be interfants in the mass spectrometer.87
However, a limitation to this method is the loss of peptides during in-gel digestion through
binding to the polyacrylamide.87 Another approach that has been developed is in-solution
digestion which entails digesting proteins directly in buffers or solvents such as ammonium
bicarbonate or acetonitrile.91 This approach is advantageous in that low abundance molecules
that may otherwise be lost in the gel can be detected. A drawback for this method includes longer
incubation times due to lower enzymatic concentrations.92 Solid phase is another digestion
approach which includes immobilization of an endoprotease on a solid support; examples include
monolithic columns for trypsin digestion93 and microfluidic devises with integrated trypsin
digestion.90 Solid phase digestion offers advantages of increased digestion rates, reduced
interferences from trypsin autolysis products, low sample consumption, and fast response.94, 95 A
limitation to this method is the use of organic solvents which improve digestion efficiency but
can damage the immobilized enzyme.96
Digestion efficiency can be improved by cysteine reduction before digestion. The
disulfide bonds are reduced with a reagent such as dithiothreitol (DTT) and an alkylation reaction
is performed with iodoacetamide to prevent new disulfide bridges from forming.97
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Many of the endoproteases and chemicals cleave proteins at specific amino acids
generating peptide fragments of varying lengths. Peptide fragments between 6–20 amino acids
are best for MS analysis and protein database searching.98 Endoproteases and chemicals used for
protein analysis are indicated in Table 1-2. The most commonly used endoprotease for proteomic
analysis is trypsin. Trypsin cleaves at lysine and arginine residues, unless followed by a proline
residue in the C-terminus direction.99 Trypsin has good activity in both in-gel and in-solution
digests.
Table 1-2. Chemicals and proteases used for enzymatic and chemical cleavage. Cleavage with
the endoproteases only occurs if the residue after the cleavage site is not proline, except for AspN.100
Endoproteases

Cleavage Specificity

Trypsin

K, R

Glu-C

E, D

Lys-C

K

Asp-N

D

Arg-C

R

Chymotrypsin

W, Y, F, L, M

Chemical Agents

Cleavage Specificity

70% Formic acid

D

Cyanogen bromide

M

2-nitro-5-thiocyanobenzoate, pH 9101

C

Hydroxylamine, pH 9102

N, G

Iodobenzoic acid

W

Many proteins contain a significant number of lysine and arginine residues that are
spaced sufficiently in the sequence so that trypsin produces fragments that are a suitable length
for MS analysis. Another complementary enzyme used is Glu-C which cleaves at the carboxyl
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side of glutamate residues.103, 104 In the presence of selected buffers such as sodium phosphate, it
can cleave at both the glutamate and aspartate residues. Other proteases listed in Table 2 with
cleavage specificities are useful for producing peptides of varying lengths depending on how
many cleavages occur. This is useful for obtaining additional sequence information, especially if
the protein is unknown.
There are also non-specific endoproteases such as pepsin as well as endoproteases with
broad specificities such as chymotrypsin that are useful for producing multiple overlapping
peptides that can increase sequence coverage.98 Proteins can also be cleaved with cyanogen
bromide, formic acid, and hydroxylamine. Cyanogen bromide is the most commonly used for
protein cleavage; it cleaves specifically at methionine residues.105
1.2.3 Separations
Two separation methods used in proteomics are gel electrophoresis and liquid
chromatography (LC). Gel electrophoresis is a sensitive method for separating and identifying
proteins in a gel matrix such as agarose or polyacrylamide.80 Agarose is typically used to
separate larger macromolecules such as nucleic acids and polyacrylamide is typically used to
separate proteins. Polyacrylamide gel electrophoresis can be used to determine the size,
isoelectric point and purity of proteins.80 The gel pores are made by crosslinking of the
polyacrylamide with bis-acrylamide to form a network of pores that allows the molecules to
move through the gel matrix like a sieve. The gel pore size is determined by the acrylamide
monomer concentration.106
Gel electrophoresis separates molecules based on the differences in migration velocity of
ions in the gel under the influence of an electric field. The migration velocity is the product of
the electrophoretic mobility and the applied electric field. The electrophoretic mobility is
proportional to the ion charge and inversely proportional to the frictional forces. The frictional
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forces depend on the analyte size and the viscosity of the solvent. Smaller analytes have a greater
mobility and migrate farther down the medium in a given time. Polyacrylamide gel
electrophoresis (PAGE) is used to separate proteins and peptides based on their size. Sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) is the most commonly used
gel based technique for separating proteins. SDS is used to denature the proteins and gives the
protein an overall net negative charge.107
Two-dimensional gel electrophoresis (2D-GE) is used to separate proteins based on their
charge and mass.107, 108 The first dimension separates proteins based on their net charge using
isoelectric focusing.108 Protein separation is performed in a pH gradient; the proteins migrate to
their isoelectric point (pI), which is the pH where the protein has a net charge of zero. A
protein’s pI is determined by the type and number of acidic and basic residues it contains.107, 108
The second dimension in 2D-GE separates proteins based on their mass and is usually performed
in a SDS gel (SDS-PAGE). 2D-GE has difficulty resolving large proteins, or those with extreme
pI or hydrophobicity, and suffers from lack of reproducibility.109
Liquid chromatography (LC) is a technique used to separate components on a stationary
phase using a liquid mobile phase. Reversed-phase high-performance liquid chromatography
(RP-HPLC) separates proteins and peptides by hydrophobicity.110 It is one of the most powerful
and commonly used liquid chromatography techniques.111 Commonly used hydrocarbon ligands
for reversed-phase resins include C4 and C18.110 C4 is commonly used for polar proteins and C18
is most used for peptides.
Ultra performance liquid chromatography (UPLC) uses smaller particles as well as high
speed and peak capacity (the number of peaks that can be resolved per unit time).112 Compared
to conventional HPLC columns which are packed with 3.5 to 5 µm particles, UPLC columns are
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packed with 1.7 µm particles.113 Smaller particles shorten the analyte’s diffusion path which
improves separation efficiency, speed, and resolution.114, 115
Ion exchange is another form of chromatography which involves the separation of
proteins and peptides based on their charge.110 A cationic or anionic resin is used and proteins or
peptides of opposite charge are retained due to charge attraction. Hydrophilic-interaction
chromatography separates proteins based on their hydrophilic properties; hence the stationary
phase is polar.116 Another separation technique is affinity chromatography, which separates
proteins and peptides based on their specific ligand-binding affinity.110 There are two fractions
collected from affinity separation, the unbound and the bound proteins and peptides. The
analyses and detection of low abundant proteins, primarily in plasma, can be difficult due to the
presence of high abundant proteins such as albumin, immunoglobulins, and transferrin.117
Therefore, affinity-based approaches can be used to remove high abundant proteins or low
abundant proteins can be enriched.109
Due to the complexity of the protein samples, one-dimensional separation techniques are
usually insufficient and multi-dimensional separations are employed. In multi-dimensional
separation, two or more separation techniques are coupled together to improve the resolving
power. These separation techniques are orthogonal to one another.
1.2.4 Mass Spectrometry
Mass spectrometry (MS) is an analytical technique used for measuring the mass and
chemical structure of molecules and is widely used for proteome analysis. A variety of ionization
techniques can be used for mass spectrometry but the most commonly used techniques for the
analysis of biomolecules are electrospray ionization (ESI)118 and matrix assisted laser desorption
ionization (MALDI).119-121 MALDI uses a matrix that absorbs laser energy and aids in ionization
of the analyte. The ions generated are typically singly charged. ESI can also be used to analyze
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biomolecules. Unlike MALDI, its ions are produced from solution. After the ions are formed
they are transferred into a mass analyzer by an electric field where they are separated according
to their mass-to-charge ratio. Two stages of mass separation can be coupled (either in space or in
time) to obtain additional information of the sample being analyzed which is known as tandem
mass spectrometry (MS/MS).122 Tandem mass spectrometry is used to determine peptide
sequences from proteins.83 A peptide is separated from a mixture of peptides in the first stage of
mass spectrometry and dissociated by collision with an inert gas. The generated fragments are
separated in the second stage of mass spectrometry.83, 123
There are three MS proteome analysis approaches: 1) bottom-up proteomics, 2) shotgun
proteomics, and 3) top-down proteomics. In the bottom-up approach the protein mixture is
separated usually by 1 or 2-dimensional electrophoresis and the individual protein bands or spots
are cut and digested with an enzyme such as trypsin resulting in peptides. The peptides are
analyzed by mass spectrometry using peptide mass fingerprinting or tandem mass spectrometry
(MS/MS) to create sequence tags for database searching.124-126 Some of the major advantages of
using the bottom-up approach are the ability to obtain high-resolution separations and a
comprehensive coverage of proteins. It’s the most widely used technique in proteomics,127 hence
several bioinformatics tools are available. In addition, proteins can be separated in a complex
mixture before digestion so there is a greater chance of identification. The drawback of this
approach is the limited dynamic range128 and difficulty separating membrane proteins.129, 130
In shotgun proteomics, a mixture of intact proteins is enzymatically digested and
separated using strong cation-exchange chromatography (SCX) followed by reversed-phase
liquid chromatography (RPLC).109,

131

The separated peptides are subjected to tandem mass

spectrometry and database searching.131 A major advantage of this technique is that thousands of
proteins can be identified in a single analysis and the technique is better suited to membrane
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proteins. However, limitations of this technique includes the need for complex mixtures to be
purified prior to separation,132 limited dynamic range,63 and bioinformatics challenges to identify
peptide and protein sequences from a large number of acquired spectra.63
In the top-down approach, intact proteins are separated by gel electrophoresis or HPLC
before being introduced into the mass spectrometer.124, 126 The mass of the protein is measured
and tandem mass spectrometry is used to generate sequence tags (a short sub-sequence of a
peptide sequence) for database searching. Alternately, de novo sequencing (an approach to
determining a peptide sequence without prior knowledge of the sequence) can be performed.126
Top-down sequencing can be used to locate and characterize post-translational modifications,
determine the complete protein sequence, and minimize time-consuming preparation steps such
as separation and digestion procedures. Conversely, spectra generated by multiply charged
proteins can be very complex and bioinformatics tools still needs more developing for protein
identification. In addition, top-down sequencing does not work well with intact proteins greater
than 50 kDa.
Separation can also be performed in the gas phase using ion mobility mass spectrometry
(IM-MS).133-135 Ion mobility is a gas-phase technique that separates ions based on their ability to
migrate through a gas in the presence of an electric field.133, 134 The mobility is dependent on the
collision cross section of the ion. An ion mobility spectrometer consists of a gas filled cell where
ions travel under the influence of an electric field.133 Ions with larger diameters undergo more
collisions with the buffer gas, hence their passage through the drift cell is slower, whereas
smaller molecules undergo fewer collisions and pass through the drift cell more rapidly.133 When
coupled with MS both the mass to charge and size to charge ratio of the ions can be determined.
Both MALDI and ESI can be used as an ionization source for IM-MS.136 However, many IM
studies reported in literature of peptides and proteins describe the use of an ESI source coupled
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with IM.137-139 IM can also be coupled with tandem MS for additional peptide and protein
information.140
IM-MS separations can obtain comparable resolutions to HPLC and CE.134 LC-MS, a
more commonly used proteomics technique is advantageous in that it increases the dynamic
range,141 however, coupling LC to MS limits optimization of LC and LC can take minutes to
hours for separation which limits sample throughput.142 IM offers two major advantages over LC
techniques; it reduces separation time and the post-ionization separation provides information on
the product.134 Another major advantage of IM-MS is that it adds two separation dimensions for
different chemical classes,143,

144

for example peptides, DNA, oligonucleotide and lipids or

conformational classes such as α-helix and random coil.145 However, IM-MS has its
shortcomings for proteomic applications, specifically poor sensitivity and limited peak
capacity.134 Despite the limitations of IM-MS for proteomics it has still been proven to be a
useful method for proteomics,134 metabolomics,146 and glycomics.147
1.2.5 Protein Bioinformatics
Bioinformatics is the approach used to analyze large numbers of genes and proteins148
and is important for the elaboration of mass spectrometry data due to the large amount of data
produced.149 It is used in proteomics to provide functional analysis and mining of data sets.148
Peptide and protein data can be interpreted via peptide mass fingerprinting, database searching,
or de novo sequencing.
Peptide mass fingerprinting (PMF) is a high-throughput protein identification method.150
In this method the protein is purified and cleaved using an enzymatic or chemical approach to
generate peptides. The peptides are analyzed via ESI or MALDI mass spectrometry and a
peptide mass fingerprint (the masses of the intact peptides in the sample) is obtained. The mass
fingerprint is compared to theoretical cleavages of protein sequences in databases and the protein
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matches are scored based on the best match.150, 151 Several programs have been developed for
peptide mass fingerprinting including MassSearch, Mowse, MS-FIT, PepMAPPER, PepSea,
PeptideSearch, ProFound and PeptIdent.152 Peptide mass fingerprinting will only yield hits for
proteins that are in a sequence database.
An alternate approach to database searching is mass spectral matching. This entails
matching the experimental spectrum to a library of previously obtained MS/MS data.153 This
method is a fast and precise means to identifying peptides whose proteome has been previously
identified. Its major limitation is its inability to be used for identifying or discovering new
peptides.
Another approach for database searching compares experimental spectra to theoretical
spectra to identify peptides in the protein database. Theoretical tandem mass spectra are
produced from fragmentation patterns that are known for a specific series of amino acids. Search
engines that are used for database searching includes Mascot,154, SEQUEST,155 X!TANDEM, 156
Open

mass

spectrometry

search

algorithm

(OMSSA),157

SONAR,158

ProbID,159

PeptideProphet160 and OLAV-PMF.161 Two commonly used search engines include Mascot and
SEQUEST. SEQUEST uses a cross-correlation score to match hypothetical spectra to
experimental spectra155 whereas Mascot uses a probability score that indicates the probability of
whether or not a spectral match was random.154 When some commonly used search engines were
compared, including SEQUEST and Mascot, Mascot proved to be able to better discriminate
between a correct and incorrect hit as compared to SEQUEST.162 An overall evaluation showed
that Mascot outperformed the other algorithms used in the study, which included PeptideProphet,
Spectrum Mill, SONAR and X!TANDEM.
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Mascot is based on probability scoring and the lowest probability is the best match. The
match significance criteria depend on the size of the database. The score is reported as -10log
(P), where P is the probability. Hence, the best match has the highest score.
Database searching offers several advantages including high-throughput, robustness and
well annotated proteins (detailed information on each protein). Despite these advantages there
are also some disadvantages that are associated with database searching including false positive
identification due to selection of background peaks, unidentified peptides due to post
translational modifications, scoring a longer peptide that may be from a lower quality MS/MS
spectrum (low signal-to-noise ratio) with a higher score than a shorter peptide from a higher
quality MS/MS spectrum (high signal-to-noise ratio), and, most importantly, it is impossible to
identify a peptide that is not part of a protein in the database.163
De Novo sequencing is an approach to identifying peptides without database searching,
for example for a species whose genome has not been previously sequenced. It is also used to
identify post-translational modifications. The de novo approach determines peptide sequences
using information such as the type of fragmentation method, for example collision induced
dissociation (CID),164 electron-transfer dissociation (ETD),165 or electron-capture dissociation
(ECD),164, 166 the type of enzyme used, as well as any chemical modifications. Some commonly
used de novo sequencing programs are PEAKS167 Mascot Distiller97, Lutefisk,168 PepNovo,169
and SHERENGA.170 Tandem mass spectrometry data can also be searched against expressed
sequence tag (EST) databases to identify peptides and proteins for organisms without complete
genomes. ESTs are nucleotide sequences (200 to 500 nucleotides long) that are generated by
sequencing either one or both ends of an expressed gene originating from specific tissues.171
These nucleotide sequences are translated into protein sequences for protein identification from
tandem mass spectra.
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Under CID, peptides fragment along the peptide backbone and fragment ions generated
from the N-terminus of the peptide are labeled a, b, and c, whereas fragments generated from the
C-terminus of the peptide are labeled x, y, and z.172 De novo spectra generated from low energy
CID gives only partial peptide ion coverage because of its backbone cleavage specificity; in low
energy CID spectra c, x, z and a-type fragment ions are not observed.172 Hence, it is usually
beneficial to collect peptide spectra from other fragmentation methods such as ETD or ECD.
Some of the limitations associated with CID include overlapping fragment ion peaks (which can
cause incorrect peak assignment), low signal for some of the ions in the CID spectra, difficulty
identifying post-translational modifications, and the inability to differentiate between the amino
acids leucine and isoleucine.163 The ETD and ECD techniques can be used which can
differentiate between leucine and isoleucine as well as identify post-translational modifications.
ECD also produces less specific backbone cleavage as compared to CID; therefore, more
extensive sequence information can be obtained on proteins.164 However, a limitation of ETD
and ECD is their inability to produce good quality data with shorter peptides, such as those
generated from tryptic digests.163
Basic local alignment search tool (BLAST) is a search algorithm that is used to compare
sequence similarities between experimentally determined nucleotide or protein sequences with
nucleotide or protein databases.173 This approach is useful for the identification of proteins from
organisms that have unsequenced genomes.174, 175 A BLAST alignment pairs each amino acid in
the queried sequence to those in another sequence from a protein database. BLAST begins a
search by indexing short character strings (amino acid sequences) within the peptide query by
their starting position in the query. The “word size” (length of the amino acid sequence) for a
protein-to-protein sequence comparison is typically three. The BLAST software then searches
the database to look for matches between the indexed “words” from the queried peptide to
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character strings within the sequence in the database. Whenever a word match is found, BLAST
then extends the sequence (using the database sequence) in the forward and backward direction
to create an alignment. The BLAST score value increases as long as the alignment matches and
will begin to decrease once it encounters mismatches.176, 177
The BLAST results are quantified by comparing them to the expect value (E-value). The
E-value threshold represents the number of times a good match is expected to occur by chance
and is proportional to the size of the database. BLAST determined E-values that are greater than
the threshold E-value are considered significant. The higher the similarity between the queried
sequence and the sequence in the database the lower the E-value is. This can be seen in Equation
1-1,

∗

∗

∗

EQUATION 1-1

where K is a constant (scaling factor), m is the length of the query sequence, n is the length of
the database sequence, λ is the decay constant from the extreme value distribution (scales for the
specific scoring matrix used) and S is the similarity score.176
1.3 Research Objectives
The objective of this research is to characterize the biological molecules isolated from the
Alligator mississippiensis immune system and identify antimicrobial molecules. To achieve this
goal, the specific aims of the project were (1) to isolate and characterize the proteins of the
leukocytes, (2) to purify and identify antimicrobial peptides from whole blood, and (3) to isolate
and determine the primary sequence of lectin from the serum. The first set of experiments,
described in Chapter 3, used gel electrophoresis and multidimensional gel electrophoresis to
separate a mixture of isolated leukocyte proteins for mass spectrometry detection and sequence
identification. A second set of experiments, described in Chapters 4 and 5, used a combination of
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separation techniques for purification of a novel antimicrobial peptide. Although antimicrobial
peptides have been identified and characterized in numerous organisms, antimicrobial peptides
have not yet been identified in alligators. For the third set of experiments described in Chapter 6,
a new lectin from Alligator missisissippiensis was identified using de novo sequencing with
different enzymatic digests and characterized. Chapter 7 describes deglycosylation approaches
and compares sample clean-up procedures that can be applied to glycoproteins for mass
spectrometry analysis.
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CHAPTER 2. EXPERIMENTAL*
This chapter contains a description of the instruments and methods used for analyzing
peptides and proteins isolated from the blood of alligators. A summary of the instruments and
techniques

used

for

this

research,

including

gel-based

protein

separations,

liquid

chromatography, ion mobility, mass spectrometry, and proteomic bioinformatics is described. A
detailed description of the experimental parameters and procedures used for the separation
techniques as well as the electrospray ionization time-of-flight (ESI-TOF), matrix-assisted laser
desorption ionization tandem time-of-flight (MALDI-TOF/TOF) and electrospray ionizationquadrupole-time-of-flight (ESI-QTOF) mass spectrometers is given.
2.1 Blood and Leukocyte Collection
Adult alligators were captured at night by boat at J. D. Murphree State Wildlife Refuge in
Port Arthur, Texas, with the use of a spotlight and a cable harness and housed at the Rockefeller
State Wildlife Refuge in Grand Chenier, Louisiana. The animals were kept in fiberglass-lined
concrete tanks approximately 5 m long and 2 m wide, with 50% dry bottom and 50% water of
approximate 0.2 m depth. The temperature was maintained at 31 ºC. Several alligators up to 1.5
m in length were housed in a single tank. The alligators were fed formulated dry pellets four
times per week and the cages were cleaned five times per week.
Blood samples were collected from the supravertebral branch of the internal jugular vein
using a heparinized 38 mm long 18 gauge needle and a 60 mL syringe178, 179 and transferred to
250 mL plasma bottles containing 25 mL of 500 mM EDTA. This method of blood collection
has been approved by the McNeese State University Animal Care and Use Committee and is
routinely used to collect blood from wild and captive adult alligators (See Appendix D).
*Portions reprinted by permission from the Elsevier. The work reported in this chapter has
been published in Comparative Biochemistry and Physiology Part D: Genomics and
Proteomics.6
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Leukocytes were isolated from the whole blood by differential sedimentation. Whole
blood samples were mixed with one volume of 5% dextran and the erythrocytes were allowed to
settle for approximately two hours. The leukocytes were separated manually from the top phase
using a transfer pipette.1
The leukocytes were centrifuged for 15 min. at 1500 g and the leukocyte pellet was
resuspended in approximately one volume of 10% acetic acid and stored at -80ºC until needed.
Prior to analysis, the leukocyte pellets were homogenized in a Dounce homogenizer and then
centrifuged at 20,000 g for 30 min. The clear supernatant was transferred to 1 kDa concentrator
tubes (Centriprep, Millipore Corp., Billerica, MA) and centrifuged at 5000 g to concentrate the
sample and remove the acetic acid. The concentrated extract and precipitate were resuspended in
10 mL of 0.1% acetic acid. The resuspended extract was centrifuged at 20,000 g and the clear
supernatant was used in the gel electrophoresis and HPLC analysis.
2.2 Liquid Chromatography
In this work, reversed-phase liquid chromatography was used. Both capillary and nano
capillary high performance liquid chromatography (HPLC) as well as nano ultra performance
liquid chromatography (UPLC) were used.
2.2.1 Nano HPLC
Nano capillary HPLC (nanoLC) uses columns that have an inner diameter (ID) between
50 and 100 µm and flow rates below approximately 120 nL/min.180 In this work, nanoLC was
coupled to the mass spectrometer described in Section 2.6.4. Typical columns used for nanoLC
have lengths of 50-150 mm with 3-5 µm particle diameters. For improved chromatographic
separation, acids, including trifluoroacetic acid (TFA) and formic acid (FA), are added to the
solvents at 0.1%. TFA is best for offline LC because it provides higher peak capacity with
narrower peak width. However, if the LC is coupled online with the mass spectrometer, FA is
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preferred because the high surface tension of the TFA solution makes spray formation difficult
and trifluoroacetate can form strong ion pair complexes with peptide cationic sites causing signal
suppression.181
The LC separations were performed on a LC Packings/Dionex capillary and nano HPLC
system. The HPLC system is equipped with a low pressure mixing system, micropump, flow
splitting unit that allows flow rates from 50 nL/min to 200 µL/min, a sample injector, and UV
detector. A Vydac C18 75 µm ID × 150 mm, 5.0 µm column was used. The solvents were water
in 0.1% FA and acetonitrile in 0.1% FA. The column flow rate was 200 nL/min and a linear
gradient was used for separation.
2.2.2 Capillary HPLC
Capillary HPLC is separation on a column that has an ID between 100 and 300 µm and
flow rate that is several µL/min. A capillary HPLC (Agilent 1200 series) was used both online
with the Agilent mass spectrometer (see Section 2.6.3 below) and offline with a photodiode array
(PDA) detector over a wavelength range between 190 and 400 nm. The capillary HPLC is
equipped with a binary and gradient pump, diode array detector, autosampler and thermostat. In
this work, a C18 2.1 mm ID × 50 mm, 5.0 µm column (Zorbax) and a C18 4.6 mm ID × 250 mm,
5.0 µm column (Vydac) were used. The solvents were water in 0.1% FA and acetonitrile in 0.1%
FA. The column flow rate was 300 µL/min and a linear gradient was used for separation.
2.2.3 Nano Ultra Performance Liquid Chromatography
Nano ultra performance liquid chromatography (nano UPLC) uses columns that typically
have an ID between 75 and 1000 µm and flow rates between 200 nL/min and 100 µL/min. A
UPLC system (Waters nanoAcquity) was used online with the Waters Synapt instrument
described in Section 2.6.5. The system is equipped with a binary solvent manager, sample
manager, a column heating compartment and a UV detector. In this study, an C18 column
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(Acquity) packed with 1.7 µm particles, 5 cm long × 2.1 mm ID was used. The samples were
diluted in 0.1% FA and eluted using a gradient with 3–85% 0.1% FA in acetonitrile (v/v) for 32
minutes. The column flow rate was 500 nL/min and 214 nm UV absorption was recorded.
2.3 Ion Mobility
Another separation technique used in this work was ion mobility (IM). The ion mobility
cell was built into a Q-TOF mass spectrometer (Waters Corporation), details of this mass
spectrometer are found in Section 2.6.2. The peptide samples were diluted in 0.1% FA and
injected on the UPLC system at a flow rate of 500 nL/min. The peptides were separated using a
gradient of 3–40% B over 30 minutes. Solvent A was 95% water and 5% acetonitrile containing
0.1% FA. Solvent B was 80% acetonitrile and 20% water containing 0.1% FA. The peptides
were ionized using a nano-electrospray source and analyzed via a quadrupole mass analyzer
before being introduced to travelling wave ion mobility cell. In travelling wave ion mobility
spectrometry (TWIMS) pulsed voltage waves guide the ions through the drift cell via stacked
ring electrodes.182 As the waves move, the ions are pushed for a short distance before moving
over the wave. Smaller ions undergo fewer collisions with the buffer gas so travel faster in the
traveling wave’s gradient, whereas larger ions undergo more collisions with the buffer gas
slowing them down therefore requiring a longer time to be moved by the traveling waves.140, 182
A pressure of 0.5 bar of nitrogen was maintained in the IM cell. Each set of experiments was run
in triplicate.
2.4 Gel Electrophoresis
Both one- and two-dimensional gel electrophoresis was used to separate protein mixtures
prior to digestion and mass spectrometry analysis. One-dimensional gel electrophoresis was
performed using a small format cell (BioRad mini-PROTEAN). The main components of this gel
apparatus are a gel cassette assembly, electrode assembly, clamping frame, mini tank and a lid
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(see Figu
ure 2-1). Thee electrode assembly can
n hold gels 8 cm (W) × 77.3 cm (H). IIn this work,,
precast polyacrylami
p
ide gels weree used (BioR
Rad Laboratoories).

Figure 2-1.
2 Assemblly componen
nts of the mini-PROTEA
AN 2D gel ellectrophoressis cell.
Two-dimensi
T
ional electrop
phoresis wass performed using eitherr the small fo
format or a
standard format electtrophoresis system
s
(Prottean II XL, B
Bio-Rad) (seee Figure 2-22). For isoeleectric
i sample bu
uffer containning 8 M ureaa, 2% 3-[(3-focusing,, sample wass dissolved in
cholamid
dopropyl) dim
methylammo
onio]-1 prop
panesulfonatte (CHAPS),, 50 mM dithhiothreitol (D
DTT)
and 1% carrier
c
amph
holytes. Isoellectric focusing was carrried out in ann isoelectric focusing ceell
(Protean,, Bio-Rad) at 250 V for 20
2 min and 14,000
1
V-h ((rapid rampiing). SDS-PA
AGE
electroph
horesis was performed
p
in
n slab gels (1
18.3×19.3 cm
m) with 1.000 mm thickness. The
electroph
horesis was conducted
c
att 200 V for 40
4 min.
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Figure 2-2.
2 Protean II
I XL large format
f
gel ellectrophoressis system annd isoelectricc focusing ccell.
Gels
G can be prepared
p
as a single con
ntinuous perccentage or aas a gradientt %T througgh the
gel; exam
mples of com
mmonly useed gradient gels
g include 4–15% andd 4–20%. Grradient gels have
the advan
ntage that prroteins with a wide moleecular weighht range cann be separateed and the prrotein
bands aree narrower. In
I this work,, 4–20% gels were used unless otherrwise indicatted.
Another
A
comp
ponent to the gel electro
ophoresis is tthe buffer syystem. Theree are two typpes of
buffer sy
ystems: contiinuous and discontinuou
d
us.183 A contiinuous buffeer system haas the same bbuffer
at a consstant pH and
d concentrattion. The geel used is tyypically madde of one coontinuous %
%T. A
discontin
nuous bufferr system hass a differentt buffer in tthe gel soluttion and thee solution foor the
electrodee assembly, and
a a stacking gel is alsso added to tthe resolvingg gel. The sstacking gel has a
lower acrrylamide con
ncentration and
a pH, whiich gives thee gel larger ppores allowinng the proteiins in
the samp
ple to be con
ncentrated before enterin
ng the resolvving gel. Thhe resolving gel has a hhigher
acrylamide concentrration and higher
h
pH which
w
gives the gel narrrow pores. T
This gives bbetter
n.
protein reesolution and separation
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The sample buffer system used in this work was a discontinuous buffer system that
incorporated sodium dodecyl sulphate (SDS) and a reducing agent, β-mercaptoethanol, in the
buffer. SDS is an anionic detergent that denatures and binds to proteins. The polypeptides
become rod-like in shape with a negative charge.184 Because all the proteins have the same
charge, they separate according to their molecular mass. The β-mercaptoethanol is used to reduce
the disulfide bridges in the proteins so that they can assume the random-coil configuration
required for optimum separation.106
To resolve proteins with similar molecular weights, two-dimensional polyacrylamide gel
electrophoresis (2D-PAGE) was performed. 2D-PAGE is a powerful proteomics separation tool
as it is capable of separating thousands of proteins in a typical cell.185 The first dimension,
isoelectric focusing (IEF) was performed in an isoelectric focusing cell (Bio-Rad Protean IEF).
IEF is usually performed in an immobilized pH gradient strip.186 The pH gradients used in this
work were 3–10 and 3–6. Prior to the second dimension, the proteins separated by IEF
underwent an equilibration step. The proteins were reduced and alkylated using DTT and
iodoacetamide and SDS was added to give the proteins a negative charge. This allowed the
separation based on size in the second dimension. The second dimension was performed using
the Bio-Rad Protean II 2-D electrophoresis cell.
The gels were stained to visualize the proteins. Several stains are commercially available:
Coomassie blue R-250, Bio-safe Coomassie, Sypro ruby fluorescent stain, and silver stain.106, 185
The choice of stain used depends on several factors such as sensitivity, ease of use, and type of
imaging equipment available. Coomassie R-250 stain (wool dye with a red hue) is the least
sensitive: it requires 40 ng of protein for detection.185 Bio-safe Coomasie stain is prepared with
Coomassie G-250 (wool dye with a green hue) and can be used to detect as little as 10 ng of
protein.185 The most sensitive stains are Sypro ruby fluorescent and silver stains which both can
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be used to detect as little as 1 ng of protein.185 In this work, Bio-safe Coomasie or silver stains
were used. Both stains are mass spectrometry compatible, meaning that the stains have high
sensitivity for protein detection while minimizing crosslinking of the protein to the gel, which
can inhibit recovery for mass spectrometry.187
There are also specific stains that can be used for detecting modified proteins such as
glycoproteins. The most commonly used methods for detecting glycoproteins in polyacrylamide
gels involves detection by periodic Schiff (PAS) staining using chromogenic detection, for
example acid fuchsin dye.188 Another approach utilizes Pro-Q Emerald 300 fluorescent dye, that
links to glycoproteins using periodic Schiff conjugation.189 During the staining process the
glycols in the glycoproteins are oxidized to aldehydes with periodic acid. The dye then reacts
with the aldehydes on the glycoproteins and a fluorescent conjugate is generated.189 This stain
can be used to detect as little as 0.5 ng of glycoprotein and is compatible with mass spectrometry
analysis. This glycoprotein stain was used in the initial characterization of lectin proteins studied
in this work.
Gel images were captured using a camera (Gel Doc XR System with Quantity One 1-D
analysis software, BioRad) which is capable of imaging Coomassie stained, silver stained, and
fluorescent gels.
2.5 Edman Sequencing
Edman sequencing involves labeling the N-terminal residue of a protein or peptide with
phenyl isothiocyanate. The peptide bond adjacent to the modified residue is cleaved via mild
acid hydrolysis, leaving the rest of the protein intact. The terminal amino acid residue that has
been modified is identified by liquid chromatography. The process is repeated successively for
the residues in the peptide sequence until a complete sequence is determined.69 Protein bands
were excised from SDS polyacrylamide gels and submitted to the University of Texas Medical
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Branch, Protein Chemistry Core laboratory for N-terminal sequencing using a protein sequencer
(LC 494, Applied Biosystems, Foster City, California).
2.6 Proteolysis of Isolated Proteins
Proteolysis generates peptides from proteins using either enzymatic or chemical cleavage.
Proteolysis experiments were performed for peptide sequencing. Digestions were performed both
in-gel and in-solution. Prior to proteolytic digestions, reduction and alkylation was performed to
reduce the disulfide bonds for more efficient digestion. For reduction and alkylation a reaction
buffer containing 25 mM NH4HCO3 was mixed with 10 mM dithiothreitol (DTT). To a vial
containing approximately 100 µg of lyophilized protein in 25 mM NH4HCO3, 10 µL of DTT
solution was added and the sample mixture was heated for one hour at 57ºC. The vial was
removed from the heat block and allowed to cool to room temperature and 40 µL of 55 mM of
iodacetaminde (IA) solution was added and incubated at room temperature in the dark for 30
minutes.
Several enzymatic and chemical proteolytic agents were used: trypsin, α-chymotrypsin,
Glu-C, Asp-N, Lys-C, cyanogen bromide (CNBr), and formic acid. The enzymatic digestions
were performed in a heat block at 37ºC, the CNBr digestions were performed at room
temperature in a fume hood, and the FA digestions were performed at 37ºC.
For the enzymatic digestions, a 0.2 µg/uL solution of trypsin was prepared in 1 mM HCl
and stored for a maximum of four weeks at -20ºC. The reaction solution contained 1 µl of trypsin
(0.2 µg), 9 µL of 40 mM NH4HCO3 and 9% acetonitrile by volume. For enzymatic digestions
using Lys-C, Asp-N and Glu-C, the preparations were as follows: 0.1 µg/µL of Lys-C in a 1:20
ratio (v/v), 0.04 µg/µL of Asp-N in a 1:50 ratio and 0.1 µg/µL of Glu-C in a 1:20 ratio. For
CNBr digestions a 1 M solution was prepared in acetonitrile (ACN) and stored at -20ºC. The
CNBr solution contained 5 µL of 5% TFA/50% FA and 5 µL of water (v/v).
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2.7 Masss Spectromeetry
In
n this work, four commeercial mass spectrometer
s
rs were usedd: an ESI quaadrupole-tim
me-offlight (Q
QTOF), a MALDI
M
tand
dem time-off-flight (TO
OF/TOF), ann ESI time-of-flight, aand a
quadrupo
ole/ion mobiility separato
or/orthogonaal acceleratiion time-of-fflight (Q/IM
MS/oa-TOF) mass
spectrom
meter
2.7.1 MALDI
M
TOF
F/TOF
The
T
MALDI TOF/TOF
F mass sp
pectrometer used in this work was a Bruker
UltrafleX
Xtreme. A diagram
d
of this
t
instrumeent is show
wn in Figure 2-3. The B
Bruker TOF//TOF
mass speectrometer iss equipped with
w a Nd:YA
AG laser (waavelength, 355 nm; repetition rate 1 kHz)
with beam
m homogeniization (Smaartbeam). It is also equippped with ddelayed extraaction, a colllision
cell, lineaar and reflecctron flight tu
ubes.190

Figure 2-3.
2 TOF/TO
OF mass specctrometer sch
hematic.
This
T instrumeent can be operated in both
b
linear annd reflector mode and itt can be opeerated
in MS an
nd MS/MS mode.
m
The instrument
i
can
c achieve a mass resoolution ≥ 40,,000 from 500 to
4000 Da and for intact proteins, with
w a mass accuracy < 1 ppm.191
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The
T targets provided
p
with
h the instrum
ment have ann integratedd target transsponder, whiich is
read by the
t instrumeent allowing it to recogn
nize the typee of target pplate being uused for anaalysis.
This insttrument can use severall different ty
ypes of targget plates hoowever, for purposes of this
study a 384
3 spot stain
nless steel pllate was used.
The
T proteinss and peptidees were mix
xed on the 3384 spot staiinless steel plate using a 1:1
ratio of sample
s
and saturated matrix
m
solutio
on. The matrrices were 22-hydroxy-5-methoxybennzoic
acid (sD
DHB), 2,5-diihydroxyben
nzoic acid (D
DHB), and 2,4-dimethooxy-3-hydrooxycinnamic acid
(sinapinin
nc acid, SA
A) for protein
ns, and α-cy
yano-4-hydrooxycinnamicc acid (CHC
CA) for peptides.
Structurees and applications of th
he matrices used are foound in Tabble 2-1. Thee protein sam
mples
were anaalyzed in lin
near positive ion mode and
a 500 shoots averages were colleccted using a mass
range fro
om 30–100 kDa.
k
For pep
ptides, the spectra were obtained inn reflector poositive ion m
mode,
using a mass rangee from 1–5 kDa. Massses were deetermined uusing FlexA
Analysis soft
ftware
(Version 2.0, Bruker Daltonics).
Table 2-1. Commonlly used matrrices in MAL
LDI for biom
molecules.1922
M
Mass
((Da)

Laser
λ (nm)

Applicatiions

α-cyaano-4hydroxy
ycinnamic
acid (C
CHCA)

189

3337/355

Peptide/prooteins
mass<10 kkDa

2,5dihydrox
xybenzoic
acid (DHB)
(

154

3337/355

Carbohydrrates
& Proteiins
mass<5 kkDa

Ma
atrix

Structure
S
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Table 2-1. cont’d.
transs-3,5dimeth
hoxy-4hydroxy
ycinnamic
acid
d (SA)
2-hydrroxy-5methoxy
ybenzoic
accid
(sD
DHB)

2224

168

2666/337/355

Peptide/prooteins
mass>10 kkDa

3337/355

Carbohydrrates
& Proteiins
mass<5 kkDa

2.7.2 LC
C-TOF Masss Spectromeeter
An
A ESI-TOF MS (Agilen
nt 6210) was used with a liquid chrromatographhy HPLC syystem.
The HPL
LC system used
u
with th
his instrumeent was desccribed in Seection 2.2.2. This instruument
consists of an electtrospray sou
urce, a nebu
ulizer and nnebulizer gaas inlet, cappillary, skim
mmer,
octopole ion guides,, ion pulser for the orth
hogonal accceleration TO
OF, reflectron mirror, aand a
microchaannel plate (MCP) deteector. The capillary sepparates the sspray chambber from the ion
optics an
nd has an ap
pplied poten
ntial from -4
4000 to 150 V. The ionns are focuseed by lensess and
enter the TOF mass analyzer. Th
he ions pass into the TO
OF ion pulseer and a highh voltage puulse is
t acceleratee the ions intto the flight tube. The ioons are refleected by a reeflectron intto the
applied to
detector. This instrum
ment was ussed in this sttudy to obtaiin intact prootein mass m
measurementts and
>13,000 meaasured at m/z
/z 2722. The limit
has a maass accuracy of < 2 ppm and a mass resolution >
of detecttion for this instrument using ESI is in the rannge of 1–100 ng/mL. M
Mass spectra were
acquired from 600 to 3000 m/z
m using ESI
E at 42000 V. The sspectra werre extractedd and
A
softw
ware (Versio
on 1.5, Agileent).
deconvolluted using Analyst
2.7.3 ESII-Q-TOF Mass
M
Spectro
ometer
The
T mass speectrometer ussed in this work
w
for pepttide sequenccing was a hhybrid quadruupole
time of flight
f
tandem
m mass specctrometer (A
Applied Biossystems QST
TAR XL). A diagram oof the
instrumen
nt is shown
n in Figure 2-4. The mass
m
spectroometer consiists of an E
ESI source, three
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quadrupo
oles (focusin
ng quadrupole, q0; mass selection quuadrupole, Q1; and colliision quadruupole,
q2), an orrthogonal TO
OF, reflectro
on ion mirrorr, and a MCP detector. T
This instrum
ment was opeerated
in MS/M
MS mode for these studiees. The instrrument has aan orthogonnal pulser thaat pulses thee ions
out at rep
petition rate of several kH
Hz using an applied elecctric field off 10 kV.
To
T perform MS/MS
M
expeeriments the instrument software (A
Analyst) was used to 1) sselect
the three most intensse peaks for fragmentatio
on, 2) select three differrent collisionn energies (225, 32
and 38 eV),
e
and 3) a repetition rate ranging
g between 3 to 20 kHz for pulsing the ions intto the
TOF MS.

Figure 2-4.
2 Q-TOF mass
m spectro
ometer schem
matic.

2.7.4 ESII-Q/IMS/TO
OF Mass Sp
pectrometerr
A hybrid quaadrupole tim
me-of-flight instrument
i
w
with a traveelling wave ion mobilityy cell
was used
d in this work
k (Waters Sy
ynapt; Figurre 2-5). This instrument hhas an ESI ssource, ion gguide,
quadrupo
ole, ion mob
bility section
n, and an orrthogonal tim
me-of-flight.. The ion m
mobility sectiion is
after the mass selectiion quadrupole and conssists of a linnear quadruppole ion trap which is ussed to
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accumulaate ions befo
ore the mobility separattion; the acccumulated ioons are then released intto the
ion mobiility cell.140 The traveliing wave transfer ion gguide is useed to transport the mobbilityseparated
d ions into the oa-TOF
F for mass analysis. A nano UPLC
C system iss interfaced to a
nanospraay ionization
n source of th
he mass specctrometer. T
This instrumeent has a resolution of 155,000
and a maass accuracy < 10 ppm.

2 Schemaatic of the hy
ybrid quadru
upole/ion moobility separrator/orthogonal accelerration
Figure 2-5.
time-of-fflight.
n this study
y the instru
ument was operated inn positive iion electrosppray mode. The
In
quadrupo
ole was operrated in RF mode in ord
der to recordd full mobillity spectra and the dataa was
acquired using MasssLynx software version 4.1. The pepptide samplee analysis on this instruument
was perfo
ormed at Waaters Corporration, Milford, MA.
2.7.5 Pro
otein Bioinfformatics
Two
T
approacches were used
u
to seq
quence protteins: databaase searchinng and de novo
sequencin
ng. In the first
f
method the tandem
m mass specttra from diggested proteins were used to
determin
ne peptide sequences thatt were comp
pared to prottein sequencces in databaases. In this w
work,
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the Masccot search engine was used for protein
p
idenntification. T
The databasse search enngine
calculates peptide fragment
fr
maasses in siliico using thhe enzyme specificity for each prrotein
sequencee in the dataabase. Thesee calculated fragment m
masses are ccompared w
with the measured
fragmentt masses and
d a score is calculated
c
fo
or comparisoon.152, 154 Seaarch enginess can also exxtract
partial seequence info
ormation fro
om the specttrum based on the ion sseries. The nnomenclaturre for
fragmentt ions was prroposed by Roepstorff
R
and
a Fohlmann193 and lateer modified bby Biemannn194 to
designatee peptide fraagment ionss. When thee charge is rretained on the N-termiinus the ionns are
representted by the sy
ymbols a, b, and c and when
w
the charrge is retaineed on the C-terminus thee ions
are repreesented by th
he symbols x,
x y and z (F
Figure 2-6). The most ccommon ionns produced are b
and y-ion
ns.195

Figure 2-6.
2 Common
n ions produ
uced from peeptide fragmeentation.
To
T obtain seq
quence information from
m the tandem
m mass specttrum the molecular ion oof the
peptide is
i identified
d, which is the precurso
or ion in C
CID spectra followed byy identifyingg the
sequencee ion series. The mass difference
d
beetween the frragment ion peaks is deetermined annd the
masses of
o the 20 com
mmon amino
o acids are co
onsidered.
Mascot
M
is baased on the Mowse
M
algorrithm196 whicch takes intoo account hoow many pepptides
of a given
n mass are in the databaase and also takes
t
the prootein size intto consideraation. Mascot also
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calculates the probability that the observed match between the experimental data and a protein
sequence is random.152
The second approach, de novo sequencing with database searching, is necessary for
organisms that do not have a large number of proteins in the sequence database. One source for
protein database information is the genome sequence of an organism. Protein databases can be
constructed using the translated protein sequence. Three de novo sequencing software tools were
used in this work: Mascot Distiller,197 PEAKS,167 and BioTools. Mascot Distiller (Version 2.4,
Matrix Science, Boston, MA) generates peak lists for de novo sequencing. The sequencing
software fits each peak in the mass spectrum to a hypothetical amino acid combination of the
same mass. A list of amino acid combinations corresponding to each peak is generated from the
best fit data.197
The second software used, PEAKS (Version 5.2, Bioinformatics Solutions, Waterloo,
ON), applies four processes: preprocessing, candidate computation, refined scoring, and global
and positional confidence scoring. First, the raw MS/MS data is smoothed and deconvoluted
from doubly and triply charged ions to singly charged ions, and peak centering (taking the
centroid of the first peak of the isotope distribution and removal of the other isotopic peaks) is
performed. Second, sequences of all possible combinations of amino acids for the selected
precursor mass are determined. The fragment ion series a, b, c, x and y are used to determine the
peptide sequences. Next, the best sequences are scored using a stringent scoring scheme where
the ion mass error tolerance is stricter. Last, PEAKS generates a confidence score for each of the
top-scoring peptide sequences.167
BioTools (Version 2.2, Bruker Daltonics, Billerica, MA) uses MS/MS spectra from
MALDI-TOF/TOF to generate sequence tags of various lengths and scores. Proposed sequences
are calculated from the masses in the MS/MS spectrum using sequence tags. Sequence tags are
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produced using the fragment masses and information added by the user to the software, such as
terminal amino acids and enzymes used. The suggested sequence tags are then extended to
produce a list of all peptide sequences that could fit the MS/MS data. The sequences are scored
based on the number of matched ions. Several candidate sequences may be calculated with
similar scores; in this case the proposed sequences needs to be manually fitted to the MS/MS
data. However, if the peptide sequence produced complete fragmentation in the MS/MS
spectrum one peptide sequence may be the best fit.198
The peptide sequences found by de novo sequencing are used in protein database
searches in order to find proteins with similar sequences. The protein databases used in this work
were the National Center for Biotechnology Information (NCBI) database, Mass Spectrometry
Protein Sequence Database (MSDB), and Swissprot. NCBI is a non-identical protein and nucleic
acid database that has sequences taken from multiple sources including Swissprot, the Protein
Data Bank, and translations from annotated coding regions in the GenBank. One of the major
advantages of NCBI is that it is frequently updated; therefore, this database was used the most in
this work. MSDB is also a non-identical protein database that comprises a number of other
protein databases; however, it is not updated as frequently. Swissprot is a non-redundant protein
database that provides a high level of annotations such as protein function and post-translational
modifications.
Proteins were also determined from peptide sequences using Basic Local Alignment
Search Tool (BLAST). BLAST is used for comparing high-scoring segment pairs (HSP) in
nucleotide or protein sequences to sequences in nucleotide or protein databases. HSP is a region
between a pair of sequences, either nucleotide or amino acid, that share high level of
similarity.174, 199 BLAST can also provide evolutionary relationships for the species under
consideration, which shows how two species are related with respect to their evolutionary
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descent. For this work, BLAST was used to compare peptide sequences generated from alligator
leukocyte and lectin proteins to proteins in the protein database. For BLAST searching, SwissProt and NCBI databases were used to search peptide sequences using all taxonomies. The
expect threshold was set to 20,000 and the score matrix used was PAM30.
To look for protein sequence similarities DIALIGN and CLUSTALW software were
used. The DIALIGN software uses both local and global alignment features by either aligning all
residues in each sequence or aligning only residue segments that are closely related.200
CLUSTALW allows for the alignment of multiple protein sequences in order to determine
similarities and differences.201
2.8 X-Ray Crystallography
In this work, small molecules were isolated from alligator leukocyte extracts and
submitted for structural characterization using an X-ray diffractometer with charge coupled
device (CCD) area-detector (Bruker Kappa Apex II, Madison, WI, USA). The X-ray
diffractometer provides accurate and precise measurements of the entire three-dimensional
structure of a molecule, including the bond angles and distances as well as crystal structure.
2.9 Deglycosylation
Deglycosylation is the removal of a sugar from a glycogen, especially a glycoprotein.
The oligosaccharides can be removed using either an enzyme or a chemical reagent. There are
several enzymes available for deglycosylation of N- and O-linked oligosaccharides; these
include peptide-N-(N-acetyl-β-glucosaminyl)asparagine amidase (PNGaseF), endo F and endo H
(endo-β-N-acetylglucosaminidases F and H) for removal of N-linked oligosaccharides,202 as well
as O-glycanase for removal of only galactose-N-acetylgalactosamine (Gal-GalNAc) O-linked
oligosaccharides.203 A commonly used enzyme is PNGaseF, which was used in this work.
PNGase cleaves between the innermost N-acetylglucosamine (GlcNAc) and asparagine residues
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Aldrich) that was previously autoclaved at 120ºC for 20 minutes. The TSB was prepared using
3.0 mg of TSB medium dissolved in 100 mL of nanopure water. A 20 µL volume of bacteria was
added to 15 mL of the TSB medium containing 1% (wt/vol) low-electroendomosis-type agarose
(Sigma Aldrich). The previously prepared TSB medium containing agarose (agar) was heated in
a water bath at 42ºC before use. The agar was poured into an agar plate to form a uniform layer
and allowed to solidify. Evenly spaced holes were punched using a sterilized pipette tip
connected to a vacuum for suction to create wells. Added to individual holes was 5 µL of control
sample (0.1% acetic acid) and polymyxin B, which was used as the standard and isolated peptide
samples (antimicrobial peptides). The samples were added in triplicate and the plates were
incubated for 3 hours at room temperature followed by an overnight incubation at 37ºC. After
incubation, the size of the clear zone around each well was measured. The size of a clear zone
around the well indicates the antimicrobial activity of the peptides. The absence of a clear zone
indicates no antimicrobial activity.
2.11 Reagents and Chemicals
Ammonium bicarbonate and cyanogen bromide (CNBr) were obtained from Sigma
Aldrich (St. Louis, MO). The chemicals trifluoroacetic acid (TFA) and acetic acid were
purchased from Fisher Scientific. The MALDI matrix α-cyano-4-hydroxycinnamic acid (CHCA)
was obtained from Sigma and 3, 5-dimethoxy-4-hydroxycinnamic acid (sinapic acid), DHB, and
sDHB were obtained from Fluka. Trypsin, α-chymotrypsin, endoprotease Asp-N from
Pseudomonas fragi, endoprotease Glu-C from Staphylococcus aureus, and endoprotease Lys-C
from Lysobacter enzymogenes were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Dithiothreitol (DTT), iodacetamide, HPLC grade acetonitrile, formic acid, and glu-fibrinopeptide
standards (Sigma-Aldrich) were used without further purification.
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Laemmli sample buffer, 10× SDS-tris-glycine buffer, β-mercaptanol, tris-HCl gradient
gel, Coomassie blue stain (Bio-Safe), and molecular weight marker standards were purchased
from Bio-Rad (Hercules, CA, USA). Dithiothreitol, iodacetamide, and glu-fibrinopeptide were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Trifluoromethanesulfonic acid (TFMS),
pyridine, and toluene were purchased as a kit from Prozyme (Hayward, CA, USA).
The bacteria strains used in this study were obtained from American Type Culture
Collection (ATCC) (Manassas, VA). The following American Type Culture Collection (ATCC)
bacterial strains were used: Escherichia coli (35218), Shigella flexneri (12022), Enterobacter
cloacae

(23355),

Klebsiella

oxytoca

(33496),

Staphylococcus

aureus

(51153),

and

Staphylococcus epidermidis (29887). Trypticase soy broth was purchased from Voigt Global
Distribution (Broth 23400, Lawrence, KS) and agarose Type I was purchased from Sigma.
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CHAPTER 3. PROTEOME ANALYSIS OF THE LEUKOCYTES FROM THE
AMERICAN ALLIGATOR (ALLIGATOR MISSISSIPPIENSIS) USING MASS
SPECTROMETRY*
The purpose of the research described in this chapter was to investigate proteins related to
the alligator immune system. This chapter describes the use of mass spectrometry in conjunction
with gel electrophoresis and liquid chromatography to determine peptide sequences from
American alligator (Alligator mississippiensis) leukocytes and to identify similar proteins based
on homology. Proteins from leukocyte extracts were separated using two-dimensional gel
electrophoresis and the major bands were excised, digested, and analyzed with on-line nano LC
MS/MS to generate peptide sequences. The sequences generated were used to identify proteins
and infer their function based on similarity to previously identified proteins. Similar proteins
were identified based on matching two or more peptides from the alligator protein to similar
proteins by searching against the NCBI database using Mascot and Basic Local Alignment
Search Tool (BLAST). For those proteins with only one peptide matching, the phylum of the
organism corresponding to the matching protein was considered.
3.1 Introduction
A large amount of anecdotal evidence exists to suggest that crocodilians are resistant to
bacterial, fungal and viral infections208-210 and have the ability to fight a variety of diseases that
may pose human health risks.211, 212 Several studies have shown that the serum of alligators
exhibit innate immunity against fungi, viruses and various bacterial species.208, 213, 214 It has been
reported that alligator leukocyte extracts exhibit broad-spectrum antimicrobial activity against
important human pathogens such as C. albicans, S. faecalis and E. coli.215 It is anticipated that
elucidation of the alligator blood proteome will aid in identifying these antibacterial, antifungal
*Reprinted by permission of the Elsevier. The work reported in this chapter has been published
in Comparative Biochemistry and Physiology Part D: Genomics and Proteomics.6
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and antiviral peptides believed to be responsible for these properties, which in turn could lead to
the development of new antibiotics.
Antimicrobial peptides are typically found in granulocytic leukocytes and are part of the
innate immune system;216 these antimicrobial peptides are active against a wide range of
microorganisms such as fungi, bacteria, and viruses.42,
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Various classes of antimicrobial

peptides have been isolated from organisms such as bacteria, plants and animals218-220 and are
characterized by their amino acid sequence and structure.217 The majority of the antimicrobial
peptides assume linear α-helical or disulfide-stabilized β-sheet conformations24,
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and are

typically rich in lysine and arginine; however, some are also rich in proline, histidine or
tryptophan residues.217 These antimicrobial peptides are typically less than 10 kDa in molecular
mass and are cationic and amphipathic.24,
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However, antimicrobial properties have been

reported for anionic peptides as well as for proteins.24
Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) in combination with
multi-dimensional separations have become powerful techniques for peptide and protein
identification.221, 222 Mass spectrometry-based approaches have been extensively employed for
the identification and characterization of proteins in blood components such as leukocytes,33, 223,
224

serum,225 platelets,226, 227 plasma228 and red blood cells.229 For example, online LC MS/MS

was used to identify 1444 proteins in human serum.230 In other studies, the human blood plasma
proteome has been characterized using multi-dimensional separation techniques along with
MS/MS and database searching to identify over a thousand proteins.125, 221, 228
One of the major challenges in the study of the alligator blood proteome is the limited
information available regarding the reptilian genome and proteome.33, 231 For proteomic analysis
of species with limited genomic and proteomic data, de novo sequencing can be used to
determine protein sequences.175 In de novo sequencing, proteins are isolated and enzymatically
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digested and the resulting peptides are analyzed by tandem mass spectrometry. The sequence is
determined by observing the mass differences between fragment peaks in the tandem mass
spectra which are generated by low energy collision-induced dissociation (CID) of the peptide of
interest.232 The amino acid sequence can be determined from the N-terminus using the b-ion
series or from the C-terminus using the y-ion series.233 De novo sequencing has been used to
identify a number of proteins from species with limited representation in protein databases.234-237
In the present study, proteins were isolated from the leukocytes of the American alligator
(Alligator mississippiensis) and separated by one or two dimensional gel electrophoresis. One of
the challenges in this study is limited proteome data for the alligator hence peptide sequences
were determined using de novo sequencing with database searching and BLAST search to
identify similar proteins. Using this approach 43 proteins were identified that represent abundant
proteins from the alligator leukocyte.
3.2 Experimental
Adult alligators were captured for blood samples and leukocytes were isolated as
described in Section 2.1. One-dimensional polyacrylamide gel electrophoresis (PAGE) was
performed using precast 4–20% polyacrylamide gradient gels (8.6 × 6.8 cm) on a small format
gel electrophoresis system. Leukocyte extracts were dissolved in sample diluting buffer (TrisHCl at pH 6.8, containing SDS, glycerol, 2-mercaptoethanol, and bromphenol blue dye) and
boiled for 3 min prior to loading on the gel. A 10 μl sample volume was loaded on each
individual lane and in a separate lane, 10 μl of a protein molecular weight standard solution was
loaded. Electrophoresis was conducted for 1 hr at 100 V using tris–glycine (pH 8.3) as the gel
running buffer. The gels were then stained overnight with Coomassie blue to aid in visualizing
the proteins bands. The gels were rinsed twice with distilled water for 10 min each time to
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µL/min for an additional 5 min. The peptides were then eluted onto a 75 μm × 15 cm C18 column
(Biobasic Vydac) and separated using a gradient of 5–40% B over 60 min with a flow rate of 200
nL/min. Solvent A was 95% water and 5% acetonitrile containing 0.1% FA. Solvent B was 80%
acetonitrile and 20% water containing 0.1% FA
The effluent was directed to the quadrupole time-of-flight mass spectrometer (QSTAR
XL) and ionized using a nano electrospray source at a voltage of 2.5 kV. The mass spectrometer
was operated in information dependent acquisition (IDA) mode. Three collision energies (25, 38,
and 50 eV) were selected for fragmentation of the peptides.
The peptide sequences were generated from MS/MS data using Mascot Distiller software.
The software determined amino acid sequences from MS/MS data using peak fitting and isotope
distribution.241, 242 The de novo sequencing results were verified manually.
De Novo peptide sequences were subjected to database searching using Mascot154 and
BLAST to find proteins that contain sequences matching with sequences determined by de novo
sequencing. For BLAST searching, Swiss-Prot and NCBI databases were used to search peptide
sequences using all taxonomies. The expect threshold was set to 20,000 and the score matrix
used was PAM30.
3.3 Results and Discussion
One-dimensional electrophoresis of the leukocyte extracts revealed six major bands
ranging from 10 to 75 kDa. The bands marked in Figure 3-1 were excised, digested with trypsin
and analyzed by LC-MS/MS.
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Figure 3-1. A similar strategy was followed for the other labeled bands from Figure 1 as well as
the protein spots in Figure 3-2.
For the characterization of peptides and proteins in the gel bands and spots, a three-step
strategy was adopted. First, the peptides from the digest were sequenced using de novo
sequencing as outlined above. Second, the sequences were searched against the full SwissProt
and NCBI databases using Mascot to identify similar proteins. Third, a BLAST search was
performed for de novo peptide sequences that did not match sequences in the database search of
step two.
The Mascot search results are summarized in Table 3-1. The matched peptides shown in
the table were identified from either the 1D or 2D gel as indicated in the table. The proteins
included in the table had at least two peptide matches and sequence coverage ranging from 1 to
37%. The proteins polyubiquitin, hypothetical protein LOC100158585, ubiquitin, hypothetical
protein, hypothetical protein 4732456N10, endonuclease P1, myosin alkali light chain, myosin
regulatory light chain, actin, β-actin, actin-2, talin 1, chain A, chicken annexin V {complex with
Ca2+), alkaline phosphatase-like enzyme, lysozyme C, ras-related protein O-Krev, annexin I,
hemoglobin and vimentin-4 proteins were identified.
The de novo sequenced peptides that didn’t match sequences in the database were
subjected to a BLAST search to identify proteins containing similar sequences. The results of the
BLAST search are summarized in Table 3-2 (and Appendix A, Table 1).
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Table 3-1. Proteins identified in leukocyte extract using Mascot search. Proteins were
identified by Mascot search of MS/MS data from the leukocyte peptide digest with databases,
NCBI, MSDB and SWISS-PROT. NCBI accession numbers are provided in table.
Band/Spot No.

m/z

Charge

Matched Peptides

Name

B1

B3

383.2
520.3
534.8
541.8
508.6
894.5
520.3
526.3
534.8
541.3
508.6
895.0
902.0
405.2

+2
+2
+2
+2
+3
+2
+2
+2
+2
+2
+3
+2
+2
+2

MQIFVK
EGIPPDQQR
ESTLHLVLR
TLSDYNIQK
IQDKEGIPPDQQR
TITIEVEPSDTIENVK
EGIPPDQQR
NSTLHLVLR
ESTLHLVLR
TLSDYNIQK
IQDKEGIPPDQQR
TITNEVEPSDTIENVK
TITKEVEPSDTIENVK
LASYLDK

Polyubiquitin

a

Ubiquitin

a

Hypothetical
protein
LOC100158585

b

B3

533.3
515.3

+2
+2

AQYEDLAKK
VLDELTLAR

Hypothetical
protein

b

579.3
651.4
453.3
565.8
871.8
639.3

+2
+2
+3
+2
+3
+2

QGVEADVNGLR
ALEEANADLEVK
QSVEADINGLRR
NLASAVSDLLK
AVSSAIAHLLGEVAQGNENYTGIAAR
LALDIEIATYR

Hypothetical
protein
4732456N10

b

+2
+2
+3
+3
+3
+3
+3
+2
+4
+3
+3
+3
+3
+3
+3
+3
+3
+3
+3
+3
+3
+2

SLNLDSIIAEVK
FLEQQNKVLETK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
VSDSSLSSENHAEALR
VSDSSLSSENHAEALR
FLVHFIGDMTQPLHDEAYAVGGNK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
LIGGHALSDAESWAK
LANWINEIHGSEIAK
HVLVTLGEK

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

Endonuclease P1

c

2

651.8
738.4
518.9
565.6
518.9
565.6
567.9
851.5
665.5
518.9
565.6
518.9
565.6
518.9
565.6
518.9
565.6
518.9
565.6
518.9
565.6
498.3

Myosin alkali light
chain

d

3

513.2
686.8
575.2
518.2

+2
+2
+3
+2

EAFQLFDR
ALGQNPTNAEVMK
VFDKEGNGTVMGAEIR
ELLTTMGDR

Myosin regulatory

e

B1

B2
3

1
2

4
5
7
9
11
12

a

Removal of damaged or unnecessary proteins and controlling of other cellular processes
Unknown function
c
Hydrolyzes only single stranded DNA and RNA without specificity for bases
d
Binds actin and modulates myosin motor function
e
Affect myosin motor function and kinetics
b
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Function

Accession No.

% Coverage

BAA23486

Mascot
Score
340

AAG22093

368

32

NP_001121485

70

3

XP_511487

218

3

NP_808385

187

6

P24289

82

11

P24289

255

25

P24289

72

11

P24289

100

11

P24289

72

11

P24289

381

20

P24289

72

11

P24289

98

11

AAA48979

181

30

1805343A

189

18

8

Table 3-1 cont’d.
light chain
614.8
708.3
499.7
895.9
527.3
566.7
581.3
895.9
855.4
473.2
652.0
400.2
505.9
652.0

+2
+2
+2
+2
+2
+2
+2
+2
+3
+2
+3
+2
+3
+3

LNGTDPEDVIR
FTDEEVDELYR
DLTDYLMK
SYELPDGQVITIGNER
TALAPSTMK
GYSFTTTAER
EITALAPSTMK
SYELPDGQVITIGNER
GYSFTTTAER
AVFPSIVGR
VAPEEHPVLLTEAPLNPK
AVFPSIVGR
IWHHTFYNELR
VAPEEHPVLLTEAPLNPK

499.7
566.7
581.3
473.2
505.9
652.0
499.7
652.0
855.7
499.7
505.9
652.0
654.3
505.9
652.0
499.7
378.2

+2
+2
+2
+2
+3
+3
+2
+3
+3
+2
+3
+3
+3
+3
+3
+2
+2

DLTDYLMK
GYSFTTTAER
ELTALAPSTMK
AVFPSIVGR
IWHHTFYNELR
VAPEEHPVLLTEAPLNPK
DLTDYLMK
VAPEEHPVLLTEAPLNPK
LCYDALDFEQEMQTAASSSSLEK
DLTDYLMK
IWHHTFYNELR
VAPEEHPVLLTEAPLNPK
YPIEHGIITNWDDMEK
IWHHTFYNELR
VAPEEHPVLLTEAPINPK
DLTDYLMK
LLLAVVK

501.3

+2

VLTEILASR

9

565.8
871.8
539.9

+2
+3
+2

NLASAVSDLLK
AVSSAIAHLLGEVAQGNENYTGIAAR
GTSIFGLAPSK

12
13

714.9
877.4
747.9

+2
+2
+2

DKQNLVQAWQAK
NTDGSTDYGILQINSR
INVNEIFYDLVR

701.4
851.9
578.3
627.7
561.2
510.8
560.3
566.7

+2
+2
+2
+2
+2
+2
+2
+2

GVDEATIIEILTK
GLGTDEDTLNEILASR
FGGPGTASRPS
TRSYVTTSTRTYSLG
DLYEEEMR
VLASFGEAVK
KFIVDLWAK
FHVDPENFK

6
14
17

19
33

20

35

36

37

37

B2

18
31

12

Actin

f

Actin
β-actin

f

β-actin

f

Actin-1

f

β-actin

f

Actin

f

Actin-2

f

Actin

f

Chain A, Crystal
Structures of
Chicken Annexin V
in Complex with
Ca2+

g

Talin 1

h

Alkaline
phosphatase-like

i

f

j

ACD44586

188

14

ACF32719
ABB91894

79
255

4
37

CAA27396

81

7

P02578

275

18

ABD48797

139

10

AAA20641

103

13

P45885

164

14

Q99023

119

9

1YII_A

102

5

XP_002192479

141

1

NP_001096792

114

4

Lysozyme C
Ras-related protein
O-Krev

k

LZFER
P22123

114
95

10
6

Annexin I

l

CAA39971

141

8

Vimentin-4

m

P24790

151

6

Hemoglobin β chain

n

P02130

131

19

f

Highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells
Exocytosis
h
Cytoskeletal protein in lymphocyte involved in connections of major cytoskeletal structures to the plasma membrane
i
Causes the chemical reactions that remove phosphates from a number of different molecules
j
Cell derived leukocyte that is part of the immune system to fight against infectious diseases and foreign material
k
Controls a spectrum of diverse cellular processes
l
Ca2+ dependent phospholipid binding proteins with potential anti-inflammatory activity
m
Filament protein
n
Involved in oxygen transport from the lung to the various peripheral tissues
g
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Table 3-2. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from a gel
digest were searched using BLAST and proteins were matched based on sequence similarity and evolutionary relationship
using the NCBI database. The top E-values with the closest related organisms are reported.
Band
Number

m/z

Charge

De novo Sequence

Protein

Function

B4

1060.6

+2

EINLSPDSTSAVVSGLMVATK

Fibronectin

a

B4

536.3

+2

YEVSVYALK

Fibronectin

a

B4

701.3

+2

YQINQQWER

Fibronectin

a

B1

613.9

+2

LIALLEVLSQK

Filamin-C

b

B1

487.3

+2
VYGPGVE

Filamin-C

b

AQQVSQGLDLLTAK

Vinculin

c

LGQMTDQ+ADLR

Vinculin

TVTAMDVVYALK

B2

736.4

+2

B2

739.4

+2

B2

655.9

+2

B2

628.7

+2

B6

833.9

+2

Accession Number

Protein
Length

Organism

E-Value

P11722

1256

Gallus gallus

2e-11

P11722

1256

Gallus gallus

0.33

Q91740

2481

Xenopus laevis

0.013

Q14315

2725

Homo sapiens

0.019

Q14315

2725

Homo sapiens

36

P12003

1135

Gallus gallus

5e-05

c

P12003

1135

Gallus gallus

0.006

Histone H4

d

P70081

103

Gallus gallus

6e-04

LITKAVSASK

Histone H1

e

P09987

218

Gallus gallus

0.49

FSGSGSGTDFTFTIS

Ig Κ chain V-I region
Lay

f

P01605

108

Homo sapiens

5e-06

a

Cell adhesion, cell motility, opsonization, wound healing & cell shape maintenance
Plays a central role in muscle cells, probably by functioning as a large actin-cross-linking protein
c
Involved in attachment of the actin-based microfilaments to the plasma membrane; may also play roles in cell morphology & locomotion
d
Plays a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability; a mixture of histones H2B and H4 has antimicrobial activity against Gram-positive bacterium
M.luteus
e
Condensation of nucleosome chains into higher order structures
f
Used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses
b
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Table 3-2 cont’d.
B6

751.4

+2

VFGGGTKLTVL QPK

Ig Λ chain V-III region
LOI

g

B2

510.8

+2

VLASFGEAVK

Hemoglobin, β

h

B2

500.8

+2

PISGDPK

Microtubule-actin crosslinking factor 1

B6

522.8

+2

IMSIVDPNR

B5

506.2

+3

B1

683.9

B1

P80748

111

Homo sapiens

7e-05

P02130

146

Alligator
mississippiensis

0.27

i

Q9UPN3

5430

Homo sapiens

54

α-actinin-1

j

P05094

893

Gallus gallus

0.1

QEYDESGPSIVHR

γ-Actin

k

Q5JAK2

375

Rana lessonae

3e-05

+2

STDYGILQINSR

Lysozyme C

l

P00698

147

Gallus gallus

6e-04

503.3

+2

WDAW+ALK

Acyl-CoA-binding
protein

m

Q9PRL8

86

Gallus gallus

1.7

B4

509.8

+2

MLPMQK

Myeloid protein 1

n

P08940

326

Gallus gallus

36

B1

565.3

+2

LVTDVQEAVR

Proactivator polypeptide
(Containing Saposin-A,
B, C & D)

o

O13035

518

Gallus gallus

0.084

B2

646.9

+2

ISMPDFDLNLK

Neuroblast
differentiation-associated
protein AHNAK

p

Q09666

5890

Homo sapiens

0.001

B2

772.0

+2

AVASAAAALVLK

Talin-1

q

P54939

2541

Gallus gallus

0.026

g

Activates the alternative complement pathway by binding to the short consensus repeat domain 3 (SCR3) of factor H
Involved in oxygen transport from the lung to the various peripheral tissues
i
Cross-linking actin to other cytoskeletal proteins
j
Anchor actin to a variety of intracellular structures
k
Highly conserved protein involved in various types of cell motility
l
Enhances the activity of immunoagents
m
Displace diazepam from the benzodiazepine recognition site located on the GABA type A receptor. Diazepam binding inhibitor (32-86) has antibacterial properties
n
Cell derived leukocyte that is part of the immune system to fight against infectious diseases and foreign material
o
Lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases
p
Required for neuronal cell differentiation
q
Cytoskeletal protein in lymphocyte involved in connections of major cytoskeletal structures to the plasma membrane
h
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Table 3-2 cont’d.
Histone acetyltransferase
p300
Putative tropomyosin α-3
chain-like protein

r

B2

525.8

+2

LGTFLEN

B4

821.9

+2

V+QQQADDAEER

B6

587.3

+2

PP+PPARAA

Protein bassoon

t

B5

506.8

+2

PSLPSGVD

Stromelysin-1

u

B6

583.8

+2

AAGEIIAIPRR

v

B1

831.4

+2

NSWGTSWGEDGYFR

Envelope glycoprotein
gp160
Dipeptidyl-peptidase 1
(Cathepsin C)

B5

684.9

+2

FRTTMLQDSI

Origin recognition
complex subunit 2

x

B6

586.8

+2

LP EQGT SSR

Cadherin EGF LAG
seven-pass G-type
receptor 2

y

B6

593.3

+2

AILYNYWDK

Complement component
c3

z

B6

506.8

+2

NEALIALLR

Plastin-2

aa

r

s

w

Q09472

2414

Homo sapiens

36

A6NL28

223

Homo sapiens

0.006

Q9UPA5

3926

Homo sapiens

17

P08254

477

Homo sapiens

12

Q89607

852

HIV-2 B_EHO

0.011

Q60HG6

463

Macaca fascicularis

5e-07

Q75PQ8

576

Rattus norvegicus

0.014

Q9QYP2

2144

Bos Taurus

0.36

CAC69535

401

Crocodylus niloticus

0.50

P13796

627

Homo sapiens

0.79

Functions as histone acetyltransferase and regulates transcription via chromatin remodeling
Binds to actin filaments in muscle and non-muscle cells
t
Involved in the organization of the cytomatrix at the nerve terminals active zone (CAZ) which regulates neurotransmitter release
u
Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans
v
The surface protein gp120 (SU) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4
w
Plays a role in the generation of cytotoxic lymphocyte effector function; the central coordinator for activation of many serine proteases in immune/inflammatory cells
x
Component of the origin recognition complex (ORC) that binds origins of replication
y
Receptor that may have an important role in cell/cell signaling during nervous system formation
z
Plays a central role in the complement system and contributes to innate immunity
aa
Actin-binding protein; plays a role in the activation of T-cells
s
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Peptide sequences found using BLAST was used in a search of both the SwissProt and NCBI
databases. Of the peptides found by de novo sequencing, 81% matched similar proteins in the
two databases. The proteins were identified at single peptide level by observing the E-value,
which is a statistical value indicating sequence similarity and potential evolutionary
relationship.243 A low E-value indicates a statistically significant match. The peptides listed in
Table 3-2 are those returned from the BLAST search having the lowest three E-values (the
complete Table can be found in Appendix A). Notably, the organisms associated with the low Evalue peptides are close in homology to alligators, for example Chelonia caretta (turtle), Caiman
crocodilus (caiman) and Gallus gallus (chicken). Eleven of the thirty-two de novo sequences had
chicken protein sequences in the top three hits. Also, there were several identified proteins that
are associated with leukocytes and the immune system. However, the identification of
hemoglobin β suggests contamination from red blood cells during isolation of the leukocytes
from the whole blood. Other peptides in the table matched proteins that have not, to date, been
associated with the immune system.
To assess the quality of the protein matches, several factors were considered. First, the
number of peptides matching the protein was considered. For example, three of the de novo
sequences in Table 3-2 matched the protein fibrinonectin, which increases the confidence level
that a similar protein is present in the alligator leukocyte. The percentage of matching residues
was also considered. The de novo sequenced peptides matching fibrinonectin had 100%
sequence alignment with that protein. However, the sequence coverage was only 3%.
Last, a BLAST search was performed using a limited taxonomy containing birds and
reptiles. Limiting the taxonomy search reduced the random matches and resulted in lower Evalues for the protein matches compared to the full database search. This data is shown in the
supplementary material (Appendix A, Table 2).
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The proteins were grouped based on their functionality. Protein functions were divided
into six groups: other, cytoskeletal proteins, immune proteins, enzymes, DNA/synthesis proteins,
and unknown. Proteins involved in the cytoskeletal system, immune system, and other make up
the three most abundant groups of peptides with approximately 37%, 23% and 23% respectively.
De novo sequencing coupled with Mascot and BLAST searches aided in the identification
of 43 proteins that are similar to the proteins isolated from the alligator’s leukocyte extract. To
identify and characterize the function of the proteins derived from the de novo sequenced
peptides, two approaches were employed. First, if a protein was identified from more than one de
novo sequenced peptide in the same gel band, the protein and its function were assigned. Second,
de novo sequenced peptides with only one peptide matching a protein, the phylum of the
matched protein was considered. From the three highest E-values from the BLAST search, seen
in Table 3-2 (for the complete table, refer to Appendix A), E-values less than one were first
considered and the organisms associated with the protein hit were classified by biological
phylum and only animals were considered. Matched proteins that are from closely related
species, e.g. reptiles and birds, were moved to the top of the list. Of the de novo sequenced
proteins, 29% matched invertebrates 39% mammals, 18% birds, 6% amphibians, 5% fish and 3%
reptiles. Although proteins from invertebrates are highly represented, it should be noted that 81%
of the database proteins are associated with invertebrates. The taxonomic distribution of
vertebrate proteins in the Swiss-Prot database is 50% mammal, 25% fish, 10% bird, 9%
amphibian, and 6% reptile.244 This can be compared to 55% mammal, 27% bird, 8% amphibian
6% fish, and 4% reptile, thus bird proteins are overrepresented in the matched proteins and fish
proteins are underrepresented. This is consistent with evolutionary reports that birds have a close
phylogenetic relationship to crocodilians.245
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A putative function was assigned to the de novo sequenced proteins identified based on
the function of the matched proteins. The majority of the proteins identified in the alligator
leukocyte are common to proteins identified in leukocytes of other class of animals.
A range of proteins related to the immune system were identified. The identified
immune system proteins were fibrinonectin, histone H4, Ig kappa chainV-1 region, Ig lambda
chain V-III region, lysozyme C, acyl-CoA-binding protein, myeloid protein, cathepsin C,
complement component c3, ubiquitin, and polyubiquitin. The protein ubiquitin was identified
with 32% sequence coverage, the largest observed. This is consistent with previous reports
demonstrating that ubiquitin is a highly conserved protein in eukaryotes.246 Ubiquitin has several
functions such as the removal of damaged or unnecessary proteins and controlling other cellular
processes such as antigen processing, apoptosis, immune response and inflammation.247
Although it has several functions, it is related to the immune system. A de novo sequenced
protein matched lysozyme (Chelonia mydas) from residue 50 to 61. Lysozyme was one of the
first antibacterial proteins isolated from insects and is also a component of the humans innate
immune system.248 The complement C3 protein also plays a role in innate immunity in
organisms248, 249 and plays a major role in the activation of the complement system, which helps
to remove pathogens.249 A de novo sequenced protein matched histone (Gallus gallus), a class of
proteins that are involved in DNA packaging; however, they have been reported to behave as
antimicrobial agents.250
Several cytoskeletal proteins, myosin alkali light chain, myosin regulatory light chain, βactin, actin-2, actin-1, annexin V, annexin I, ras-related protein O-krev, vimentin-4, talin 1,
filamin-C, vinculin, microtubule-actin cross-linking factor 1, α-actinin-1, actin, plastin-2, and
putative tropomyosin γ-3 chain-like protein were identified. These were the major group of
proteins identified and play an important role in the function of leukocytes. Actin is the most
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abundant protein in all eukaryotic cells251 and is responsible for muscle contraction and cell
motility and works in conjunction with myosin protein through actin-myosin interactions.251, 252
Examples of cell movements include invasion of tissue by white blood cells to fight infection
and migration of cells involved in wound healing.252 Actin has multiple functions but is also
related to the immune system; it regulates the integrin function, which is important for
inflammation and immunity. Other identified cytoskeletal proteins, talin, α-actinin, plastin-2, and
filamin-C, also play a role in the actin cytoskeletal system.253-256 Variations of myosin and
tropomyosin proteins work along with actin to assist in phagocytosis of microorganisms.257
Annexins have various functions such as regulation of membrane organization and of Ca2+
concentrations within cells as well as participation in phagocytosis.258 Vinculin, another
cytoskeleton protein, is necessary for cell movement and changes in cell shape.259 Vimentin, a
filament protein, is involved in structural processes such as wound healing and is also found to
be secreted by macrophages.260 Also identified in this study was a ras-related protein; these
proteins are GTPases that are a part of the Ras superfamily of proteins and are involved in
regulating cell behavior such as cell growth and action.261
A class of enzymes known as endonucleases was also identified with high Mowse scores.
These enzymes are commonly found in bacteria and behave like an immune system: bacteria use
these enzymes to cut DNA from foreign material destroying them.262 Although endonucleases
are typically found in bacteria, alligator leukocyte may contain proteins that are similar to
endonuclease protein and play a similar role. Alkaline phosphatase is a key enzyme involved in
the process of dephosphorylation. It is also found to be involved in the protection against
endotoxins, which may be lethal after an infection.263
Three matched proteins are hypothetical proteins from the western clawed frog, (Xenopus
tropicalis), house mouse (Mus musculus), and chimpanzee (Pan troglodytes). The Pan
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troglodyte’s hypothetical protein had four matching peptide sequences suggesting that a similar
protein is expressed in the alligator leukocyte. However, the function of these hypothetical
proteins is not known and their relationship to the immune system cannot be determined.
There were proteins identified from the Mascot search that had a score greater than 57 but only
one matching peptide: lysozyme C and ras-related protein O-krev (Table 3-2). These proteins
cannot be identified with the same degree of confidence as the other proteins that had more than
one peptide matching the protein. The proteins characterized as other have not been previously
identified in leukocytes of other organisms. However, the E-values are high which suggests
limited sequence identity and evolutionary relationship.
3.4 Summary
In the work described in this Chapter, proteins from the leukocytes of the American
alligator (Alligator mississippiensis) were identified and their functions were characterized by
adopting a general proteomics approach. A three-step strategy was performed to identify similar
proteins in the gel bands and spots: de novo sequencing, Mascot search, and BLAST search.
Mascot search results identified eighteen proteins with sequence similarity to the alligator
leukocyte proteins. The identified proteins are common among eukaryotes and are associated
with the immune system. The BLAST search results showed that 81% of de novo sequenced
proteins matched similar proteins in the database. Among the identified proteins, the majority
were related to the cytoskeletal system.
The BLAST search identified proteins most closely related to vertebrates. Proteins
originating from birds, particularly chicken, were overrepresented in the matched proteins and
correlated with immune related proteins reported for other species. Fish species was the least
represented species among the matched proteins.
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CHAPTER 4. SMALL MOLECULE INTERFERENCES IN ALLIGATOR
MISSISSIPPIENSES LEUKOCYTE EXTRACT
In this chapter, experiments in which small molecule interferants in the leukocyte extracts
from Alligator mississippiensis were separated and purified using reversed phase liquid
chromatography are described. Seven bacterial species including Escherichia coli, Enterobacter
cloacae, Shigella flexneri, Klebsiella oxytoca, Salmonella, Staphylococcus aureus, and
Staphylococcus epidermidis were assessed for antimicrobial activity. The active fractions were
characterized using tandem mass spectrometry and X-ray crystallography. The results from the
mass analysis and X-ray crystallography suggest that the component exhibiting antimicrobial
activity was ethylenediaminetetraacetate (EDTA), the anticoagulant agent used during the
collection of the alligator blood. Tandem mass spectrometry data along with accurate mass
measurements suggests that the other small molecule interferant is spermine.
4.1 Introduction
Antimicrobial drug resistance is a growing problem. Numerous bacteria such as
Staphylococcus aureus, Salmonella, E. coli, Pseudomonas aeruginosa, and Streptococcus
pneumoniae have developed resistance to antibiotics.264 One of the most resistant bacteria
affecting hospital settings is Staphylococcus aureus: over 50% of its bacterial strains have
become resistant to penicillin.264, 265 Due to this problem, new antibiotics with broad spectra of
activity must be developed.
Studies have shown that when extracts of alligator leukocytes from blood are exposed to
bacterial pathogens, the growth of the bacteria is inhibited.266 Several anticoagulant agents that
prevent blood clotting are available, such as EDTA, heparin, citrate, and oxalate. EDTA is a
chelating agent that synergistically inhibits growth of bacteria with antimicrobial agents267 such
as

sulfamethoxazole,

trimethoprim,268

penicillin
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G,

ampicillin,

tetracycline,

and

chloramphenicol.269 Studies have shown that EDTA can also inhibit bacterial growth
independently.270 EDTA enhances the effectiveness of antibiotics against bacteria, particularly
gram-negative bacteria, and chelates Ca+2 and Mg+2 which disrupts the bridge between them and
lipopolysaccharide (LPS) in the bacterial outer membrane.267, 271
Peptides and small molecules have the potential for therapeutic use. Small molecules are
less costly and easy to synthesize and are stable, therefore longer half-life.272 However, small
molecules can potentially interact with multiple targets and accumulate in tissues causing
toxicity.272 Unlike small molecules, peptides are more specific and can be chemically modified
to make the peptide less susceptible to proteolysis in vivo.272
Another small molecule that exhibits antimicrobial activity is spermine. Spermine is a
biological polyamine that is found to be widely distributed in animal tissues.273 It has
antibacterial activity, providing resistance to a wide range of microorganisms such as S. aureus,
S. albus, and B. anthracis.273,
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Spermine was first isolated from semen and exhibits

antimicrobial activity against gram-positive microorganisms.275
In this chapter, we report that EDTA and spermine are present and isolated from
leukocyte extracts of alligators. These molecules can potentially cause interferences with the
activity measurements.
4.2 Experimental
Leukocyte extracts were obtained from the blood of alligators as described in Section 2.1.
In this study, which was the first studies performed on isolation of peptides from alligator
leukocytes, 0.1 mM EDTA was used as the blood anticoagulant.
A Bradford protein assay was used to determine the concentration of proteins in the
alligator leukocyte extracts. A 2 mg/mL quantity of bovine serum albumin (BSA) was used to
prepare five BSA dilutions from 125 to 2000 µg/mL. A 0.1% acetic acid buffer was used to
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perform the dilutions. Each standard and leukocyte protein extract was pipette into clean test
tubes and mixed with the protein dye reagent. The protein samples were assayed in triplicate and
incubated for 5 min before UV-Vis analysis. Absorbance was measured at 595 nm for both the
protein standard and leukocyte protein extracts. The concentration of the leukocyte protein
mixture was determined using a standard Bradford curve.276
The leukocyte extract was tested for antimicrobial activity before chromatographic
separation. A radial diffusion assay was used to monitor bacterial growth inhibition.277
Leukocyte extracts and chromatographic fractions of the leukocyte extracts were pipetted into
wells on the activity plate, incubated overnight at 37ºC, and zones of bacterial growth inhibition
were measured the following day.
Alligator leukocyte extracts were separated by reverse phase liquid chromatography (RPLC) and peak fractions were monitored with a photodiode array (PDA) detector and manually
collected in 2 minute intervals. For PDA detection, the UV spectrum was recorded between 190
and 400 nm. The fractions were tested for antimicrobial activity and the active fractions were
lyophilized and re-suspended in 0.01% (v/v) aqueous acetic acid. The fractions that exhibited
antimicrobial activity were injected onto the C18 reversed phase (RP) column using a gradient of
10–90% acetonitrile over 40 minutes for further purification and analyzed using ESI-TOF mass
spectrometry.
The purified fraction that exhibited antimicrobial activity was submitted for structural
characterization using X-ray crystallography. Tandem mass spectrometry (MS/MS) using the
nano ESI-Q-TOF was also performed to obtain structural information on the molecules.
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4.3 Resu
ults and Disccussion
4.3.1 Sep
paration of Leukocyte
L
Ex
xtract
The
T
alligatorr leukocyte was separrated into 335 fractionss using C188 reversed-pphase
chromato
ography (Fig
gure 4-1). The
T fractionss from the leeukocyte exxtract were ccollected annd the
initial fractions colllected within the first six minutess (labeled F
F2 and F3) were tested for
antimicro
obial activity
y.

4
Separattion of alligator leukocy
yte using reeversed-phasse separationn and moniitored
Figure 4-1.
between 190 and 400
0 nm.
The colleected fractio
ons F2 and F3 were furrther purifieed using RP
P chromatoggraphy as seen in
Figures 4-2
4 (A) and (B).
(
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Figure 4-2.
4 (A) Puriffication of Fractions 2 an
nd (B) Fracttion 3 using reversed-phase separatioon.
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4.3.2 Antimicrobial Activity
Results from this study showed that Fractions 2 and 3 exhibited antimicrobial activity
against Escherichia coli, Shigella flexneri, Salmonella, Staphylococcus aureus, and
Staphylococcus epidermidis (Table 4-1). When tested against Klebsiella oxytoca, a gramnegative bacterium, neither of the fractions exhibited activity. However, growth inhibition was
observed for Fraction 2 against Enterobacter cloacae, a gram-negative bacterium, but not for
Fraction 3. The largest antimicrobial activities from Fractions 2 and 3 were observed for
Staphylococcus epidermidis, a gram-positive bacterium; zones of inhibition were 17 and 14 mm
respectively. The lowest activity was observed in Salmonella, a gram-negative bacterium, at 5
and 4 mm respectively.
Table 4-1. Antibacterial activity of Fractions 2 and 3 from leukocyte extract against bacterial
species tested using radial diffusion assay.
Zone of Inhibition (mm)

Zone of Inhibition (mm)

(F2)

(F3)

Escherichia coli

10.0

5.0

Enterobacter cloacae

7.0

0

Shigella flexneri

6.0

5.0

Klebsiella oxytoca

0

0

Salmonella

5.0

4.0

Staphylococcus aureus

15.0

10.0

Staphylococcus epidermidis

17.0

14.0

Bacterial Strain

Both fractions exhibited antimicrobial activity towards both gram-negative and gram-positive
bacteria; however growth inhibition was highest for gram-positive bacteria.
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The
T negative control, 0.01% acetic accid, showed no antibacteerial activityy and the positive
controls, polymyxin B and synth
hesized EDTA
A and sperm
mine showedd antibacteriaal activity aggainst
d microbes.
the tested
4.3.3 ESII-MS Analyssis
ESI-MS
E
was used to analyze fractio
ons F2 and F3 as seenn in Figure 44-3 (A) andd (B).
Because of the high mass
m accuraacy of the ES
SI-TOF instrrument it waas possible too assign chem
mical
formulas to the peak
ks present in
n the mass spectrum.
s
Thhe ion at m//z 203.2250 was observved in
both fracctions F2 an
nd F3 and was the mo
ost abundannt ion preseent. The moolecular form
mula,
C10H26N4, for the mo
olecule meassured at m/z 203.2250 w
was confirmeed with a maass accuracyy of 6
ppm.

Figure 4-3.
4 ESI-MS of fractions (A) F2 and (B) F3 isolaated from allligator leukoocyte extract.
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Figure 4--3. cont’d.

Another intense peaak in Fraction 2 was at
a m/z 315.00807 with a mass accuuracy of 3 ppm,
correspon
nding to molecular
m
forrmula C10H16N2O8Na. H
However, thhis moleculle was abseent in
Fraction 3. This sugg
gests that th
his molecule could have contributedd to the antim
microbial acctivity
of Fractiion 2 becau
use growth inhibition was observved against Enterobacteer cloacae from
Fraction 2 but not fro
om Fraction 3.
Previous stud
dies have sho
own that anttimicrobial ccomponents isolated froom plants, innsects
and mam
mmals are offten peptidess with 12–60 amino aciids and havee masses lesss than 10 kkDa.24
The resu
ults from this study show
w that the antibacterial
a
properties oof the fractiions are eithher 1)
produced
d by small molecules
m
witth masses less than 400 Da, 2) produuced by largger molecules that
are preseent at conceentrations beelow the maass spectrom
meter detectiion limit, orr 3) produceed by
small and
d large moleecules acting synergisticcally (as nooted above) w
with the larger moleculle not
detected in the mass spectrometry
y analysis.
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Tandem
T
MS of the smaall moleculees identifiedd from MS analysis w
was performeed to
identify their structu
ure. Figure 4-4 shows the MS/MS
S data for the productt ions 315.11 and
203.2Da..

Figure 4-4.
4 Tandem mass spectrrometry dataa of (A) the m
m/z 315.1 ionn from Fracttion 2 and (B
B) the
203.2 ion
n from Fractions 2 and 3.
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The MS//MS results for the ion
n at m/z 20
03.2250 shoowed fragmeents previouusly reported for
sperminee, C10H26N4, by Q-TOF analysis.278 These fragm
ments are baased on the cleavages oof the
carbon an
nd nitrogen chain,
c
as seeen on Figuree 4-5.

4 Fragmen
ntation of speermine.
Figure 4-5.
The fragm
ments observ
ved from thee ion at m/z 203.2250 inn Figure 4-4 (B), for exaample 84.1 1112.1,
and 129.1, are characteristic of the
t fragmenttation patterrn of spermine ion. The tandem MS
S data
o
from
m the MS acccurate masss results. Reesults
are consiistent with the moleculaar formula obtained
from the MS/MS speectrum of thee ion at m/z 315.1
3
ion didd not allow ffor structuree assignmentt.
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4.3.4 X-rray Crystallo
ography
Fraction 2 waas dried and formed crysstals that weere analyzed using X-rayy crystallograaphy.
s
in the
t Cambriddge Structurral Databasee for organicc and
The crysstallographicc data was searched
organom
metallic comp
pounds and
d eight hits of possiblee structuress were geneerated, incluuding
phenylam
mmonium nitrate
n
(C6H8N2O3), ED
DTA disodiium salt (C
C10H18N2Naa2O10)n, 3a,44,7,7Tetrametthyl- (3aR,4
4S,6aR,10aS))-perhydronaaphtho(8a, 11-b)furan-2--one (C16H266O2), 7-Iodoo-2,9dimethyll-4,4-ethylen
nedioxy-11-o
oxatricycloun
ndec-2-ene

(C14H19I1O3),

7--Methoxy-4,,9,13-

trimethyll-6-oxa-1,13:10,11-diepo
oxytricyclotrridec-3-en-55-one (C16H20O5), catenna-((µ2-Benzene1,3-dicarrboxylato)-aq
qua-(propane-1,3-diamin
ne)-copper(iii)monohydrrate)
(C11H16Cu
C 1N2O5)n,n((H2O)),

catena-(tettra-sodium

bis(µ2-m
methylenediiphosphonatoo)-di-

copper(iii)dehydrate) ((C2H4Cu2O12P44-)n,4n(Na1+),2n(H
H2O)), and 33-(4-Methoxxybenzylidenne)-2oxo-2,3-d
dihydro-1H--imidazo(1,2
2-a)pyridiniu
umbromide (C15H13N2O2). Based on the crrystal
structure, seen on Fig
gure 4-6, and
d the crystal’s space grooup values, thhe structure was a best m
match
A disodium salt.
for EDTA

Figure 4-6.
4 Crystal structure
s
of EDTA
E
disod
dium salt obttained from aalligator leuukocyte extraact.
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4.4 Summary
In the work described in this Chapter, leukocyte extracts were subjected to purification
and characterization by LC ESI-MS, MS/MS and X-ray crystallography analysis. The results
from this study suggest that EDTA, a blood anticoagulant, in the presence of a protein might
contribute to inhibition of bacterial growth. In addition, previous studies have shown that EDTA
contributes to bacterial growth inhibition at both high and low concentrations.270 An alternate
explanation is that the antimicrobial activity resulted from a molecule that was not detected in
the mass spectrometry analysis. RP separation was capable of reducing the complexity of the
leukocyte protein mixture; however, the chromatographic fractions were still not sufficiently
pure to identify the specific molecules that contributed to antimicrobial activity. Additional offline RP separations assisted in small molecule purification and antimicrobial activity was
identified for fractions collected within the first six minutes. The masses of the small molecules
detected in the active fractions were measured by ESI-MS and the small molecules were
identified by empirical formula calculations based on accurate mass measurement. A molecule,
from the active fractions, F2 and F3 at m/z 203.2 had the formula, C10H26N4 with 6 ppm mass
error. In addition, tandem MS analysis revealed fragmentation patterns for this ion that matched
the molecule spermine. Another molecule from fraction F2 at m/z 315.1 (3 ppm accuracy) had
the formula C10H16N2O8Na and X-ray crystallography was used for further characterization
where results from the structural database identified the structure from the active fraction as
EDTA disodium salt.
The results from this study suggest that EDTA may not be a suitable anticoagulant agent
for isolation of blood proteins when testing for antimicrobial activity. As a result, for future
studies the anticoagulant agent heparin was used as a substitute. The other small molecule that
was identified was spermine, which is typically found in all animal cells and is usually excreted
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from semen and pancreatic tissue. Blood contains various proteins that are secreted or shed from
cells and tissues throughout the body.78 Therefore, it may not be possible to eliminate spermine
as an interferant, hence for the studies described in the following chapters, small molecules
eluting within the first six minutes from the leukocyte extracts were not considered as potential
candidates for antimicrobial molecules.
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CHAPTER 5. ISOLATION AND DE NOVO SEQUENCING OF ANTIMICROBIAL
PEPTIDES FROM LEUKOCYTES OF THE AMERICAN ALLIGATOR (ALLIGATOR
MISSISSIPPIENSIS)
The goal of the research in this chapter was to isolate novel peptides with antimicrobial
activity from American alligator blood (Alligator mississippiensis). Reversed-phase high
performance liquid chromatography (RP-HPLC) was used to separate and purify peptides from
leukocyte extracts and the HPLC fractions were checked for activity. A partially purified fraction
containing two major peptides at 4.7 and 4.9 kDa was tested for antimicrobial activity against E.
coli, E. cloacae, and K. oxytoca. The peptides were analyzed using ion mobility spectrometry
mass spectrometry. Matrix assisted laser desorption ionization time-of-flight/time-of-flight mass
spectrometry (MALDI-TOF/TOF) was used to generate MS/MS data for the peptides and de
novo sequencing was used to determine their sequence. The 4.7 kDa peptide was aligned to other
antimicrobial peptides and showed 36% sequence identity with Pilosulin 4 and the 4.9 kDa
peptide showed 33% sequence identity to SpStrongylocin 2.
5.1 Introduction
Increasing bacterial resistance to antibiotics has become the driving force behind the
development of new anti-infectives to replace or supplement conventional antibiotics.279
Antimicrobial proteins and peptides from natural sources show promise as new antibiotics.
Antimicrobial peptides (AMP) are important components of the innate immune system that have
been isolated in plants,280 vertebrates,281 and invertebrates282 and have potential for
pharmaceutical use. Most antimicrobial peptides are small (<10 kDa), cationic, lysine and
arginine containing molecules; however, some anionic peptides have also been reported.25
Cationic proteins and peptides have an affinity for microbe cell surfaces, which have negatively
charged groups. This attraction is dependent on electrostatic interactions and their tertiary
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structure.283 Cationic proteins and peptides vary in their size, structure, and mechanism of
action.283
In some vertebrates such as mammals and reptiles, antimicrobial proteins and peptides
are found in the blood, particularly in the neutrophils. There are several classes of antimicrobial
proteins and peptides associated with neutrophils, such as lactoferrin, cathelicidins, calprotectin
and defensins.283 Defensins are small cationic peptides around 4 kDa with a broad antimicrobial
activity against bacteria, fungi, viruses, and parasites.284 β-defensins serve as effector molecules
of innate immunity, providing an initial defense against infectious agents,285 and have been
identified in bovine neutrophils,286 turtle33 and avian leukocytes,287 and human plasma.288
Leukocytes in the blood of crocodilian species have a range of antimicrobial, antifungal, and
antiviral activity,1,

289, 290

but little is known about antimicrobial peptides in Alligator

mississippiensis.
There is limited information about reptile antimicrobial peptides. To date there are very
few reptilian antimicrobial peptide sequences identified among the nearly 400 that have been
reported from other sources.33, 36 The Alligator mississippiensis leukocytes have a broad range of
activity towards bacteria, viruses and fungi.1 Some studies have been performed to characterize
the proteins and peptides from alligator leukocytes;291 however, none have been sequenced.
De Novo sequencing is a common approach for mass spectrometry based sequencing of
peptides and proteins that are not in a protein sequence database. De Novo sequencing entails
identifying peptide sequences without any previous knowledge of the protein sequence.164
In this study, we isolated two novel peptides that exhibit antimicrobial activity from the
leukocytes of the American alligator (Alligator mississippiensis) using reversed-phase
chromatography separation. The peptides were sequenced using de novo sequencing and
compared to other known antimicrobial peptides.
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5.2 Experimental
5.2.1 Isolation and Extraction of Antimicrobial Peptides
Blood was drawn from farm and wild alligators ranging in size from 5 to 12 feet for
isolation of leukocytes using an approach described in Section 2.1.
5.2.2 Microbial Strains
All bacterial strains were obtained from American Type Culture Collection (ATCC). The
following bacterial strains were used: Escherichia coli (ATCC 43827), Enterobacter cloacae
(ATCC 23355), and Klebsiella oxytoca (ATCC 33496).
5.2.3 Antimicrobial Activity
The antimicrobial activity of the leukocyte extracts and the peptide fractions from HPLC
eluents were determined using an antimicrobial assay.278 Trypticase soy broth containing 1%
agarose was sterilized and 15 mL aliquots were transferred to centrifuge tubes. The nutrient
broth was inoculated with 20 µL of a log phase culture of bacteria and added to petri dishes.
Wells were cut into the petri dish using a sterilized pipette with a vacuum line attached for
suction. Five microliters of leukocyte extract dissolved in aqueous 0.1% acetic acid (v/v) was
added to each well and allowed to diffuse at room temperature for 3 hours. The plates were then
incubated at 37oC overnight and the zones of bacterial growth inhibition were measured. The
antibiotic polymyxin B at 2 × 10-5 M was used as a positive control and aqueous 0.1% acetic acid
(v/v) was used a negative control.
5.2.4 Peptide Separation
Leukocyte extract in 0.1% acetic acid was centrifuged to remove any insoluble residue. A
10 µL volume of concentrated sample was injected with an autosampler system onto a 0.3 × 1
mm trapping column on a LC system (Agilent) at a flow rate of 0.3 ml/min. The sample was
eluted onto a 2.1 × 30 mm, 3.5 µm particle size C18 column (Zorbax) and separated using a
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gradient of 5 to 60% B (80% acetonitrile (v/v) and 20% water (v/v) containing 0.1% formic acid
(v/v)) over 70 min with a flow rate of 0.3 mL/min. The eluent was monitored by UV absorbance
from 190 to 480 nm. A fraction collector was used to collect the eluent at timed intervals for
further characterization and activity studies.
5.2.5 Ion Mobility Mass Spectrometry
The peptide samples were diluted in 0.1% formic acid and injected on the nanoAcquity
ultra pressure liquid chromatography (UPLC) system at a flow rate of 500 nL/min. The peptides
were separated using a gradient of 3–40% B over 30 minutes. The peptides were ionized using a
nano-electrospray source, operated in positive ion mode and analyzed via a quadrupole mass
analyzer before being introduced to the ion mobility spectrometry (IMS) on the ESI-Q/IMS/TOF
MS. The quadrupole was operated in RF mode in order to record full mobility spectra and the
data was processed using MassLynx software. A pressure of 0.5 bar of nitrogen was maintained
in the ion mobility (IM) cell.
5.2.6 MALDI Mass Spectrometry
Alligator leukocyte fractions were mixed on a stainless steel plate using a 1:1 ratio of 1
µL sample and 1 µL saturated matrix including α-cyao-4-hydroxycinnamic acid (CCA) and 2hydroxy-5-methoxybenzoic acid (sDHB) matrix solution containing 0.1% v/v TFA for molecular
mass determination. The sample and matrix solution was air-dried at room temperature and
analyzed in TOF mode on the MALDI TOF/TOF MS. Mass spectra were recorded in reflector
positive ion mode with external calibration using a standard calibration mixture. Spectra were
500 shot averages collected using a mass range from 420–5000 Da. Masses were determined
using FlexAnalysis software. MS/MS data was obtained by LIFT/CID fragmentation. MS/MS
experiments were carried out in reflectron mode and more than 5000 laser shots were collected.
The MS/MS data were processed in FlexAnalysis.
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5.2.7 ESI Mass Spectrometry
The fraction containing the two peptides of interest was also analyzed on the ESI-QTOF.
The peptide sample was diluted twofold with 50% ACN solution containing 0.1% FA (v/v).
MS/MS experiments were performed on the selected parent ion and the collision energies were
varied from 25 to 60 eV in 5 eV intervals.
5.2.8 De Novo Sequencing and Sequence Analysis
De Novo sequencing of the peptide fragments generated using MALDI MS/MS was
performed with BioTools. The de novo sequencing results were verified manually. The peptide
sequences produced by de novo sequencing were aligned with β-defensins peptide sequences
from other vertebrates for sequence comparison.
The alligator antimicrobial peptide sequence was compared to other antimicrobial
peptides in the Antimicrobial Peptide Database.292 The alligator antimicrobial peptide was also
aligned to find the most similar peptides in the database.
5.3 Results and Discussion
5.3.1 Antimicrobial Activity of Leukocyte Extracts
The antimicrobial activity of the alligator leukocyte extracts was tested against three
species of bacteria. The leukocyte extracts exhibited antimicrobial activity against gram negative
bacterium E.coli, K. oxytoca, and E.cloacae with approximately 0.5 mm zone of inhibition.
5.3.2 Peptide Purification
Several RP separations were run to separate and collect the active peptides. The
separation of the peptide and protein mixture from the alligator leukocytes produced more than
12 fractions (Figure 5-1). The fraction collected at 15 min at 20% acetonitrile showed
antimicrobial activity against the tested bacteria. The deconvoluted masses from the ESI data
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(Figures 5-1B and 5--1C) showed
d at least thrree peptidess present in tthe active frraction at 46618.3,
4745.4, and
a 4961.9 m/z.
m

Figure 5-1.
5 (A) Thee leukocyte extract
e
in 0.1% acetic aacid was sepparated usingg RP-HPLC on a
C18 Vyd
dac column. (B) Mass spectrum of
o the bioloogically acttive fractionn eluted at 20%
acetonitrile. (C) Deco
onvoluted mass
m spectrum
m of the peptides eluted at 15% acettonitrile.
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Figure 5--1. cont’d.

In
n addition to
o the major peptides
p
iden
ntified in thhe active fracction, there w
were other m
minor
impuritiees in the lower mass range
r
which
h may suggeest the pressence of othher antimicrrobial
peptides in lower quaantities.
n Mobility Mass
M Spectro
ometry of thee Active Pepptides
5.3.3. Ion
The
T two pepttides from the
t alligator leukocyte eextract at 47745.4 and 4961.9 Da haave a
mass diff
fference of ~200
~
Da; theerefore, nan
no liquid chrromatographhy-ion mobility spectrom
metry
mass speectrometry (L
LC-IMS) waas used to separate them
m based on their chargee, size and shape.
The basee peak chrom
matogram seeen in Figurre 5-2 corressponds to m
multiple pepttides with siimilar
retention
n times, indiccating that th
hese two pep
ptides coelutte. Figures 55-3 and 5-4 sshow plots oof m/z
versus drrift time and m/z versus retention
r
tim
me of the ionns separated bby ion mobility.
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Figgure 5-2. Base peak
p
chromatog
gram of the nan
noflow LC-IMS experiment forr a mixture of ppeptides from allligator leukocyyte extracts.
Thee values above the peaks represent both the elu
ution time and m/z
m value for ions measured at thhe respective tim
mes.
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(A))

Figgure 5-3. (A) 2D
D Plot of m/z verrsus ion arrival time for active peptides
p
from leeukocyte extractt. (B) Ion mobillity drift times.
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Figure 5--3. cont’d.
(B)

The two peptides, frrom the RP fraction exh
hibiting antim
microbial acctivity, with similar reteention
a 18 min (seen
(
in Figu
ure 5-4B andd C) were seeparated in tthe IM cell bbased
times bettween 17.5 and
on their ion
i mobility drift times as
a seen in Fiigure 5-4A. T
The peptide ions were m
measured at m
m/z =
827.8 with a charge state of +6 and
a m/z = 94
49.9 with a ccharge state of +5. Thesse results inddicate
that thesee two peptid
des can be sep
parated on th
he basis of thheir net charrge.
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(A)

Figgure 5-4. (A) 2D
D plot of m/z verrsus retention time representing
g the coupling of
o nanoLC to ionn mobility separration. Circled iin red is the
separation of the 4.7 (top) and 4.9
9 kDa (bottom) peptide.
p
(B) Extracted ion chro
omatograms recoorded for the 4..7 kDa peptide aand (C) 4.9
kDaa peptide.
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Figure 5--4. cont’d.

(B)

(C)

The
T peptides measured at
a 4745.4126
6 and 4961.44771 Da thaat were sepaarated usingg IMS
were sub
bjected to MS fragmentaation. Howev
ver, insufficiient fragmennts from the parent ions were
generated
d; therefore, the MS dataa could not be
b used for dde novo sequuencing.
5.3.4 MA
ALDI MS/M
MS of Peptidees
Due
D to limitted fragmen
ntation from
m the ion-moobility specctrometry-maass spectrom
metry
analysis, the leukocy
yte fraction exhibiting antimicrobiaal activity w
was analyzeed using MA
ALDI
MS/MS. The two maajor peaks were
w
observeed at 4.7 andd 4.9 kDa (F
Figure 5-5A
A), which weere in
agreemen
nt with the ESI-MS
E
dataa (Figure 5-1
1). The peptiides at 4.7 aand 4.9 kDa were selecteed for
89

MALDI LIFT-MS/M
MS analysis (Figures
(
5-5
5B and 5-6C
C) and the priimary structture was obtained
for

thee

4.7

kD
Da

peptidee

via

dee

novo

ssequencing.

The

pepptide

sequuence

RDHRTK
KKLKKFDK
KSMMPECEKCKESKD
DFKKNKKT
was determ
mined for thee 4.7
TWECGA w
kDa pepttide using bo
oth automateed and manu
ual de novo sequencing.. Fragment iions predicteed for
the 4.7 kD
Da peptide sequence
s
weere confirmed
d in the masss spectrum sshown in Taable 5-1.

5 (A) MA
ALDI spectrrum of leuko
ocyte fractioon exhibitinng antimicrobial activityy. (B)
Figure 5-5.
MALDI LIFT-TOF/T
TOF spectru
um of the 4.7
7 kDa peptidde and (C) 4.9 kDa peptidde.
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Figure 5--5. cont’d.

Table 5-1. Fragmentt ions predictted and conffirmed in thee mass specttrum for the 4.7 kDa pepptide.
N-teerm
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Residue
R
D
H
R
T
K
K
L
K
K
F
D
K
S
M
M
P
E
C
E
K
C
K
E
S
K
D
F
K
K
N
K
K
T
W

y-series
4746.3921
4590.2910
4475.2641
4338.2052
4182.1041
4081.0564
3952.9614
3824.8665
3711.7824
3583.6874
3455.5925
3308.5241
3193.4971
3065.4022
2978.3701
2847.3296
2716.2892
2619.2364
2490.1938
2387.1846
2258.1420
2130.0471
2027.0379
1898.9429
1769.9003
1682.8683
1554.7733
1439.7464
1292.6780
1164.5830
1036.4880
922.4451
794.3502
666.2552
565.2075
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b-seeries
157..1084
272..1353
409..1942
565..2954
666..3430
794..4380
922..5330
10355.6170
11633.7120
1291 .8069
14388.8754
15533.9023
1681 .9973
17699.0293
19000.0658
2031 .1103
21288.1630
22577.2056
23600.2148
24899.2574
26177.3524
27200.3615
28488.4565
29777.4991
30644.5311
31922.6261
33077.6530
34544.7215
35822.8164
37100.9114
38244.9543
39533.0493
40811.1442
41822.1919
43688.2712

C-term
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5

Table 5-1. cont’d.
36
37
38
39

E
C
G
A

379.1282
250.0856
147.0764
90.0550

4497.3138
4600.3230
4657.3445
4728.3816

4
3
2
1

Mass tolerance: 0.5 Da
MS/MS tolerance: 0.5 Da
Bold represents ions found in the mass spectrum.
Peptides in the low mass range of the spectrum were absent due to inefficient fragmentation of
the 4.7 kDa peptide. However, the fragments in the higher m/z range correlated with the “b” and
“y” ions in the mass spectrum, and allowing the determination of the peptide sequence from the
C- to N-terminus.
The 4.9 kDa peptide was sequenced in a similar manner to the 4.7 kDa peptide and the
sequence obtained for this peptide is
MGAKTKWKRFRGLDTCVFFLLSCKKHCCLLHHTKGRNKTKAAV.
The peptide primary structure was determined based on the fragment ions in Table 5-2.
Fragments in the mass spectrum that were not present in either the b- or y-ion series for the 4.9
kDa peptide were predicted by the de novo software.
Table 5-2. Fragment ions predicted and confirmed in the mass spectrum for the 4.9 kDa peptide.
N-term
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Residue
M
G
A
K
T
K
W
K
R
F
R
G
L
D
T
C
V
F
F
L
L
S
C
K
K

y-series
4961.6449
4830.6044
4773.5829
4702.5458
4574.4509
4473.4032
4345.3082
4159.2289
4031.1339
3875.0328
3727.9644
3571.8633
3514.8418
3401.7578
3286.7308
3185.6832
3082.6740
2983.6056
2836.5371
2689.4387
2576.3847
2463.3006
2376.2686
2273.2594
2145.1644
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b-series
132.0478
189.0692
260.1063
388.2013
489.2490
617.3439
803.4233
931.5182
1087.6193
1234.6877
1390.7889
1447.8103
1560.8944
1675.9213
1776.9690
1879.9782
1979.0466
2126.1150
2273.1834
2386.2675
2499.3516
2586.3836
2689.3928
2817.4877
2945.5827

C-term
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19

Table 5-2
2. cont’d.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

H
C
C
L
L
H
H
T
K
G
R
N
K
T
K
A
A
V

2017.0695
1880.0106
1777.0014
1673.9922
1560.9081
1447.8241
1310.7651
1173.7062
1072.6586
944.5636
887.5421
731.4410
617.3981
489.3031
388.2554
260.1605
189.1234
118.0863

30822.6416
31855.6508
32888.6600
34011.7440
35144.8281
3651 .8870
37888.9459
38899.9936
40188.0886
40755.1100
4231 .2111
43455.2541
44733.3490
45744.3967
47022.4917
47733.5288
48444.5659
49433.6343

18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

Mass toleerance: 0.5 Da
D
MS/MS tolerance:
t
0.5 Da
Bold reprresents ions found in thee mass spectrrum.
5.3.5 ESII MS/MS off Peptides
ESI
E MS/MS experimentss were performed to colllect correspoonding sequuence inform
mation
on the peeptides from
m the fractio
on exhibiting
g antimicrobbial activity,, to overlap with the peeptide
sequencees obtained from
f
the MA
ALDI TOF/T
TOF experim
ments. The ioon measuredd at m/z 940.5 (5+
charge), was subjecteed to MS/M
MS fragmentaation and daata was acquuired using ddifferent colllision
energies. The specctrum generrated using 45 eV ccollision ennergy showss the folloowing
fragmenttation pattern
n in Figure 5-6.
5

Figure 5-6.
5 MS/MS of on the ion
n measured at
a m/z 940 w
with a 5+ chaarge.
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Incomplete sequence information was determined from the spectrum due to the lack of
fragmentation of the parent ion. Fragmentation with lower collision energies (e.g. 25 eV) and
higher collision energy (e.g. 60 eV) were the same. This data suggests that 1) the size of the
intact peptide is too large to fragment using low energy CID and 2) disulfide bond(s) may be
present which will stabilize the peptide structure and make it difficult to fragment.
5.3.6 Alligator Peptide Sequence Analysis
The alligator peptide sequence generated from the 4.7 kDa peptide was searched against
the antimicrobial peptide database for sequence similarity and it showed 36% sequence similarity
to Pilosulin 4, an antimicrobial peptide from an Australian ant and 33% sequence homology to
NA-CATH, a snake cathelicidins. The similarities between the antimicrobial peptides are seen in
Figure 5-7.
Ant Peptide Alignment
-Alignment Result-: P D + I T + K L N I K K L T K + + + A T C + K V I S K G A S M C K V L F D K + K K + Q
E + + +
--Input Sequence--: R D H R T K K L + + K K F D K S M M P E C E K + + C K + E S + + K + D F K K N K K T W
E C G A

Snake Peptide Alignment
-Alignment Result-: + + K R F K K F F K K + L K N S + + + + + V K + K R A K K F F K K P K V I G V T F P F
--Input Sequence--: R D H R T K K + L K K F D K + S M M P E C E K C K + E S K D F K K N K + K T W E C G A

Figure 5-7. Sequence comparison among antimicrobial peptides with alligator 4.7 kDa peptide.
Residues highlighted in blue represent identity in the sequence.
The alligator peptide sequence has low sequence homology when compared to antimicrobial
peptides from other species, including snakes, from the antimicrobial peptide database. This
suggests that the alligator sequence may function as an antimicrobial peptide based on its
antimicrobial characteristics but its sequence does not share strong homology to other reptilian
antimicrobial peptides.
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The 4.7 kDa peptide has a theoretical isoelectric point (pI) of 9.63 which is close to the
average pI of antimicrobial peptides which is 9.26.293 However, a high positive net charge is also
required for antimicrobial peptides to carry out their function. The 4.7 kDa peptide sequence has
a net charge of +8 at pH 5.5, indicating that it will also be cationic under in vivo conditions near
physiological pH. The cationic nature of antimicrobial peptides is conserved and it may be
essential for the initial electrostatic attraction to the phospholipid membrane of bacteria and
fungi.24
There are seven hydrophobic residues at positions 8, 11, 15, 16, 28, 35, and 39 and the
peptide may form an alpha helix. The total net charge, hydrophobic ratio, and Boman index for
the peptides were calculated using the antimicrobial peptide prediction server. The antimicrobial
peptide prediction server predicts whether a new peptide sequence has the potential to be
antimicrobial based on principles such as size, net charge, hydrophobic percentage and residue
composition. The system can also perform simple structural predictions, for example if
hydrophobic residues occur at every two to three residues in the peptide sequence an
amphipathic helix will be predicted.292
The Boman index is an estimate of the antimicrobial peptide’s potential to bind to other
proteins.294 A lower index value (≤1) indicates that the peptide will most likely have more
antibacterial activity with little side effects in vivo whereas a higher index value indicates that the
peptide is multifunctional.294 The sequence determined for the peptide measured at 4.7 kDa has
a Boman index of 3.8 kcal/mol. It also has an even number of cysteines which suggests that it
may form a disulfide-bond linked beta structure,292 similar to defensins. The percent
hydrophobicity of this peptide is 25%, which is similar to that for defensins;295 suggesting that
the peptide may have antimicrobial activity.296
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The sequence similarity search for the 4.9 kDa peptide showed 33% sequence identity to
SpStrongylocin 2 from sea urchin and Brevinin-2PTa from frog. The sequences of the peptides
can be seen in Figure 5-8.

Sea urchin Peptide Alignment
-Alignment Result-:
K F F G K T I L K A
--Input Sequence--:
K G R N K T + + K A

W
P
M
+

N
E
G
+

P
C
A
+

F
T
K
A

R
V
T
V

K
I
K
+

L Y R K E C N D V T S C D T V S G V K T C T K K N C C + + + H R
S
W K R F R G L D + T + C + + V F F L L S C + K K H C C L L H H T
+

Frog Peptide Alignment
-Alignment Result-: + G A I K D A L K + + + G A A K T + V A V E L L + + K K A Q C + + + + + K +
L E K T + + + C
--Input Sequence--: M G A + K T K W K R F R G + L D T C V + F F L L S C K K H C C L L H H T K G
R N K T K A A V

Figure 5-8. Sequence similarity between antimicrobial peptides with alligator 4.9 kDa peptide.
Highlighted in blue represent identical peptides.
Like the 4.7 kDa peptide, the sequence similarity with the alligator 4.9 kDa peptide to other
peptides in the database is low.
The 4.9 kDa peptide sequence has a net charge of +13 at pH 5.5 and a theortical pI of
10.26. The peptide has 19 hydrophobic residues, 2 Val, 5 Leu, 3 Phe, 4 Cys, 1 Met, 3 Ala, and 1
Trp and the percent hydrophobicity of the peptide is 44%. The peptide sequence of the 4.9 kDa
peptide contains an even number of cysteines; therefore it may form a disulfide-bond linked beta
structure similar to β-defensins. The Boman index for this peptide is 1.68 kcal/mol, which is
similar to defensins,295 suggesting that the peptide may have antimicrobial activity.294
5.4 Summary
Peptides and proteins were extracted from alligator leukocyte and the mixture was tested
for antimicrobial activity. The extract was separated, each fraction tested for antimicrobial
activity, and the peptides from the active fraction were sequenced using mass spectrometry and
de novo sequencing. Based on ESI and MALDI MS measurements, the masses of the
predominant peptides in the active fraction were found to be 4.7 and 4.9 kDa. The peptides were
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not separated by RP-HPLC; hence ion-mobility mass spectrometry was used to separate the
peptides by their size, mass, and charge for MS analysis and sequencing. Due to limited
fragmentation from IM-MS, MALDI MS/MS was used with de novo sequencing to determine
the sequence of the 4.7 kDa peptide. The putative sequence has 39 residues and a net charge of
+8 at pH 5.5 and the 4.9 kDa peptide has a putative sequence containing 43 residues and a net
charge of +13 at pH 5.5. Based on the peptide’s primary structures, size, cationicity, and its
predicted antimicrobial activity; the 4.7 and 4.9 kDa peptide properties are consistent with the
characteristics of antimicrobial peptides.
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CHAPTER 6. ISOLATION AND DETERMINATION OF THE PRIMARY STRUCTURE
OF A LECTIN PROTEIN FROM THE SERUM OF THE AMERICAN ALLIGATOR
(ALLIGATOR MISSISSIPPIENSIS)*
In this chapter mass spectrometry in conjunction with de novo sequencing for
determining the amino acid sequence of a 35 kDa lectin protein isolated from the serum of the
American alligator (Alligator mississippiensis) that exhibits calcium-dependent binding to
mannose is described. The protein was isolated from alligator serum using mannose affinity
chromatography and the N-terminal sequence was determined using Edman degradation.
Enzymatic digestion with trypsin, α-chymotrypsin, Lys-C, Glu-C, and Asp-N proteases was used
to generate peptide fragments for analysis by liquid chromatography tandem mass spectrometry
(LC-MS/MS). Separate analysis of the protein digests with multiple enzymes extended the
protein sequence coverage. De novo sequencing was accomplished using Mascot Distiller and
PEAKS software and the sequences were searched against the NCBI database using Mascot and
BLAST to identify homologous peptides. A 35 kDa protein was identified as an alligator lectin.
6.1 Introduction
Animal lectins comprise three major families: S-type lectins, P-type lectins, and C-type
lectins.297 S-type lectins (also known as galectins) are found in the cytoplasm and nucleus of
cells and sometimes on cell surfaces.298 This family of lectins is involved in cell adhesion and
plays an important role in normal development of multicellular animals.298 P-type lectins target
lysosomal enzymes in their subcellular compartment,299 and they differ from other lectins in that
they have the ability to recognize phosphorylated mannose residues. The C-type lectins bind to
carbohydrates in a calcium-dependent manner and are grouped into three classes: endocytic
lectins, collectins, and selectins.298
*The work reported in the chapter has been submitted to Comparative Biochemistry and
Physiology – Part B: Biochemistry & Molecular Biology. The protein sequence data reported in
this paper will appear in the UniProt Knowledgebase under the accession number P86928.
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Endocytic lectins are found in cell membranes and are specific for different sugars, for example
mannose, which is found on the cell surface of microorganisms.298 Endocytic lectins act as
opsonins, binding to the cell surface carbohydrates on microorganisms, stimulating phagocytisis
by leukocytes, and eventually death. Collectins function in a similar way to endocytic lectins;
they bind to microorganisms that have mannose glycans on their surfaces, leading to lysis of the
pathogen and activation of the innate immune system.297 Selectins direct the movement of
leukocytes to sites of inflammation.300 The importance of animal lectins is increasingly
recognized and studied because of their critical roles in host defense and potential for novel
medical applications.301
Among the family of animal lectins, the C-type lectin known as mannose-binding lectin
(MBL) has been well characterized in humans and some other animals.302, 303 Mannose-binding
lectin is a calcium-dependent protein found in the serum of mammals.304 This protein, which is
generated in the liver, tags the surface of bacteria making them susceptible to destruction.304 The
C-type lectin consists of a collagen-like domain which interacts with cells that have been
targeted by the innate immune system.305 Binding of MBL to target cells activates the serum
complement component of the immune system, which is an important element of innate
immunity305 and consists of a set of plasma proteins that attack extracellular pathogens.306
Complement proteins play an important role in innate immunity. The innate immune system can
identify foreign material by recognizing pattern receptors, such as mannose, that are found on the
surface of pathogens.306, 307
Another family of animal lectins that bind to carbohydrates in a calcium-dependent
manner is intelectins.307 Intelectins exhibit high sequence homology and have been identified in
many organisms including human,308 mice,309 frogs,310 trout,311 and ascidians.312 The principal
function of intelectins is to participate in cell differentiation,313 apoptosis,314 and recognize tumor
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antigens.315 However, they also recognize pathogens and bacterial components and have roles in
innate immunity.307 Hence, they behave similarly to C-type lectins.
Reptilian lectins such as those from lizards316 and snakes317 have been isolated and
characterized. However, limited information is available for alligator lectins. Alligators have a
potent immune system and their serum produces a broader antibacterial activity compared to
other vertebrates such as humans.318 Hence, characterization of lectins from alligator serum may
provide a better understanding of the structure-function relationship of their immune system.
Lectins from different species such as Turbo (Lunella) coreensis,319 Bubalus bubalis,320
Halocynthia roretzi,312 and Salmo salar321 have been isolated and identified using Edman
degradation and cDNA cloning.322-324 However, mass spectrometry is a more commonly used
tool for protein sequencing and identification.325 Tandem mass spectrometry (MS/MS) in
conjunction with separation techniques is a commonly used approach to sequence and
characterize proteins derived from complex mixtures.325 A recent study showed the use of mass
spectrometry to characterize the primary sequence of a galactose-binding lectin from the seeds of
a legume plant.326 In addition to this study, several other studies have been conducted that
demonstrate the utility of mass spectrometry for identifying lectin sequences.327-329
One of the major challenges in the study of alligator proteins is the limited information
available on the reptilian genome and proteome. For proteomic analysis of species with limited
proteomic data, de novo sequencing can be used to determine protein sequences.330 In typical de
novo sequencing methods, proteins are isolated and enzymatically digested, and the resulting
peptides are analyzed by tandem mass spectrometry. The sequence is determined by observing
the mass differences between fragment peaks in the tandem mass spectra that are generated by
fragmentation of the peptide of interest.331 De novo sequencing was previously used to sequence
peptides from proteins of the American alligator leukocytes.332
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In the present study, mannose affinity separation was used to isolate a 35 kDa lectin
protein from the serum of the American alligator (Alligator mississippiensis). Liquid
chromatography ESI-MS and MALDI-MS was used to obtain the mass of the intact protein. The
protein was digested using several different proteases. Peptide sequences were determined using
de novo sequencing. Database searching and BLAST search was also used to match peptides
with more than 50% homology. Using mass spectrometry and different enzymes independently,
peptides of different lengths were generated and aligned to determine the sequence of the
American alligator lectin.
6.2 Experimental
Proteins were isolated from alligator serum with affinity chromatography. Mannan
agarose (3 mL) was equilibrated with 3 mL of mixing buffer (10 mM Tris-HCl, pH 7.8, 1.25 M
NaCl) and allowed to settle into a column prepared from a Pasteur pipette plugged with cotton.
Fresh alligator serum (5 mL) was mixed with 5 mL of loading buffer (20 mM Tris-HCl, pH 7.8,
2.5 M NaCl). The diluted serum was allowed to filter through the column and the column was
washed with 10 volumes of loading buffer. The proteins were eluted with 5 mL of elution buffer
(10 mM Tris-HCl, pH 7.8, 1.25 M NaCl, 2 mM EDTA). The isolated lectin protein was
transferred to 10 kDa centrifugal concentrator tubes and centrifuged at 7500 g to concentrate and
desalt the sample. A portion of the concentrate was used for mass analysis before enzymatic
digestion.
The collected lectin samples were analyzed by reverse phase liquid chromatography (RPLC) ESI time-of-flight mass spectrometry (Agilent 6210) and matrix-assisted laser desorption
ionization time-of-flight/time-of-flight tandem mass spectrometer to obtain the mass of the intact
protein. For LC/MS, 10 µg of sample obtained from affinity separation was dissolved in 10 µl of
water containing 0.1% formic acid (FA) and loaded onto a C18 reverse phase column 5 µm 250 ×
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mm (Vydac) which had been equilibrated with 0.1% FA in water. A linear gradient from 0% to
60% of B over 60 minutes was used for protein separation. Solvent A was water containing 0.1%
FA and solvent B was acetonitrile containing 0.1% FA. The eluent from the LC column was
directed towards the mass spectrometer and mass spectra were acquired from 600 to 3000 m/z
using ESI at 4200 V. The spectra were extracted and deconvoluted using Analyst software.
The protein samples for MALDI analysis were deposited on a ground-steel target using a
1:1 ratio (v/v) of sample and saturated matrix solution. The matrices used were a 9:1 mixture of
2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid (sDHB) and 2,4-dimethoxy-3hydroxycinnamic acid (sinapinic acid, SA). The samples were analyzed in positive ion mode and
500 shots were collected. The mass spectra were collected using a mass range from 20 to 90
kDa. Exact masses from the spectra were determined using Bruker FlexAnalysis software.
One-dimensional SDS-PAGE was performed using pre-cast 4–20% polyacrylamide
gradient tris-HCl gels on the small format gel electrophoresis system. The samples were mixed
1:1 v/v with sample buffer containing 62.5 mM tris-HCl at pH 6.8, 2% SDS, 25% glycerol (w/v),
0.01% w/v bromophenol blue, and, in both the presence and absence of 10% 2-mercaproethanol
(v/v), heated at 95ºC in a water bath for 5 minutes before loading on the gel. Samples were run at
100 V for 1 h using tris-glycine (pH 8.3) as the gel running buffer. Gels were stained with
Coomassie blue for 1 h and rinsed twice with distilled water for 10 min (each time) to remove
the stain. The gel images were captured using the Gel Doc XR System and with BioRad Quantity
One 1-D analysis software. Samples were excised from the SDS polyacrylamide gel and
submitted for N-terminal sequencing by Edman degradation using a protein sequencer (Model
494, Perkin Elmer Applied Biosystems).
A purified alligator lectin (40 µg) was incubated in the presence of 40 µL of mannan-,
mannose-, D-lactose-, N-acetylgalactosmine-, N-acetylglucosamine-, and β-D-glucose-agarose.
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After 30-minute incubation at ambient temperature, the samples were centrifuged and a 20 µL
aliquot of the supernatant (containing the unbound protein) was subjected to SDS-PAGE. Onedimensional SDS-PAGE was performed and the gels were stained with Coomassie blue. The
experiment was repeated three times. The density of the bands, in pixels, was evaluated and
compared using ImageJ software.333
To obtain maximum sequence coverage, separate aliquots of lectin protein obtained from
affinity separation were subjected to several different enzymatic digestions. The protein fractions
were dissolved in a 100 mM ammonium bicarbonate buffer adjusted to the pH range in which
each endoprotease was most active. The protein was reduced using 50 mM DTT in 25 mM
ammonium bicarbonate buffer and incubated at 37ºC for one hour. Following reduction, the
protein was alkylated with 50 mM iodacetamide in 25 mM ammonium bicarbonate buffer for 45
minutes at room temperature in the dark. The in-solution digestions were performed separately
using trypsin, α-chymotrypsin, Lys-C, Glu-C, or Asp-N according to the manufacturer’s
protocol. Briefly, digestion with trypsin was performed using a 1:20 ratio of enzyme to substrate
in 100 mM ammonium bicarbonate, pH 8.5; with α-chymotrypsin using a 1:20 ratio at pH 8.5;
with Lys-C using a 1:20 ratio at pH 8.5; with Glu-C using a 1:20 ratio at pH 7.8; and with Asp-N
using a 1:50 ratio at pH 8.5. All digestions were run at 37ºC overnight. The enzymatic digests
were dried in a vacuum centrifuge and resuspended in 0.1% FA for LC separation.
Bands from the one-dimensional gels were excised and cut into ~1 mm cubes, and the
stain was removed with 200 mM NH4HCO3 and 40% acetonitrile (2×30 min). After destaining,
the gel pieces were dried in a vacuum centrifuge, rehydrated with 20 μL of 0.4 μg trypsin in 40
mM ammonium bicarbonate containing 9% acetonitrile to completely cover the gel pieces. The
tubes were then incubated overnight at 37°C.334 A similar approach was used for digesting the
protein gel pieces using α-chymotrypsin, Lys-C, Glu-C, and Asp-N proteases.335, 336 Peptides
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were extracted from gel pieces with 60% acetonitrile and 40% water containing 0.1%
trifluoroacetic acid (TFA). CNBr digestions were performed overnight with 1 M CNBr at room
temperature in the dark. The following day the CNBr digestion was dried completely using a
speed-vac and resuspended in water containing 0.1% FA for ESI analysis. FA digestions were
performed overnight at 37ºC.
Liquid chromatography electrospray tandem mass spectrometry (LC MS/MS) was used
to analyze the peptides derived from the in-gel and in-solution digests. The peptides were
dissolved in 20 µL of 0.1% FA and 10 µL of the digest was injected onto a 0.3 × 1 mm trapping
column (PepMap) on a nano-LC system (Ultimate,) at a flow rate of 10 µL/min. The peptides
were eluted onto a 75 µm × 15 cm C18 column (Biobasic) and separated using a gradient of 5 40% B over 90 minutes with a flow rate of 200 nL/min. The peptides were analyzed via a
quadrupole time-of-flight mass spectrometer (QSTAR) and ionized using a nano-electrospray
source at a voltage of 2.5 kV. The mass spectrometer was operated in information-dependent
acquisition (IDA) mode. Three collision energies (25, 38, and 50 eV) were selected to fragment
the peptides.
The peptide sequences were generated from MS/MS data using Mascot Distiller and
PEAKS software. The Mascot Distiller software determined amino acid sequences from MS/MS
data using-peak fitting and isotope distribution241 and PEAKS software computes peptides for
whose ions matches as many of the most abundant peaks in the spectrum.167 The de novo
sequencing results were also verified manually. De novo peptide sequences were searched using
Mascot and BLAST for protein identification based on homology searches. For Mascot and
BLAST search NCBI database were used to compare to peptide sequences derived from all
taxonomies.
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Figure 6-1.
6 SDS-PA
AGE analysiss of non-redu
uced and redduced alligattor lectin prootein on a 4––20%
gel. (A) Lane 1, mo
olecular weiight markerr; lane 2, noon-reduced alligator lecctin. (B) Laane 1,
moleculaar weight maarker; lane 2,, reduced allligator lectinn.
LC
L ESI-MS and MALD
DI-MS was performed to obtain thhe intact mass of the llectin
protein and
a oligomerrs. Figure 6-2a shows a LC separattion of the ccrude extracct of the alliigator
lectin and
d Figure 6-2
2b shows maass spectrum
m of the majoor peak that eluted at RT between 322 and
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35 minuttes. The decconvoluted mass
m
spectru
um of the m
major peak reeveals the avverage massses of
the eluted lectin protein to be 34.6, 69.3, 103.9, and 1338.6 kDa, coonsistent wiith the monoomer,
dimer, triimer and tetrramer of thee 35 kDa protein.

Figure 6-2.
6 (A) The chromatogrram of alligaator lectin elluted from a C18 reverseed phase collumn.
The lectiin protein waas eluted between 32 an
nd 35 minutees. (B) The mass windoow of the isootopic
distributiion for the prrotein massees.
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Figure 6-3 shows a MALDI mass
m
spectrum
m of the crrude extractt, the observved masses from
MALDI--MS analysiss were 34.7, 69.3, 104.0,, and 138.6 kkDa.

Figure 6-3.
6
Linear mode (+) MALDI maass spectrum
m showing the average masses oof the
oligomerrs from the 35
3 kDa alligaator lectin.
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peptides were produced from Asp-N digest. A less specific endoprotease, α-chymotrypsin, was
also used to obtain additional overlapping peptides. The endoprotease α-chymotrypsin produced
seven fragments that overlapped with fragments generated from trypsin, Asp-N, and Lys-C.
There was no additional sequence coverage obtained from the CNBr and FA digest.
Peptides obtained from the in-solution and in-gel digests of the 35 kDa band were de
novo sequenced. Figure 4 shows mass spectra for a Glu-C and tryptic digest of the protein to
illustrate peptide sequence determination. Figures 6-4a and 6-4b show examples of mass spectra
acquired at 57 and 58 min, respectively, in the separation of the Glu-C and tryptic digests.
Tandem MS data were collected and peptide sequences were determined via de novo sequencing.
Figures 6-4c and 6-4d illustrate the peptide fragment series generated from the MS/MS data
acquired from the ion 492.8 in Figure 4a and 743.8 in Figure 6-4 b. The sequences were searched
against the NCBI protein database using Mascot and no protein matches were found. The de
novo sequenced peptides were subjected to a BLAST search to identify proteins with similar
sequences. Peptide sequences found with BLAST exhibited strong similarity to intelectin-1 and
intelectin-2 proteins from mammals. Some of the lectin peptide sequences showed a high degree
of similarity to the intelectin peptides, with few amino acid differences; these regions of
similarity appear to be conserved among the lectins. The de novo sequenced peptides that did not
match peptides in the protein database with a high degree of similarity appear to be regions of
the alligator lectin sequence that are unique.
The peptides from the different enzymatic digests produced overlapping data that were
aligned to create the primary sequence of the protein (Figure 6-5). Partial protein sequences were
generated when peptide sequences from the different digests were overlapped. Multiple
alignments of the 35 kDa alligator lectin peptides with peptides of other lectin proteins provided
sequence positioning of the alligator lectin peptides.
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Figure 6-4.
6
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Figure 6--4. cont’d.
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NNQLALKLAA TGGSTNSLPA LALQNLLNTW EDTSCCSQTS PGQQSWPRDG AQDGLYTLST ADGEIYQTFC

DMSTHGGGWT LVASVHENNA HGKCTVGDRW SSQQGNSPLY PEGDGNWANN NIFGSAMGST SDDYKNPGYY

DLQAGDLSVW HVPDRAPLRK EMIESSVLLF YRTGFLSSEG GNLLRLYEKY PVKYGAGSCK VDNGPAVPIV

YDFGSAEKTA AYYSPSGRGE FTAGFVQFRV FNNEKAPMAL CSGLKVTGCN TEHHCIGGGG FFPEGNPRQC

GDFPAFDWDG YGTHQSWSTS REMIESSVLL FYR

Trypsin
Lys-C
Asp-N
Glu-C
α-chymotrypsin

Figure 6-5. Primary structure of the 35 kDa lectin protein isolated from American alligator
assembled from different endoprotease digestions. The peptide sequences were generated using
ESI-MS/MS. Peptides obtained from the different enzymes was highlighted using different
colors.
6.3.3

Binding Activity of Alligator Lectin
The alligator lectin-binding activity was determined for four carbohydrates, and the

results are shown in Figures 6-6A and 6-6B.
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6.3.4

Comparison of the 35 kDa Alligator Lectin Sequence with Other Animal Lectins
The alligator lectin sequence was compared with other calcium-dependent animal lectins,

specifically mannose-binding lectins and intelectins, from six other species: Homo sapiens, Mus
musculus, Rattus norvegicus, Pan troglodytes, Gallus gallus, and Xenopus tropicalis using
DIALIGN software. A sequence comparison for the lectin of the above organisms to the alligator
lectin sequence resulted in 13%, 3%, 1%, 5%, and 4% sequence similarity, respectively.
Sequence comparison of the alligator lectin sequence to intelectin-1 from Homo sapiens,
Mus musculus, Rattus norvegicus, and Xenopus tropicalis, exhibited 57%, 59%, 60%, and 57%
similarity respectively (Figure 6-7). A sequence comparison of the 35 kDa alligator lectin protein
was also made with intelectin-2 from Homo sapiens (58% identity) and Mus musculus (59%
identity). The degree of similarity of alligator lectin protein sequence to intelectin-2 sequence
(Appendix B, Figure 1) is close to that of the intelectin-1. Both mannose-binding lectin and
intelectin proteins bind in a calcium-dependent manner.307 However, sequence comparisons
suggest that the lectin protein isolated here is more closely related to intelectins rather than to
mannose-binding lectins.
For the human intelectin-1, residue 154 is the start of the consensus sequence (Asn-XThr/Ser) indicating a site of N-linked glycosylation. However, this site is not present in the
alligator lectin sequence, indicating that it lacks N-glycosylation at this site. There are several
possible sites of glycosylation in the alligator lectin sequence, for example at the serine and
threonine residues, suggesting that O-linkage is possible. BLAST search of the alligator lectin
sequence showed a conserved fibrinogen-related domain near the N-terminus region of the
sequence between residues 50 to 80. The fibrinogen related domain has been shown to be similar
to the calcium-dependent carbohydrate-recognition domains.338 Both mouse and human
intelectin-1 sequences have a fibrinogen domain between residues 32 to 251 and 32-255
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respectively. A comparison of the alligator lectin sequence to both mouse and human intelectin-1
fibrinogen domain sequences showed a high degree of sequence similarity (63% and 61%
respectively).

Mouse
Rat
Human
Frog
Alligator

MTQLGFLLFIMVATRG-----------------------CSAAEENLDTNRWGNSFFSSL
MTQLGFLLFLIVATRG-----------------------GSAAKEDLETNKGTHSFFDSL
MNQLSFLLFLIATTRG-----------------------WSTDEANTYFKEWTCSSSPSL
MLVYSLLVFALGFPAGHAGSCEQASISEKKEKILNLLACWTEDKTDNSGSRFSGSPTGDM
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.
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P---RSCKEIKQEHTKAQDGLYFLRTKNGVIYQTFCDMTTAGGGWTLVASVHENNMRGKC
S---RSCKEIKEENTGAQDGLYFLRTENGVIYQTFCDMTTAGGGWTLVASVHENNMGGKC
P---RSCKEIKDECPSAFDGLYFLRTENGVIYQTFCDMTSGGGGWTLVASVHENDMRGKC
SYGYRSCNEIKSSDPSAPDGIYTLATEHGESYQTFCDMTTNGGGWTLVASVHENNMFGKC
T----SPGQQSWPRDGAQDGLYTLSTADGEIYQTFCDMSTHGGGWTLVASVHENNAHGKC
.
* : .
* **:* * * .* *******:: *************: ***

94
94
94
120
94

Mouse
Rat
Human
Frog
Alligator

TVGDRWSSQQGNRADYPEGDGNWANYNTFGSAEAATSDDYKNPGYFDIQAENLGIWHVPN
TVGDRWSSQQGNRADYPEGDGNWANYNTFGSAEGATSDDYKNPGYFDIQAENLGIWHVPN
TVGDRWSSQQGSKAVYPEGDGNWANYNTFGSAEAATSDDYKNPGYYDIQAKDLGIWHVPN
TVGDRWSTQQGNTLQNPEGDGNWANYATFGLPEGATSDDYKNPGYYDIQAKNLALWHVPN
TVGDRWSSQQGNSPLYPEGDGNWANNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWHVPD
*******:***.
*********
** . .:**********:*:** :*.:****:

154
154
154
180
154

Mouse
Rat
Human
Frog
Alligator

KSPLHN--WRKSSLLRYRTFTGFLQHLGHNLFGLYKKYPVKYGEGKCWTDNGPALPVVYD
NSPLHS--WRNSSLLRYRTFTGFLQHLGHNLFGLYQKYPVKYGEGKCWTDNGPALPVVYD
KSPMQH--WRNSSLLRYRTDTGFLQTLGHNLFGIYQKYPVKYGEGKCWTDNGPVIPVVYD
NTPMFN--WRNSSILRYRTQNSFFTEEGGNLFELYKKYPVKYDIGKCLADNGPAVPVVYD
RAPLRKEMIESSVLLFYR--TGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYD
.:*:
..* :* ** ..*:
* **: :*:******. *.* .****.:*:***

212
212
212
238
212

Mouse
Rat
Human
Frog
Alligator

FGDARKTASYYSPSGQREFTAGYVQFRVFNNERAASALCAGVRVTGCNTEHHCIGGGGFF
FGDAQKTASYYSPYGQKEFTAGFVQFRVYNNERAASALCAGMKVTGCNSEAHCIGGGGFF
FGDAQKTASYYSPYGQREFTAGFVQFRVFNNERAANALCAGMRVTGCNTEHHCIGGGGYF
LGSAEKTSSLYSPNGRNEFTAGFVQFRVVNTEKAALALCPGVKVKGCNAEHHCIGGGGYF
FGSAEKTAAYYSPSGRGEFTAGFVQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFF
:*.*.**:: *** *: *****:***** *.*:*. ***.*::*.***:* *******:*

272
272
272
298
272

Mouse
Rat
Human
Frog
Alligator

PEGNPVQCGDFASFDWDGYGTHNGYSSSRKITEAAVLLFYR
PEGNPLQCGDFGAFDWNGYGTHIGYSSSREITEAAVLLFYR
PEASPQQCGDFSGFDWSGYGTHVGYSSSREITEAAVLLFYR
PEGSPRQCGDFSAFDWDGYGTHAGWSASKEITEAAVLLLYR
PEGNPRQCGDFPAFDWDGYGTHQSWSTSREMIESSVLLFYR
**..* ***** .***.***** .:*:*::: *::***:**

313
313
313
339
313

Figure 6-7. The Alligator mississippiensis 35 kDa lectin amino acid sequence was compared to
intelectin-1 protein of Homo sapiensis, Mus musculus, Rattus norvegicus, and Xenopus
tropicalis.
Previous reports show that many vertebrate lectins contain homologous amino acid
sequences.303 The 35 kDa alligator lectin sequence shows a high degree of similarity to
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intelectins; however, intelectin proteins are animal lectins that typically have an affinity to
galactose- and galactofuranose-binding C-type lectins and require calcium for carbohydratebinding activity.307 Although intelectins have been previously reported in other organisms, few
studies have identified their binding specificity. In this study, the 35 kDa protein identified as
alligator lectin had an affinity to mannose with a calcium-binding dependence. A previous report
indicated that a rainbow trout intelectin had a binding specificity for both N-acetylglucosamine
(GlcNAc) and mannose saccharides.311 The alligator lectin could be a similar intelectin-like
protein that has a binding specificity for mannose residues.
Intelectin proteins are oligomeric; for example, human intelectin-1 is a trimeric
protein.339 ESI and MALDI analysis (Figures 6-2b and 6-3) suggests that the alligator lectin is an
oligomeric protein that exists primarily as a 35 kDa monomer in vitro.
Mammalian intelectins usually have at least 10 conserved cysteine residues339 for
example as in human intelectin-1 (Figure 6-6); the 35 kDa alligator lectin sequence has nine
cysteine residues. It has cysteine residues at positions 35 and 36 at the N-terminus region that are
not present in the intelectin sequences of other vertebrates. Also, the alligator lectin sequence
lacks a cysteine at position 42 that is conserved in the other organisms. These cysteine residues
can influence tertiary protein structure, as well as carbohydrate-recognition specificity and
oligomer formation and structure. When comparing the sequence to those derived from other
vertebrates, the lack of a cysteine residue at position 41 in the alligator lectin sequence, as well
as the different locations of the other cysteine residues may result in lower thermal stability of
the protein.
In addition to the presence of the cysteine residues that allow for oligomers to form via
disulfide bonding, intelectins also have carbohydrate recognition domains.340 The calciumdependent carbohydrate-recognition domains are similar to the fibrinogen-like domain.
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Fibrinogen-like proteins typically contain fibrinogen domains at the C-terminal region in both
vertebrates and invertebrates.338, 341 An example of a human fibrinogen-like protein is ficolin.
Although ficolin does not show sequence homology to C-type lectins or intelectins, it plays a
vital role in innate immunity in a manner similar to the mannose-binding lectin.342 There are two
types of ficolins found in humans, ficolin-α which is a 326 amino acid protein and has a
fibrinogen terminal domain at residues 109 to 326, and ficolin-β, a 313 amino acid protein with a
fibrinogen terminal domain at residues 96 to 313.338 The alligator lectin sequence has low
sequence similarity to both the fibrinogen domains in human ficolin-α (16% similarity) and
ficolin-β (9% similarity) (Appendix B, Figure 2), suggesting that its carbohydrate-recognition
domain is different to that found in ficolin proteins. BLAST results for the alligator lectin
showed that it has a fibrinogen-related domain between residues 50 and 80, suggesting that its
carbohydrate recognition domain is near the N-terminal region of its sequence as previously
shown in the Halocynthia roretzi lectin from ascidian plasma.312
Binding studies were conducted with several carbohydrates leading to the conclusion that
the alligator lectin exhibits strong selectivity for both mannan and mannose, which functions as a
recognition molecule in the complement system. The alligator lectin showed some binding
activity towards D-lactose suggesting that the lectin may also bind to terminal galactose as
observed with intelectins from other organisms. The weak binding of the lectin observed in the
presence of β-D-glucose, N-acetylglucosamine, and N-acetylgalactosamine, suggests that the
lectin has limited binding specificities for these carbohydrates.
6.4 Summary
Sequence data collected from a 35 kDa protein isolated from the serum of Alligator
mississippiensis, using a mannose affinity column, indicated that it is a lectin protein comprising
approximately 313 amino acids. Mass spectrometry analysis of different enzymatic digests, from
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both in-gel and in-solution, was used to generate peptide sequences by MS/MS and de novo
sequencing as well as database searching with Mascot and BLAST. Using sequence alignment
tools, peptides from the lectin protein were aligned with lectin proteins from other vertebrates
and peptides from the different digests were overlapped to assemble the protein sequence.
The primary structure of the alligator lectin exhibited more than 50% similarity to human,
mouse, rat and frog intelectin-1 protein and less than 15% homology to mannose-binding lectin
from other vertebrates. Although the alligator lectin showed a higher degree of similarity to
intelectin protein, the differences of the conserved cysteine residues between the alligator and
other vertebrate intelectins may result in structural differences. Strong homology to the
fibrinogen-like domain of the alligator lectin was observed near the N-terminus region. There
were no putative N-glycosylation sites identified in the alligator lectin sequence; however it has
potential O-linkages. The isolated alligator lectin exhibited strong binding affinities toward
mannose and mannan as compared to other tested carbohydrates.
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CHAPTER 7. A MASS SPECTROMETRY APPROACH FOR THE STUDY OF
DEGLYCOSYLATED PROTEINS*
The work described in this chapter focuses on preparatory steps to remove salts and
buffers for mass spectrometry (MS) analysis after enzymatic or chemical deglycosylation. In this
work, the glycosylated protein fetuin and a lectin protein isolated from the serum of Alligator
mississippiensis were used to evaluate methods for desalting samples after an enzymatic or
chemical deglycosylation. Precipitation and dialysis were used to prepare the deglycosylated
samples for MS analysis. Both the precipitation and dialysis methods were suitable for sample
preparation prior to analysis by matrix assisted laser desorption ionization (MALDI) MS.
7.1 Introduction
Proteomics is the study of the structure and functions of proteins in an organism or tissue,
and mass spectrometry is now a routinely used method for protein identification in complex
mixtures.125 Prior to a typical mass spectrometry analysis, separation techniques such as twodimensional gel electrophoresis and high performance liquid chromatography (HPLC) are used
to reduce the complexity of protein mixtures.125, 325
Some proteins are post-translationally modified to help regulate gene expression, protein
turnover, and cellular structure.343 Glycosylation is a common post-translational modification
that is involved in biological functions such as immune recognition and inflammation.344 There
are two major types of protein carbohydrate linkages: N- and O-linked glycosylation. With Nglycosylation, the glycan is attached to an asparginine residue followed by any amino acid other
than proline, which is linked to a serine or threonine residue. During O-glycosylation, the glycan
is attached to a serine or threonine residue. Glycoproteins have been characterized by mass
spectrometry, but this is challenging due to the heterogeneity of the carbohydrate moieties and
*Reprinted by permission of the Elsevier. The work reported in this chapter has been
published in the Microchemical Journal.4
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the complexity of the resulting mass spectra.345 Glycosylation of the protein may also limit the
extent of proteolytic digestion. To avoid this, the N- and/or O-linked carbohydrates can be
removed prior to analysis.346, 347
Enzymatic or chemical removal of the glycan can be used for analysis of the protein
without the attached oligosaccharides. An enzymatic approach using peptide: N-glycosidase
(PNGase F)204 and a chemical approach using trifluoromethanesulfonic acid (TFMS) have been
used to remove the oligosaccharides.205,

348

PNGase F is an enzyme that removes N-linked

oligosaccharides, leaving both the protein and oligosaccharides intact for further analysis. There
is no enzyme that cleaves O-linked oligosaccharides. TFMS is a non-specific deglycosylating
agent that cleaves both N-linked and O-linked oligosaccharides to leave the intact protein.349
The proteins used in this study were enzymatically or chemically deglycosylated
followed by matrix assisted laser desorption ionization (MALDI) MS. The steps for both
chemical and enzymatic deglycosylation have been reported previously,205,

350, 351

but the

deglycosylated product requires cleanup prior to MALDI mass spectrometry. We have developed
important sample desalting procedures that follow deglycosylation prior to mass spectrometry
analysis, which are not clearly outlined in many procedures. This study focuses on the treatment
of deglycosylated proteins for mass spectrometry analysis.
7.2 Experimental
7.2.1 Materials
Fetuin, a plasma glycoprotein produced by the liver, was obtained from Sigma-Aldrich
and the lectin protein was isolated from the blood plasma of Alligator mississippiensis. Blood
from seven American alligators was collected, heparin added for anticoagulation, and the blood
allowed to clot overnight at ambient temperature. The serum was collected and the lectin was
isolated using mannan-agarose affinity chromatography.
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7.2.2 Enzymatic Deglycosylation
Proteins containing oligosaccharides attached through N-linked glycosylation were
deglycosylated as described in Section 2.9. Approximately 100 µg of protein was dissolved in 18
µl of nanopure water. Denaturing buffer (2 µl), containing 0.6 mg/mL SDS and 0.5 mg/mL DTT,
was added and heated at 100ºC for 10 minutes to increase the rate of deglycosylation. The
sample was incubated on ice at 0ºC for five minutes and centrifuged for 10 sec. To the denatured
sample, a non-ionic detergent (NP-40) was added to prevent loss of enzyme activity. The
PNGaseF enzyme was added to the sample and it was incubated at 37ºC for four hours.204, 352
The intact protein was isolated from the mixture via protein precipitation, which removed the
buffers that can interfere with the MALDI signal. Acetone or trichloroacetic acid (TCA) was
used to precipitate the protein.353
7.2.3 TCA Precipitation
TCA precipitation was accomplished by the addition of one volume of 60% TCA. The
sample was gently vortexed and incubated on ice overnight. The sample mixture was centrifuged
at 10,000 g for 30 min and the supernatant was removed. Chilled acetone was added to wash the
precipitate and it was centrifuged again at 10,000 g.80 This procedure was repeated twice. The
precipitate was air-dried and suspended in aqueous 0.1% trifluoroacetic acid (TFA) or 0.1%
formic acid (FA) for MALDI analysis.
7.2.4 Acetone Precipitation
Acetone precipitation was achieved by the addition of four volumes of acetone to the
protein sample, followed by an overnight incubation on ice. The sample was centrifuged at
10,000 g for 30 min at 4ºC. The supernatant was removed and the precipitate was air dried for 30
min, then suspended in the same buffer as used above in the TCA precipitation.
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7.2.5 Chemical Deglycosylation
In-solution deglycosylation was performed using a deglycosylation kit (Prozyme)
containing trifluoromethanesulphonic acid (TFMS). TFMS removes most glycan types from
glycoproteins and leaves the protein intact.205 Briefly, approximately 0.3 mg of protein in a vial
was dried overnight using a lyophilizer. The dried protein was capped with a septum and placed
on a dry ice-ethanol bath for 20 seconds to reduce the temperature of the reaction. A mixture of
TFMS and toluene solution was prepared and 50 µl was slowly added using a gas-tight syringe.
Precautions were taken to prevent the dried protein from being exposed to moisture due to the
potential for hydrolysis of the peptide bonds.205, 354 The vials containing the protein with TFMS
mixture were incubated at -20ºC for five minutes then shaken briefly to help dissolve the protein.
The solvation process was repeated and followed by a four-hour incubation at -20ºC.
7.2.6 Dialysis
Dialysis was performed prior to mass spectrometry analysis. After the four-hour
incubation, the vials containing the samples were placed in a dry ice-ethanol bath for 20 seconds,
and then 150 µl of pyridine solution was added to each vial. The vials were incubated on dry ice
for five minutes, and then in a dry ice-ethanol bath for 15 minutes. A 400 µl quantity of 0.5%
ammonium bicarbonate was added to each vial to neutralize the sample. Following
deglycosylation, the protein was isolated using dialysis. Each sample was added to a dialysis
cassette (Thermo Scientific, Rockford, IL, USA) and dialyzed against 10 mM ammonium
formate for two hours at room temperature. The buffer was changed and dialysis was continued
for an additional two hours. After a final buffer change, the sample was dialyzed overnight at
room temperature.

121

7.2.7 Mass Spectrometry
Glycoproteins and deglycosylated proteins were analyzed in linear MS mode with the
Bruker UltrafleXtreme MALDI mass spectrometer. The glycoproteins and the deglycosylated
proteins (after dialysis or precipitation) were mixed on a steel target using a 1:1 ratio of sample
and saturated matrix solution. The matrices used were 2-hydroxy-5-methoxybenzoic acid
(sDHB) and 2,4-dimethoxy-3-hydroxycinnamic acid (sinapininc acid, SA). The samples were
analyzed in positive ion mode and 500 shot averages were collected using a mass range from 30
to 100 kDa. Masses were determined using FlexAnalysis software.
7.3 Results and Discussion
Two methods were used for deglycosylation: PNGaseF and trifluoromethanesulfonic
acid. The N- and O-linked glycoprotein protein, fetuin, was enzymatically deglycosylated to
remove N-linked oligosaccharides and chemical deglycosylation was used to remove both Nand O-linked oligosaccharides. Fetuin is a glycoprotein with 359 amino acids containing Nlinked glycosylation sites at Asn 99, 156 and 176, and numerous O-linked glycosylation sites.355
As seen in Figure 7-1a, a mass of 45.3 kDa was measured for fetuin before deglycosylation
which is consistent with previous studies.356 The deglycosylated fetuin was analyzed with
MALDI after deglycosylation with PNGaseF and no further cleanup. No signal was observed
possibly due to buffers used during the deglycosylation. Using acetone and TCA precipitation
independently, the protein was separated from the PNGaseF released oligosaccharides. The
deglycosylated protein from the pellet of fetuin gave a 39.5 kDa in the mass spectrum and was
compared with the glycosylated fetuin using MALDI and a mass shift of 5.8 kDa was observed
in the mass spectrum (Figure 7-1b). Both acetone and TCA precipitation yielded sufficient
protein recovery for MALDI analysis and the MALDI results were comparable.
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Figure 7-1.
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ALDI spectraa comparing glycosylatedd and deglyccosylated fettuin after acetone
precipitattion, (c) fetu
uin after TFM
MS deglycossylation folloowed with ddialysis.
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Figure 7--1. cont’d.
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Figure 7-2.
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CHAPTER 8. CONCLUSIONS AND FUTURE DIRECTIONS
In this dissertation, mass spectrometry based proteomics was used to study the alligator
blood proteome. Proteins and peptides found in the leukocyte extracts from the alligators were
identified using gel electrophoresis techniques, liquid chromatography, and mass spectrometry
sequencing, including bottom-up and top-down sequencing. Several peptides and proteins with
immunological functions, including lectin and antimicrobial peptides were isolated and
identified. The significance of this work lies in that it provides insight on the function and
evolution of both innate and adaptive immune systems of crocodilians.
In Chapter 3, the proteome of the leukocytes was investigated because they are one of the
most important cells in the body to participate at the site of an infection and play an important
role in innate immunity. A 1- and 2-D gel electrophoresis system was used to separate leukocyte
proteins, and enzymatic digest of the protein bands and spots using trypsin was applied to cleave
the proteins to peptides for peptide sequencing. Using Mascot, a comparison was made between
the experimentally observed fragment ions and the predicted fragments for all hypothetical
peptides of a particular mass. From the MASOT search, 17 proteins were identified based on
sequence homology. For MS/MS data that did not match any proteins in the database, peptide
sequences were determined using de novo sequencing. Using the de novo sequencing results, 23
proteins were identified based on peptide matching using BLAST.
To further investigate peptides from the acidic leukocyte extracts that exhibited
antimicrobial activity, a series of separations and antimicrobial tests were performed. Using
reversed-phase chromatography, the leukocyte extracts (which consisted of a mixture of peptides
and proteins) were separated, collected, and tested for antimicrobial activity. The initial eluents
collected within the first 10 min exhibited activity and were further characterized using mass
spectrometry and X-ray crystallography for identification, which was described in Chapter 4.
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Small molecules less than 500 Da were identified, and the results indicated that the
anticoagulant, EDTA, which was used during the blood collection, may have contributed to the
antimicrobial activity. Due to the antimicrobial activity interferences from EDTA used in the
work in Chapter 4, heparin was used as an alternative anticoagulant for the studies described in
Chapter 5.
To investigate the specific peptides and proteins from the alligator leukocytes that exhibit
antimicrobial activity, peptides and proteins isolated from alligator leukocyte extracts were
separated by reversed phase chromatography as described in Chapter 5. The antimicrobial
activity of the peptides from the chromatographic fractions was tested for growth inhibition of
various microbes to determine the antimicrobial spectrum of the peptides. Among the microbes
studied, growth inhibition was observed for E. coli, E. cloacae and K. oxytoca indicating that the
antimicrobial peptides from the alligator are active against gram-negative bacteria. Within a
fraction that exhibited antimicrobial activity, two peptides at masses 4.7 and 4.9 kDa were
identified using mass spectrometry. Due to the close mass of the peptides, ion mobility was used
to determine whether the peptides can be separated based on their charge, size and shape. The
separated peptide was analyzed using tandem mass spectrometry; however, limited sequence
information was determined due to incomplete fragmentation. Therefore, the peptides were
subjected to MALDI MS/MS for sequencing. Peptide sequences were determined using de novo
and manual sequencing. From this work, the first antimicrobial peptides were isolated and
partially characterized from Alligator mississippiensis and showed to have a net charge of +8 and
+13 respectively at pH 5.5, indicating that they are cationic. Based on size and charge, these
peptides exhibit strong characteristics similar to previously identified antimicrobial peptides.
In Chapter 6, another class of immunological proteins, lectins, was studied which
provides insight on the structure-function relationship of another class of proteins involved
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within crocodile’s innate immune system. A new calcium-dependent binding lectin protein was
isolated from the serum of the Alligator mississippiensis by affinity chromatography using
mannose columns. The sequence of this novel class of proteins from the blood serum of the
alligator was determined with mass spectrometry and Edman sequencing and was used for
homologous comparison with other lectins. Molecular masses of the isolated lectin were
determined by ESI-MS and were found to be oligomeric which are consistent with the monomer,
dimer, trimer and tetramer of the 35 kDa monomer lectin protein. The monomeric protein was
enzymatically digested using four different proteases, creating small and large peptides, which
were overlapped to enhance protein sequence coverage. The primary sequence of a novel lectin
protein isolated from Alligator mississippiensis was determined, and its binding specificity to
selected carbohydrates was studied.
An approach to analyze proteins that have been glycosylated also was evaluated. In
Chapter 7, preparatory steps used after deglycosylation procedures and before mass spectrometry
analysis were described. Here, glycosylated proteins, fetuin and alligator lectin, were
deglycosylated and methods for sample desalting and concentrating, such as precipitation and
dialysis were used. The dialysis and precipitation methods were both suitable for sample
preparation prior to MS analysis. A comparison between precipitation and dialysis procedures
showed that precipitation methods produce higher protein signal, indicating a larger protein
recovery.
One of the future directions is to investigate other properties of the peptides, other than
bacterial properties. Some antimicrobial peptides have shown to have anti-inflammatory,
antifungal, antiviral and anti-tumor activity, so these properties should be investigated. Prior
work showed that the crude leukocyte extract exhibited antimicrobial activity, so it is
hypothesized that the activity may be due to multiple peptides. Therefore, the alligator leukocyte
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extract should be further investigated for other antimicrobial peptides or proteins, other than the
two peptides isolated in this work and their antimicrobial activity should be characterized,
including the minimal inhibitory concentration (MIC) and the antimicrobial spectrum.
The interaction of alligator antimicrobial peptides in the presence of microbes should also
be investigated using a technique such as atomic force microscopy (AFM). This study can help
provide an understanding of how alligator antimicrobial peptides affect bacterial cells. This
effect may be based on the different models proposed as discussed in Section 1.1.1., for example,
the carpet model, where peptides cover the membrane like a carpet and destroy the bacteria lipid
bilayer.357 By reducing the AFM cantilever size to approximately 1000 times smaller than the
normal size, the imaging speed can be increased without destroying the bacteria.358 The bacteria
can be immobilized on poly-L-lysine coated cover slides (which will provide stronger cell
adhesion) and imaged in aqueous solution to keep the cells alive. Alligator antimicrobial peptide
can be added to the liquid droplet comprised of bacteria, at a concentration above the minimal
inhibitory concentration (MIC) to acquire images.359 It is also necessary to evaluate the
antimicrobial peptides presented in this dissertation for their suitability in commercial products,
such as topical creams. They can be added to existing products to enhance the antimicrobial
activity of the product and/or they can potentially be used as an antiseptic cream for cuts or an
antifungal cream for infections such as athlete’s foot.
The research in this dissertation also showed that lectin proteins are present and can be
isolated from alligators. Therefore, additional studies should be performed to further characterize
the identified lectin in this work, such as investigating the temperature and pH effect, and the
effect of the identified alligator lectin on bacteria induced hemagglutination activity; which will
indicate whether or not the lectin protects against bacterial induced erythrocyte damage. Because
carbohydrates play a vital role in biological processes and diseases, lectins can be used to
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identify certain diseases. Depending on the specificity of the alligator lectin it can potentially be
used as a means to identify a particular disease state. Finally, antibodies against the alligator
lectin discussed in this work can be prepared and used for isolation of lectins from other
crocodilian species. This will provide more insight on lectins and their function within
crocodilian species.
Lastly, an exhaustive MS-based proteomics study should be performed to map all the
proteins involved in the alligator’s immune system. The immune system is complex and made of
several types of cells and proteins that play different roles in fighting infections. Therefore, a
more comprehensive study of the structure-function relationship of the immune related proteins
will help provide a better understanding of crocodilian immunity as well as provide more insight
on the evolutionary development of reptile’s immune system.
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APPENDIX A. PROTEINS MATCHED FROM DE NOVO SEQUENCING
The peptide sequences in the table were generated from MS/MS data using de novo sequencing. De novo peptide sequences were
subjected to database searching using BLAST to find proteins that contain sequences matching with the determined de novo
sequences. The results were used to identify biological components that comprise the alligator leukocyte proteome (Chapter 3, Section
3.3).
Table A.1. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from gel digest were
searched using BLAST and proteins were matched based on sequence similarity and evolutionary relationship using the SwissProt and
MSDB database. The top three E-values are reported.
Band
Number

B4

B4

m/z

1060.6

536.3

Charge

De novo Sequence

Protein

Accession Number

Protein
Length

Organism

E-Value

+2

EINLSPDSTSAVVSGLMVATK
EINLSPDSTSAVVSGLMVATK

Fibronectin

P11722.3

1256

Gallus gallus

2e-11
(1st hit)

EINLSPDSTSAVV+GLMVATK

Fibronectin

Q91289.1

1328

Pleurodeles waltl

9e-11
(2nd hit)

EINLSPDSTS +VSGLMVATK

Fibronectin

P04937.2

2477

Rattus norvegicus

7e-10
(3rd hit)

YEVSVYALK
YEVSVYALK

Fibronectin

P07589.4

2478

Bos taurus

0.33
(1st hit)

YEVSVYALK

Fibronectin

P11722.3

1256

Gallus gallus

0.33
(2nd hit)

YEVSVYALK

Fibronectin

P11276.3

2477

Mus musculus

0.33
(3rd hit)

YEVSVYALK

Fibronectin

P04937.2

2477

Rattus norvegicus

0.33
(4th hit)

YEVSVYALK

Fibronectin

Q91289.1

1328

Pleurodeles waltl

0.33
(5th hit)

+2
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B4

701.3

+2

YEVSVYALK

Fibronectin

Q28275.2

522

Canis lupus familiaris

0.33
(6th hit)

YEVSVYALK

Fibronectin

Q28377.2

522

Equus caballus

0.33
(7th hit)

YEVSVYALK

Fibronectin

P02751.4

2386

Homo sapiens

0.33
(8th hit)

YEV+VYALK

Fibronectin

Q91740.1

2481

Xenopus laevis

1.9
(9th hit )

Y+VSVYA

Collagen alpha-1(XII)
chain

Q60847.3

3120

Mus musculus

117
(10th hit)

Y VS+YALK

RNA 2-thiouridine
synthesizing protein B

NP_240337.2

95

Buchnera aphidicola

117
(11th hit)

YEVSVY

Neuronal acetylcholine
receptor subunit β-4

NP_434693.1

495

Rattus norvegicus

117
(12th hit)

YEVSVY

Neuronal acetylcholine
receptor subunit β-4

NP_000741.1

498

Homo sapiens

117
(13th hit)

YEVSVY

Neuronal acetylcholine
receptor subunit β-4

NP_683746.1

495

Mus musculus

117
(14th hit)

YQINQQWER
YQINQQWER

Fibronectin

P07589.4

2478

Bos taurus

0.013
(1st hit)

YQINQQWER

Fibronectin

P11276.3

2477

Mus musculus

0.013
(2nd hit)

YQINQQWER

Fibronectin

Q91740.1

2481

Xenopus laevis

0.013
(3rd hit)

YQINQQWER

Fibronectin

P04937.2

2477

Rattus norvegicus

0.013
(4th hit)

YQINQQWER

Fibronectin

P02751.4

2386

Homo sapiens

0.013
(5th hit)

INQQWE

Protein lava lamp

NP_525064.1

2779

Drosophila melanogaster

27
(6th hit)

YQINQQ

DNA topoisomerase 2associated protein pat1

NP_595976.2

754

Schizosaccharomyces pombe

65
(7th hit)

YQINQQ

Dynamin-like protein C

XP_645576.2

904

Dictyostelium discoideum

65
(8th hit)

YQINQQ

Ornithine

YP_672340.1

326

Escherichia coli 536

65
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(9th hit)

carbamoyltransferase
QI QQW R

Protein Cpn60

NP_849007.1

526
Cyanidioschyzon merolae

B1

B1

613.9

487.3

+2

+2

65
(10th hit)

YQINQQ

Thymidylate kinase

NP_077850.1

230

Ureaplasma parvum

65
(11th hit)

YQINQQ

Ornithine
carbamoyltransferase

NP_757196.2

334

Escherichia coli O6

65
(12th hit)

YQINQQ

Exodeoxyribonuclease V
gamma chain

ZP_07124340.1

1122

Escherichia coli K-12

65
(13th hit)

LIALLEVLSQK
LIALLEVLSQK

Filamin-C

NP_001449.3

2725

Homo sapiens

0.019
(1st hit)

LIALLEVLSQK

Filamin-C

NP_001074654.1

2726

Mus musculus

0.019
(2nd hit)

LIALLEVLSQK

Filamin-B

Q80X90.2

2602

Mus musculus

0.019
(3rd hit)

LIALLEVLSQK

Filamin-A

CAT00728.1

2647

Mus musculus

0.019
(4th hit)

LIALLEVLSQK

Filamin-A

NP_001104026.1

2647

Homo sapiens

0.019
(5th hit)

LIALLEVLSQK

Filamin-B

NP_001448.2

2602

Homo sapiens

0.019
(6th hit)

+IALL+VLSQ

Autophagy-related protein
6

A5DIV5.2

461

Pichia guilliermondii

5.1
(7th hit)

L+ALLEVLS QK

Nesprin-1

NP_892006.2

8797

Homo sapiens

5.1
(8th hit)

LI+LLEVLS

Bullous pemphigoid
antigen 1

AAK83382.1

1678
Mus musculus

9.2
(9th hit)

50S ribosomal protein L25
1

YP_076110.1

205

Symbiobacterium thermophilum

15
(1st hit)

+YGPGVEP

50S ribosomal protein L25
2

YP_076123.1

194

Symbiobacterium thermophilum

15
(2nd hit)

VYGPGVE

Filamin-C

NP_001449.3

2725

Homo sapiens

36
(3rd hit)

VYGPGVE

Filamin-C

NP_001074654.1

2726

Mus musculus

36
(4th hit)

VYGPGVE

Actin-binding protein
120

P13466.1

857

Dictyostelium discoideum

36
(5th hit)

GPGVEPR

Apolipoprotein Nacyltransferase

B9J8B4.1

217

Thermosipho africanus TCF52B

49
(6th hit)

VYGPGVEPR
+YGPGVEP

161

Table A.1. cont’d.
B2

B2

736.4

739.4

+2

+2

VYGP VEP

50S ribosomal protein L25

B7IFM6.1

217

Thermosipho africanus TCF52B

49
(7th hit)

AQQVSQGLDLLTAK
AQQVSQGLDLLTAK

Vinculin

P12003.4

1135

Gallus gallus

5e-05
(1st hit)

AQQVSQGLD+LTAK

Vinculin

P85972.1

1066

Rattus norvegicus

AQQVSQGLD+LTAK

Vinculin

P26234.4

1135

Sus scrofa

7e-04
(2nd hit)
7e-04
(3rd hit)

AQQVSQGLD+LTAK

Vinculin

Q64727.4

1066

Mus musculus

7e-04
(4th hit)

AQQVSQGLD+LTAK

Vinculin

P18206.4

1134

Homo sapiens

7e-04
(5th hit)

QV+QGLD L AK

Macrophage colonystimulating factor 1
receptor

Q9I8N6.1

977

Danio rerio

3.8
(6th hit)

MLGQMTDQVADLR
MLGQMTDQVADLR

Vinculin

P85972.1

1066

Rattus norvegicus

2e-05
(1st hit)

MLGQMTDQVADLR

Vinculin

1135

Sus scrofa

2e-05
(2nd hit)

MLGQMTDQVADLR

Vinculin

1066

Mus musculus

2e-05
(3rd hit)

MLGQMTDQVADLR

Vinculin

P18206.4

1134

Homo sapiens

2e-05
(4th hit)

LGQMTDQ+ADLR

Vinculin

P12003.4

1135

Gallus gallus

0.006
(5th hit)

MLGQM +QV

Uncharacterized protein
SE_2353

Q8CQQ7.1

300

Staphylococcus epidermidis ATCC 12228

6.8
(6th hit)

L QMT D +ADLR

Pre-mRNA-processing
ATP-dependent RNA
helicase

Q2HAD8.1

1064

Chaetomium globosum

6.8
(7th hit)

TVTAMDVVYALK

Histone H4

P83865.2

103

Litopenaeus vannamei

6e-04
(1st hit)

TVTAMDVVYALK

Histone H4

P82888.2

103

Olisthodiscus luteus

6e-04
(2nd hit)

TVTAMDVVYALK

Histone H4

103

Tetrahymena pyriformis

6e-04
(3rd hit)

TVTAMDVVYALK

Histone H4

103

Mytilus chilensis

6e-04
(4th hit)

TVTAMDVVYALK

Histone H4

103

Aplysia californica

6e-04
(5th hit)

P26234.4
Q64727.4

B2

655.9

+2

TVTAMDVVYALK

P02310.2
Q6WV74.3

Q8MTV8.3

162

Table A.1. cont’d.
TVTAMDVVYALK
Histone H4

P50566.2

103

Chlamydomonas reinhardtii

6e-04
(6th hit)

Histone H4

P91890.3

103

Trichogramma cacoeciae

6e-04
(7th hit)

Histone H4

P91882.3

103

Diadromus pulchellus

6e-04
(8th hit)

Histone H4

P70081.3

103

Gallus gallus

6e-04
(9th hit)

Histone H4

Q43083.3

103

Pyrenomonas salina

6e-04
(10th hit)

Histone H4

P91849.3

103

Apis mellifera

6e-04
(11th hit)

Histone H4

P62786.2

103

Triticum aestivum

6e-04
(12th hit)

Histone H4

P59259.2

103

Arabidopsis thaliana

6e-04
(13th hit)

Histone H4

P08436.2

103

Volvox carteri

6e-04
(14th hit)

Histone H4

Q6WV72.3

103

Mytilus trossulus

6e-04
(15th hit)

Histone H4

P62776.2

103

Holothuria tubulosa

6e-04
(1tht hit)

Histone H4

P69151.2

103

Tetrahymena pyriformis

6e-04
(17th hit)

Histone H4

P35057.2

103

Solanum lycopersicum

6e-04
(18th hit)

Histone H4

P35059.2

103

Acropora Formosa

6e-04
(19th hit)

Histone H4

Q27443.2

103

Ascaris suum

6e-04
(20th hit)

TVTAMDVVYALK

Histone H4

Q9U7D0.3

108

Mastigamoeba balamuthi

6e-04
(21st hit)

TVTAMDVVYALK

Histone H4

Q41811.3

103

Zea mays

6e-04
(22nd hit)

TVTAMDVVYALK

Histone H4

103

Physarum polycephalum

6e-04
(23rd hit)

TVTAMDVVYALK

Histone H4

P84040.2

103

Drosophila melanogaster

6e-04
(24th hit)

TVTAMDVVYALK

Histone H4

P40287.1

118

Entamoeba histolytica

6e-04

TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK
TVTAMDVVYALK

P04915.2
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(25st hit)
TVTAMDVVYALK
Histone H4

Q76NW2.1

108

Dictyostelium discoideum

6e-04
(26th hit)

Histone H4

P27996.2

103

Solaster stimpsoni

0.003
(27th hit)

TVTA+DVVYALK

Histone H4

P80737.3

103

Blepharisma japonicum

0.011
(28th hit)

TVTA+DVVYALK

Histone H4

P62790.2

104

Sterkiella nova

0.011
(29th hit)

Histone H4

Q27765.3

103

Styela plicata

0.011
(30th hit)

Histone H4

P90516.1

89

Blepharisma japonicum

0.011
(31st hit)

Histone H4

P62792.2

103

Phanerochaete chrysosporium

0.011
(32nd hit)

Histone H4

P80739.3

107

Moneuplotes crassus

0.011
(33rd hit)

LITKAVSASK

Histone H1.5

P43276.2

223

Mus musculus

0.49
(1st hit)

LITKAVSASK

Histone H1.03

P08285.2

224

Gallus gallus

0.49
(2nd hit)

LITKAVSASK

Histone H1.10

P08286.3

220

Gallus gallus

0.49
(3rd hit)

LITKAVSASK

Histone H1.11

P08287.2

225

Gallus gallus

0.49
(4th hit)

LITKAVSASK

Histone H1.01

P08284.2

219

Gallus gallus

0.49
(5th hit)

LITKAVSASK

Histone H1

P09987.2

218

Gallus gallus

0.49
(6th hit)

LITKAVSASK

Histone H1.11R

P08288.2

219

Gallus gallus

0.49
(7th hit)

LITKAV+ASK

Histone H1

P16403.2

213

Homo sapiens

2.9
(8th hit)

P02251.1

213

Cryctolagus cuniculus

2.9
(9th hit)

TVT+MDVVYALK

TVTA+DVVYALK
TVTA+DVVYALK
TVTA+DVVYALK
TVTA+DVVYALK
B2

628.7

+2

LITKAVSASK

Histone H1.3
LITKAV+ASK
LITKAV+ASK

Histone H1.4

P10412.2

219

Homo sapiens

2.9
(10th hit)

LITKAV+ASK

Histone H1.3

P16402.2

221

Homo sapiens

2.9
(11th hit)
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B6

B6

833.9

751.4

+2

+2

LITKAV+ASK

Histone H1.1

P02253.1

104

Bos taurus

2.9
(12th hit)

LITKAV+ASK

Histone H1.2

P15865.3

219

Rattus norvegicus

2.9
(13th hit)

LITKAV+ASK

Histone H1.2

P15864.2

212

Mus musculus

2.9
(14th hit)

LITKAV+ASK

Histone H1.4

P02252.1

73

Oryctolagus cuniculus

2.9
(15th hit)

LITKAV+ASK

Histone H1.4

P43274.2

219

Mus musculus

2.9
(16th hit)

LITKAV+ASK

Histone H1

P09426.3

218

Anas platyrhynchos

2.9
(17th hit)

LITKAV+ASK

Histone H1.5

P16401.3

226

Homo sapiens

2.9
(18th hit)

LITKAV+ASK

Histone H1

P43277.2

221

Mus musculus

2.9
(19th hit)

LI KAVSASK

Histone H1

P84408.3

55

Salmo salar

LI KAVSASK

Histone H1

P06350.2

207

Oncorhynchus

9.3
(20th hit)
9.3
(21st hit)

FSGSGSGTDFTFTIS

Ig Κ chain V-I region Lay

P01605.1

108

Homo sapiens

5e-06
(1st hit)

FSGSGSGTDFTFTIS

Ig Κ chain V-I region
WAT

P80362.1

108

Homo sapiens

5e-06
(2nd hit)

FSGSGSGT+FTFTIS

Ig Κ chain V-I region OU

P01606.1

108

Homo sapiens

9e-06
(3rd hit)

FSGSGSGTDFT TISR

Ig Κ chain V-III region
HIC

P18136.1

129

Homo sapiens

2e-05
(4th hit)

FSGSGSGTDFT TISR

Ig Κ chain V-III region Ti

P01622.1

109

Homo sapiens

2e-05
(5th hit)

FSGSGSGTDFT TISR

Ig Κ chain V-III region
SIE

P01620.1

109

Homo sapiens

2e-05
(6th hit)

FSGSGSGTDFT TISR

Ig Κchain V-III region
HAH

P18135.1

129

Homo sapiens

2e-05
(7th hit)

FSGSGSGTDFT TISR

Ig Κ chain V-III region
WOL

P01623.1

109

Homo sapiens

2e-05
(8th hit)

FSGSGSGTDFT TISR

Ig Κchain V-III region
GOL

P04206.1

109

Homo sapiens

2e-05
(9th hit)

FSGSGSGTDFTFTISR

VFGGGTKLTVLGQPK
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VFGGGTKLTVL QPK

Ig Λ chain V-III region
LOI

P80748.1

111

Homo sapiens

7e-05
(1st hit)

VFGGGT+LT+LGQPK

IΛ-like polypeptide 1

P20764.2

209

Mus musculus

6e-04
(2nd hit)

VFGGGTKLTVLG

Ig Λ-1 chain V regions
MOPC

P01724.1

129

Mus musculus

0.006
(3rd hit)

Ig Λ chain V-I region BL2

P06316.1

130

Homo sapiens

0.006
(4th hit)

VFGGGTKLTVLG

Ig Λ chain V-V region
DEL

P01719.1

108

Homo sapiens

0.006
(5th hit)

VFGGGTKLTVLG

Ig Λ chain V-VI region
EB4

P06319.1

131

Homo sapiens

0.006
(6th hit)

VFGGGTKLTVLG

Ig Λchain V-II region VIL

P01711.1

111

Homo sapiens

0.006
(7th hit)

VFGGGTKLTVLG

Ig Λ-1 chain V region
H2020

P01726.1

129

Mus musculus

0.006
(8th hit)

VFGGGTKLTVLG

Ig Λ-1 chain V region S43

P01727.1

129

Mus musculus

0.006
(9th hit)

VFGGGTKLTVLG

Ig Λ-1 chain V region
S178

P01725.1

110

Mus musculus

0.006
(10th hit)

VFGGGTKLTVLG

Ig Λ chain V-VI region
SUT

P06317.1

111

Homo sapiens

0.006
(11th hit)

VLASFGEAVK

Hemoglobin, β

P02131.1

146

Caiman crocodilus

0.27
(1st hit)

VLASFGEAVK

Hemoglobin, β

P02130.1

146

Alligator mississippiensis

0.27
(2nd hit)

VL+SFGEAVK

Hemoglobin, ε

P02128.2

147

Gallus gallus

1.6
(3rd hit)

VL+SFGEAVK

Hemoglobin, ρ

P02127.2

147

Gallus gallus

1.6
(4th hit)

VL SFGEAVK

Hemoglobin , ε

Q28496.3

147

Microcebus murinus

2.1
(5th hit)

VLASFGEAV

Hemoglobin, β

P02129.1

146

Crocodylus niloticus

2.1
(6th hit)

VL SFGEAVK

Hemoglobin, ε

P19759.2

147

Otolemur crassicaudatus

2.1
(7th hit)

P13274.1

146

Chrysemys picta bellii

2.1
(8th hit)

VFGGGTKLTVLG

B2

510.8

+2

V(I/L)ASFGEAVK

VL SFGEAVK

Hemoglobin, β
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VL SFGEAVK

Hemoglobin, β

P83133.

146

Dipsochelys dussumieri

2.1
(9th hit)

VL SFGEAVK

Hemoglobin, β

P02125.1

146

Ciconia ciconia

2.1
(10th hit)

VL SFGEAVK

Hemoglobin, β

P14524.1

146

Turdus merula

2.1
(11th hit)

VL SFGEAVK

Hemoglobin, β

P08851.1

146

Accipiter gentilis

2.1
(12th hit)

VL SFGEAVK

Hemoglobin, β

P02116.1

146

Ara ararauna

2.1
(13th hit)

VL SFGEAVK

Hemoglobin, β

P07411.1

146

Vultur gryphus

2.1
(14th hit)

VL SFGEAVK

Hemoglobin, β

P15165.1

146

Apus apus

2.1
(15th hit)

VL SFGEAVK

Hemoglobin, β

P08261.1

146

Larus ridibundus

2.1
(16th hit)

VL SFGEAVK

Hemoglobin, β

P21668.1

146

Psittacula krameri

2.1
(17th hit)

VL SFGEAVK

Hemoglobin, ε

Q95238.3

147

Propithecus verreauxi

2.1
(18th hit)

VL SFGEAVK

Hemoglobin, β

P02120.1

146

Anseranas semipalmata

2.1
(19th hit)

VL SFGEAVK

Hemoglobin, β

146

Phalacrocorax carbo

2.1
(20th hit)

VL SFGEAVK

Hemoglobin, ε

P08223.2

146

Eulemur fulvus fulvus

2.1
(21st hit)

VL SFGEAVK

Hemoglobin, β

P07406.1

146

Passer montanus

2.1
(22nd hit)

VL SFGEAVK

Hemoglobin, β

P68061.1

146

Aegypius monachus

2.1
(23rd hit)

VL SFGEAVK

Hemoglobin, β

P02122.1

146

Aquila chrysaetos

2.1
(24th hit)

VL SFGEAVK

Hemoglobin, ε

Q28338.3

147

Cheirogaleus medius

2.1
(25th hit)

VL SFGEAVK

Hemoglobin, β

P02109.3

147

Didelphis virginiana

2.1
(26th hit)

VL SFGEAVK

Hemoglobin, β

P02121.1

146

Phoenicopterus ruber ruber

2.1
(27th hit)

P10782.1
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B2

B6

500.8

522.8

+2

+2

VL SFGEAVK

Hemoglobin, β

Q98905.3

147

Geochelone carbonaria

2.1
(28th hit)

VL SFGEAVK

Hemoglobin, β

P82113.1

146

Stercorarius maccormicki

2.1
(29th hit)

LSSPISGDPK
PISGDPK

Microtubule-actin crosslinking factor 1

Q9UPN3.3

5430

Homo sapiens

54
(1st hit)

PISGDPK

Microtubule-actin crosslinking factor 1, isoform 4

Q96PK2.2

5938

Homo sapiens

54
(2nd hit)

PISGDPK

Microtubule-actin crosslinking factor 1

Q9QXZ0.1

5327

Mus musculus

54
(3rd hit)

SP+SGDPK

TonB-dependent heme
receptor A

P44523.1

744

Haemophilus influenza

129
(4th hit)

L SPIS DP

M-phase inducer
phosphatase 1-B

P30309.1

550

Xenopus laevis

175
(5th hit)

L SPIS DP

M-phase inducer
phosphatase 1-A

P30308.1

550

Xenopus laevis

175
(6th hit)

LSSP I+G+PK

Hemoglobin subunit β-3

P02136.2

147

Rana catesbeiana

175
(7th hit)

L SPIS DP

M-phase inducer
phosphatase 3

P30311.1

572

Xenopus laevis

175
(8th hit)

L SPIS DP

M-phase inducer
phosphatase 2

P30310.1

599

Xenopus laevis

175
(9th hit)

IMSIVDPNR

α-actinin-1

Q3B7N2.1

892

Bos taurus

IMSIVDPNR

α-actinin-1

Q2PFV7.1

892

Macaca fascicularis

0.1
(1st hit)
0.1
(2nd hit)

IMSIVDPNR

α-actinin-1

Q7TPR4.1

892

Mus musculus

0.1
(3rd hit)

IMSIVDPNR

α-actinin-1

P05094.3

893

Gallus gallus

IMSIVDPNR

α-actinin-1

P12814.2

892

Homo sapiens

0.1
(4th hit)
0.1
(5th hit)

IMSIVDPNR

α-actinin-1

Q9Z1P2.1

892

Rattus norvegicus

0.1
(6th hit)

IMS+VDPN

α-actinin-4

A5D7D1.1|

911

Bos taurus

6.2
(7th hit)

IMS+VDPN

α -actinin-4

Q9QXQ0.2

911

Rattus norvegicus

6.2
(8th hit)

IMS+VDPN

α-actinin-4

P57780.1

912

Mus musculus

6.2
(9th hit)

IMSIVDPNR
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B5

506.2

+3

IMS+VDPN

α-actinin-4

Q5RCS6.1

911

Pongo abelii

15
(10th hit)

IMS+VDPN

α-actinin-2

P20111.1

897

Gallus gallus

15
(11th hit)

IMS+VDPN

α-actinin-4

O43707.2

911

Homo sapiens

15
(12th hit)

IMS+VDPN

α-actinin-4

Q90734.1

904

Gallus gallus

15
(13th hit)

QEYDESGPSIVHR
QEYDESGPSIVHR

γ-Actin

P20359.2

375

Emericella nidulans

QEYDESGPSIVHR

Actin

P53455.2

375

Ajellomyces capsulatus G186AR

3e-05
(1st hit)
3e-05
(2nd hit)

QEYDESGPSIVHR

POTE ankyrin domain
family member E

Q6S8J3.3

1075

Homo sapiens

3e-05
(3rd hit)

QEYDESGPSIVHR

Actin

Q0PGG4.1

375

Bos grunniens

3e-05
(4th hit)

QEYDESGPSIVHR

β-Actin

P84856.1

361

Chlorocebus pygerythrus

3e-05
(5th hit)

Homo sapiens
QEYDESGPSIVHR

Chimeric POTE-actin
protein

A5A3E0.2

1075

3e-05
(6th hit)

QEYDESGPSIVHR

γ-Actin

Q5JAK2.1

375

Rana lessonae

3e-05
(7th hit)

QEYDESGPSIVHR

Actin, cytoplasmic 2

Q6P378.1

375

Xenopus tropicalis

QEYDESGPSIVHR

Κ-actin

Q9BYX7.1

375

Homo sapiens

3e-05
(9th hit)

QEYDESGPSIVHR

Actin

Q2U7A3.1

375

Aspergillus oryzae

3e-05
(10th hit)

QEYDESGPSIVHR

β-Actin

P84336.1

375

Camelus dromedarius

3e-05
(11th hit)

QEYDESGPSIVHR

β-Actin

Q6NVA9.1

375

Xenopus tropicalis

3e-05
(12th hit)

QEYDESGPSIVHR

β-Actin

Q7ZVI7.2

375

Danio rerio

3e-05
(13th hit)

QEYDESGPSIVHR

Actin, cytoskeletal 3

Q25379.1

172

Lytechinus pictus

3e-05
(14th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q964E1.1

376

Biomphalaria obstructa

3e-05
(15th hit)
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(8th hit)
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QEYDESGPSIVHR

Actin, cytoplasmic

P12716.1

376

Pisaster ochraceus

3e-05
(16th hit)

QEYDESGPSIVHR

Actin-3

P41340.1

376

Limulus polyphemus

3e-05
(17th hit)

QEYDESGPSIVHR

Actin, cytoplasmic A3

P04829.3

376

Bombyx mori

3e-05
(18th hit)

QEYDESGPSIVHR

Actin-2

P26197.1

377

Absidia glauca

3e-05
(19th hit)

QEYDESGPSIVHR

Actin-2

P92176.1

376

Lumbricus

3e-05
(20th hit)

QEYDESGPSIVHR

Actin

P91754.1

372

Lumbricus rubellus

3e-05
(21st hit)

QEYDESGPSIVHR

Actin, cytoskeletal 3A

P53474.1

376

Strongylocentrotus purpuratus

3e-05
(22nd hit)

QEYDESGPSIVHR

Actin, cytoskeletal 3B

P18499.1

376

Strongylocentrotus purpuratus

3e-05
(23rd hit)

QEYDESGPSIVHR

Actin-3

P41113.1

376

Podocoryna carnea

3e-05
(24th hit)

QEYDESGPSIVHR

Actin, cytoskeletal 2A

Q07903.1

376

Strongylocentrotus purpuratus

3e-05
(25th hit)

QEYDESGPSIVHR

Actin, cytoplasmic A3a

Q25010.1

376

Helicoverpa armigera

3e-05
(26th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q964E3.1

376

Biomphalaria alexandrina

3e-05
(27th hit)

QEYDESGPSIVHR

γ-Actin

P63256.1

375

Anser anser anser

3e-05
(28th hit)

QEYDESGPSIVHR

Actin

P18602.1

327

Artemia species

3e-05
(29th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

P92179.2

376

Biomphalaria glabrata

3e-05
(30th hit)

QEYDESGPSIVHR

β-Actin

P68142.1

375

Takifugu rubripes

3e-05
(31st hit)

QEYDESGPSIVHR

Actin

P53461.1

376

Halocynthia roretzi

3e-05
(32nd hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q93131.1

375

Branchiostoma floridae

3e-05
(33rd hit)

QEYDESGPSIVHR

Actin, cytoskeletal 1

P53465.1

376

Lytechinus pictus

3e-05
(34th hit)

QEYDESGPSIVHR

Actin

P10365.1

375

Thermomyces lanuginosus

3e-05
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(35th hit)
QEYDESGPSIVHR

Actin-1

O18499.1

376

Saccoglossus kowalevskii

3e-05
(36th hit)

QEYDESGPSIVHR

β-Actin

Q91ZK5.1

375

Sigmodon hispidus

3e-05
(37th hit)

QEYDESGPSIVHR

Actin, cytoplasmic type 8

P53506.1

376

Xenopus laevis

3e-05
(38th hit)

QEYDESGPSIVHR

Actin-1

P92182.1

376

Lumbricus terrestris

3e-05
(39th hit)

QEYDESGPSIVHR

γ-Actin

Q8JJB8.1

375

Triakis scyllium

3e-05
(40th hit)

QEYDESGPSIVHR

Actin-15A

P10990.1

376

Strongylocentrotus franciscanus

3e-05
(41st hit)

QEYDESGPSIVHR

γ-Actin

Q9UVW9.1

375

Acremonium chrysogenum

3e-05
(42nd hit)

QEYDESGPSIVHR

Actin, cytoskeletal 2

P53466.1

376

Lytechinus pictus

3e-05
(43rd hit)

QEYDESGPSIVHR

Actin-1/2

P41112.1

376

Podocoryna carnea

3e-05
(44th hit)

QEYDESGPSIVHR

Actin, cytoskeletal

P53464.1

376

Heliocidaris tuberculata

3e-05
(45th hit)

QEYDESGPSIVHR

Actin, adductor muscle

Q26065.1

376

Placopecten magellanicus

3e-05
(46th hit)

QEYDESGPSIVHR

Actin, cytoskeletal 1B

P53473.1

376

Strongylocentrotus purpuratus

3e-05
(47th hit)

QEYDESGPSIVHR

β-Actin

P48975.1

375

Cricetulus griseus

3e-05
(48th hit)

QEYDESGPSIVHR

Actin-15B

P69004.1

376

Strongylocentrotus franciscanu

3e-05
(49th hit)

QEYDESGPSIVHR

Actin, muscle

P17304.1

376

Aplysia californica

3e-05
(50th hit)

QEYDESGPSIVHR

β-Actin

P60711.1

375

Rattus norvegicus

3e-05
(51st hit)

QEYDESGPSIVHR

Actin, muscle-type

Q25472.1

378

Molgula oculata

3e-05
(52nd hit)

QEYDESGPSIVHR

Actin

Q8X119.1

375

Exophiala dermatitidis

3e-05
(53rd hit)

QEYDESGPSIVHR

Actin-42A

P02572.3

376

Drosophila melanogaster

3e-05
(54th hit)
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QEYDESGPSIVHR

β-Actin

P79818.2

375

Oryzias latipes

3e-05
(55th hit)

QEYDESGPSIVHR

β-Actin

P83750.1

375

Cyprinus carpio

3e-05
(56th hit)

QEYDESGPSIVHR

Actin CyI, cytoplasmic

P69002.1

376

Heliocidaris erythrogramma

3e-05
(57th hit)

QEYDESGPSIVHR

Actin-1

P30163.1

376

Onchocerca volvulus

3e-05
(58th hit)

QEYDESGPSIVHR

Actin-2

P30162.1

376

Onchocerca volvulus

3e-05
(59th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q93129.1

375

Branchiostoma belcheri

3e-05
(60th hit)

QEYDESGPSIVHR

Actin, non-muscle

P17126.1

376

Hydra vulgaris

3e-05
(61st hit)

QEYDESGPSIVHR

β-Actin

O93400.1

375

Xenopus laevis

3e-05
(62nd hit)

QEYDESGPSIVHR

Actin-2

O18500.1

376

Saccoglossus kowalevskii

3e-05
(63rd hit)

QEYDESGPSIVHR

Actin, clone 403

P18603.1

376

Artemia species

3e-05
(64th hit)

QEYDESGPSIVHR

β-Actin

P15475.1

376

Xenopus borealis

3e-05
(65th hit)

QEYDESGPSIVHR

Actin, cytoskeletal 1A

P53472.1

376

Strongylocentrotus purpuratus

3e-05
(66th hit)

QEYDESGPSIVHR

β-Actin

O42161.1

375

Salmo salar

3e-05
(67th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q964E0.1

376

Biomphalaria tenagophila

3e-05
(68th hit)

QEYDESGPSIVHR

Actin

O13419.1

375

Botryotinia fuckeliana

3e-05
(69th hit)

QEYDESGPSIVHR

β-Actin

P53486.1

375

Takifugu rubripes

3e-05
(70th hit)

QEYDESGPSIVHR

Actin-5

P41339.1

376

Limulus polyphemus

3e-05
(71st hit)

QEYDESGPSIVHR

γ-Actin

Q9URS0.1

375

Penicillium chrysogenum

3e-05
(72nd hit)

QEYDESGPSIVHR

Actin, cytoskeletal

P53463.1

376

Heliocidaris erythrogramma

3e-05
(73rd hit)

QEYDESGPSIVHR

Actin

P50138.1

375

Puccinia graminis

3e-05
(74th hit)
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QEYDESGPSIVHR

Actin-1/3

P10983.2

376

Caenorhabditis elegans

3e-05
(75th hit)

QEYDESGPSIVHR

Actin, cytoplasmic type 5

P53478.1

376

Gallus gallus

3e-05
(76th hit)

QEYDESGPSIVHR

β-Actin B

P53485.1

375

Takifugu rubripes

3e-05
(77th hit)

QEYDESGPSIVHR

Actin-3

Q03342.1

309

Echinococcus granulosus

3e-05
(78th hit)

QEYDESGPSIVHR

Actin, muscle

P12717.1

376

Pisaster ochraceus

3e-05
(79th hit)

QEYDESGPSIVHR

β-Actin

P29751.1

375

Oryctolagus cuniculus

3e-05
(80th hit)

QEYDESGPSIVHR

Actin-2

P10984.3

376

Caenorhabditis elegans

3e-05
(81st hit)

QEYDESGPSIVHR

Actin, muscle

Q25381.1

172

Lytechinus pictus

3e-05
(82nd hit)

QEYDESGPSIVHR

Actin-6

P53459.1

373

Diphyllobothrium dendriticum

3e-05
(83rd hit)

QEYDESGPSIVHR

Actin-11

P41341.1

376

Limulus polyphemus

3e-05
(84th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q964E2.1

376

Biomphalaria pfeifferi

3e-05
(85th hit)

QEYDESGPSIVHR

Actin

Q24733.1

33

Dictyocaulus viviparus

3e-05
(86th hit)

QEYDESGPSIVHR

Actin, cytoplasmic type 5

P53505.1

376

Xenopus laevis

3e-05
(87th hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q00215.1

375

Styela plicata

3e-05
(88th hit)

QEYDESGPSIVHR

Actin

O17320.1

376

Crassostrea gigas

3e-05
(89th hit)

QEYDESGPSIVHR

Actin-4

P10986.2

376

Caenorhabditis elegans

3e-05
(90th hit)

QEYDESGPSIVHR

Actin-1

P35432.1

375

Echinococcus granulosus

3e-05
(91st hit)

QEYDESGPSIVHR

Actin, cytoplasmic

O17503.1

375

Branchiostoma lanceolatum

3e-05
(92nd hit)

QEYDESGPSIVHR

Actin, cytoplasmic

Q964D9.1

376

Helisoma trivolvis

3e-05
(93rd hit)
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B1

683.9

+2

QEYDESGPSIVHR

Actin, muscle

Q00214.1

379

Styela plicata

3e-05
(94th hit)

QEYDESGPSIVHR

Actin-5C

P10987.4

376

Drosophila

3e-05
(95th hit)

QEYDESGP+IVHR

Actin-1

P04751.1

377

Xenopus laevis

2e-04
(96th hit)

QEYDE+GPSIVHR

α-Actin-1

P53479.1

377

Cyprinus carpio

2e-04
(97th hit)

QEYDE+GPSIVHR

α-cardiac actin

P04751.1

377

Xenopus laevis

2e-04
(98th hit)

QEYDE+GPSIVHR

Actin, α cardiac

P53480.

377

Takifugu rubripes

2e-04
(99th hit)

STDYGILQINSR

Lysozyme C

P84492.1

130

Chelonia mydas

STDYGILQINSR

Lysozyme C

Q7LZI3.1

129

Tragopan satyra

6e-04
(1st hit)
6e-04
(2nd hit)

STDYGILQINSR

Lysozyme C

Q7LZQ1.3

131

Pelodiscus sinensis

6e-04
(3rd hit)

STDYGILQINSR

Lysozyme C

P24364.1

129

Lophura leucomelanos

6e-04
(4th hit)

STDYGILQINSR

Lysozyme C

P81711.1

129

Syrmaticus soemmerringii

6e-04
(5th hit)

STDYGILQINSR

Lysozyme C

P00702.2

147

Phasianus colchicus colchicus

6e-04
(6th hit)

STDYGILQINSR

Lysozyme C

P00703.2

147

Meleagris gallopavo

6e-04
(7th hit)

STDYGILQINSR

Lysozyme C

Q7LZP9.1

129

Lophophorus impejanus

6e-04
(8th hit)

STDYGILQINSR

Lysozyme C

P49663.1

130

Phasianus versicolor

6e-04
(9th hit)

STDYGILQINSR

Lysozyme C

P00698.1

147

Gallus gallus

6e-04
(10th hit)

STDYGILQINSR
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B1

503.3

+2

STDYGILQINSR

Lysozyme C

P00705.1

147

Anas platyrhynchos

6e-04
(11th hit)

STDYGILQINSR

Lysozyme C

P19849.1

129

Pavo cristatus

6e-04
(12th hit)

STDYGILQINSR

Lysozyme C

P00701.2

147

Coturnix japonica

6e-04
(13th hit)

STDYGILQINSR

Lysozyme C

Q7LZQ3.1

129

Crax fasciolata

6e-04
(14th hit)

STDYGILQINSR

Lysozyme C

P37156.1

125

Tachyglossus aculeatus aculeatus

6e-04
(15th hit)

STDYGILQINSR

Lysozyme C

P24533.1

129

Syrmaticus reevesii

6e-04
(16th hit)

STDYGILQINSR

Lysozyme C

Q7LZT2.1

129

Tragopan temminckii

6e-04
(17th hit)

STDYGILQINSR

Lysozyme C

P00707.1

129

Ortalis vetula

6e-04
(18th hit)

STDYGILQINSR

Lysozyme C

P22910.1

129

Chrysolophus amherstiae

6e-04
(19th hit)

STDYG+LQINSR

Lysozyme C

P00704.2

129

Numida meleagris

0.003
(20th hit)

STDYG+LQINSR

Lysozyme C

P00699.1

129

Callipepla californica

0.003
(21st hit)

STDYG+LQINSR

Lysozyme C

P00700.2

129

Colinus virginianus

0.003
(22nd hit)

STDYGIL+INSR

Lysozyme C

P00706.1

129

Anas platyrhynchos

0.004
(23rd hit)

STDYGIL+INSR

Lysozyme C

Q7LZQ2.1

129

Aix sponsa

0.004
(24th hit)

WDAWDALK
WDAW+ALK

Acyl-CoA-binding protein

Q9PRL8.1

86

Gallus gallus

1.7
(1st hit)

Peroxisomal 3,2-transenoyl-CoA isomerase

Q9WUR2.2

391

Peroxisomal 3,2-transenoyl-CoA isomerase

Q5XIC0.1

WDAW+AL
WDAW+AL

Mus musculus

175

391

Rattus norvegicus

13
(2nd hit)
13
(3rd hit)
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394

Homo sapiens

13
(4th hit)

P12026.2

87

Sus scrofa

18
(5th hit)

Acyl-CoA-binding protein

Q8WN94.3

87

Oryctolagus cuniculus

18
(6th hit)

WDAW+ LK

Acyl-CoA-binding protein

P07108.2

87

Homo sapiens

18
(7th hit)

WDAW+ LK

Acyl-CoA-binding protein

P07107.2

87

Bos taurus

18
(8th hit)

Peptidoglycan hydrolase
flgJ

Q9I4P4.1

400

Pseudomonas aeruginosa

15
(1st hit)

Myeloid protein 1

P08940.2

326

Gallus gallus

36
(2nd hit)

Q71Z77.1

398

Listeria monocytogenes str. 4b F2365

49
(3rd hit)

WDAW+AL

B4

509.8

+2

O75521.4

WDAW+ LK

Peroxisomal 3,2-transenoyl-CoA isomerase
Acyl-CoA-binding protein

WDAW+ LK

IGTMLPMQK
I TMLPM QK
MLPMQK
IG MLPM K

B1

565.3

+2

Arginine biosynthesis
bifunctional protein argJ

IG MLPM K

Arginine biosynthesis
bifunctional protein argJ

Q8Y6U2.1

398

Listeria monocytogenes

49
(4th hit)

G+MLPM+K

Replicase large subunit

P18339.2

1609

Tobacco mild green mosaic virus

49
(5th hit)

Proactivator polypeptide
(Containing Saposin-A, B,
C & D)

O13035.1

518

Gallus gallus

0.084
(1st hit)

LVTDVQEA+R

Hypothetical protein

YP_001608779.1

525

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q21XJ9.1

278

Rhodoferax ferrireducens

17
(3rd hit)

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q2SVN0.1

335

Burkholderia thailandensis E264

17
(4th hit)

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q39GW5.1

319

Burkholderia species 383

17
(5th hit)

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q0BFQ0.1

319

Burkholderia ambifaria AMMD

17
(6th hit)

LVT DVQEAV

Aliphatic sulfonates

Q3JSR6.1

335

Burkholderia pseudomallei 1710b

17

LVTDVQEAVR
LVTDVQEAVR

176

Bartonella tribocorum CIP 105476

1.2
(2nd hit)
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(7th hit)

import ATP-binding
protein
ssuB

B2

B2

646.9

772.0

+2

+2

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q62K56.2

335

Burkholderia mallei

17
(8th hit)

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q1BWL4.1

319

Burkholderia cenocepacia AU 1054

17
(9th hit)

LVT DVQEAV

Aliphatic sulfonates
import ATP-binding
protein
ssuB

Q63TW1.1

327

Burkholderia pseudomallei

17
(10th hit)

ISMPDFDLNLK

Neuroblast differentiationassociated protein
AHNAK

Q09666.2

5890

Homo sapiens

0.001
(1st hit)

ISMPDFD++

DNA polymerase III
subunit alpha

Q1RKF9.1

1172

Rickettsia bellii RML369-C

5.1
(2nd hit)

ISMPDFD++

DNA polymerase III
subunit alpha

Q68VX1.1

1180

Rickettsia typhi

5.1
(3rd hit)

ISMPDFD++

DNA polymerase III
subunit alpha

Q92GB2.1

1181

Rickettsia conorii

5.1
(4th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

Q4UK40.1

1207

Rickettsia felis

5.1
(5th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

O05974.2

1182

Rickettsia prowazekii

5.1
(6th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

O51526.2

1147

Borrelia burgdorferi

5.1
(7th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

O83675.1

1170

Treponema pallidum

5.1
(8th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

Q9RX08.1

1335

Deinococcus radiodurans

5.1
(9th hit)

ISMPDFD++

DNA polymerase III
subunit alpha

P57332.1

1161

Buchnera aphidicola

5.1
(10th hit)

Q9HXZ1.1

1173

ISMPDFD

DNA polymerase III
subunit alpha

Pseudomonas aeruginosa

6.8
(11th hit)

ISMPDFDLNLK

AVASAAAALVLK
AVASAAAALVLK

Talin-1

P26039.1

2541

Mus musculus

0.026
(1st hit)

AVASAAAALVLK

Talin-1

P54939.2

2541

Gallus gallus

0.026
(2nd hit)
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Q9Y490.3
AVASAAAALVLK
AVA+AAA LVLK

Talin-1
Talin-2

Q9Y4G6.4

2541

Homo sapiens

2542

Homo sapiens

0.026
(3rd hit)
3.8
(4th hit)

AVA+AAA LVLK
Talin-2

Q71LX4.2

2375

Mus musculus

3.8
(5th hit)

Phycocyanin-645 α-1
chain

P23815.1

70

Chroomonas species

6.8
(6th hit)

Glutamyl-tRNA reductase

Q2FTL0.1

424

Methanospirillum hungatei JF-1

36
(1st hit)

LGTFLEN

Histone acetyltransferase
p300

Q09472.2

2414

Homo sapiens

36
(2nd hit)

L TFLEN K

Probable nucleoporin
C890.06

Q9URX8.3

1315

Schizosaccharomyces pombe

87
(3rd hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

354

Chlamydia trachomatis L2b/UCH-1/proctitis

AVA AAALVLK
B2

525.8

+2

LGTFLENEK
LGTFLE+E

117
(4th hit)

B0BBM4.1

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

B0B7F9.1

354

Chlamydia trachomatis

117
(5th hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

Q254I9.1

359

Chlamydophila felis

117
(6th hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

Q5L612.1

359

Chlamydophila abortus

117
(7th hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

Q823E0.1

359

Chlamydophila caviae

117
(8th hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

Q9PKF1.1

354

Chlamydia muridarum

117
(9th hit)

TFL+NEK

UDP-3-O-[3hydroxymyristoyl]
glucosamine Nacyltransferase

O84245.1

354

Chlamydia trachomatis

117
(10th hit)
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B4

821.9

+2

V(I/L)QQQADDAEER
V+QQQADDAEER

Putative tropomyosin α-3
chain-like protein

A6NL28.2

223

Homo sapiens

0.006
(1st hit)

V+QQQADDAEER

Tropomyosin α-3 chain

Q63610.2

248

Rattus norvegicus

0.006
(2nd hit)

QQQADDAE+R

Tropomyosin α-4 chain

P09495.3

248

Rattus norvegicus

0.20
(3rd hit)

Tropomyosin α-4 chain

Q6IRU2.3

248

Mus musculus

0.20
(4th hit)

QQQAD+AE+R

Tropomyosin α-4 chain

P67937.3

248

Sus scrofa

1.2
(5th hit)

QQQAD+AE+R

Tropomyosin α-4 chain

P02561.2

248

Equus caballus

1.2
(6th hit)

PP+PPARAA

Protein bassoon

Q9UPA5.4

3926

Homo sapiens

17
(1st hit)

PPKPPAR

Frizzled-8

O93274.1

581

Xenopus laevis

30
(2nd hit)

IPPKPP R

Sodium/hydrogen
exchanger 2

Q9UBY0.1

812

Homo sapiens

30
(3rd hit)

PPKPPAR

Structure-specific
endonuclease subunit slx4

Q7SFJ3.1

1013

Neurospora crassa

30
(4th hit)

PP+PPARA

Protein bassoon

O88737.3

3942

Mus musculus

97
(5th hit)

PPKPPA A

DNA polymerase subunit
γ-1

P54098.1

1239

Homo sapiens

97
(6th hit)

PP+PPARA

Protein bassoon

O88778.3

3938

Rattus norvegicus

97
(7th hit)

P PPAR+AR

Stress response protein
NST1

Q5KHY3.1

1353

Filobasidiella neoformans

97
(8th hit)

IPSLPSGVDK
PSLPSGVD

Stromelysin-1

P08254.2

477

Homo sapiens

12
(1st hit)

PSLPSG+D

Stromelysin-1

Q28397.1

477

Equus caballus

54
(2nd hit)

IP LPSGV+

Amino-acid
acetyltransferase

A1C6J2.1

718

Aspergillus clavatus

72
(3rd hit)

Envelope glycoprotein
gp160

Q89607.1

852

HIV-2 B_EHO

0.011
(1st hit)

Envelope glycoprotein
gp160

P15831.2

859

Human immunodeficiency virus type 2

17
(2nd hit)

QQQADDAE+R

B6

B5

B6

587.3

506.8

583.8

+2

+2

+2

IPPKPPARAAR

AAGEIIAIPRR
AAGEIIAIPRR
AA IIAIPRR
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B1

B5

B6

B6

831.4

684.9

586.8

593.3

+2

+2

+2

+2

EIIAIP+R

Porphobilinogen
deaminase

A7GBW3.1

290

Clostridium botulinum F str. Langeland

22
(3rd hit)

IIAIPRR

Envelope glycoprotein
gp160

Q76638.1

857

HIV-2 B_UC1

22
(4th hit)

Dipeptidyl-peptidase 1
(Cathepsin C)

Q60HG6.1

463

Macaca fascicularis

5e-07
(1st hit)

NSWGTSWGE+GYFR

Dipeptidyl-peptidase 1
(Cathepsin C)

Q3ZCJ8.1

463

Bos taurus

3e-06
(2nd hit)

NSWGT WGEDGYFR

Dipeptidyl-peptidase 1
(Cathepsin C)

Q5RB02.1

463

Pongo abelii

5e-06
(3rd hit)

Origin recognition
complex subunit 2

Q75PQ8.1

576

Rattus norvegicus

0.014
(1st hit)

FRTTMLQDSI

Origin recognition
complex subunit 2

Q60862.1

586

Mus musculus

0.014
(2nd hit)

FRTTMLQDSI

Origin recognition
complex subunit 2

Q13416.2

577

Homo sapiens

0.014
(3rd hit)

FRTTMLQD I

Origin recognition
complex subunit 2

A6QNM3.2

577

Bos taurus

0.20
(4th hit)

FRT++LQDS

Origin recognition
complex subunit 2

Q91628.1

558

Xenopus laevis

22
(5th hit)

LPPEQGTTSSR

Cadherin EGF LAG
seven-pass G-type
receptor 2

XP_002686199.1

2920

Bos Taurus (flamingo homolog, Drosophila)

0.36
(1st hit)

LPPEQGTTSSR

Cadherin EGF LAG
seven-pass G-type
receptor 2

NP_001179860.1

2920

Bos Taurus

0.36
(2nd hit)

LPPE+GTTS

26S proteasome
regulatory subunit 7,
putative

XP_002778882.1

543

Perkinsus marinus ATCC 50983

173
(3rd hit)

LPPE+GTT S

Hypothetical protein
LELG_03374

XP_001525446.1

716

Lodderomyces elongisporus NRRL YB-4239

173
(4th hit)

PPE+GTTS R

Thiamine ABC
transporter, permease
protein

YP_002827746.1

540

Rhizobium sp. NGR234

232
(5th hit)

AILYNYWDK

Complement component
c3

CAC69535.1

401

Crocodylus niloticus

0.50
(1st hit)

ILYNYWD

Collagen-like cell surfaceanchored protein SclD

YP_002745264.1

324

Streptococcus equi subspecies Zooepidemicus

24
(2nd hit)

NSWGTSWGEDGYFR
NSWGTSWGEDGYFR

FRTTMLQDSIR
FRTTMLQDSI

LPPEQGTTSSR

AILYNYWDK
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B6

506.8

+2

ILYNYWD

Collagen-like cell surfaceanchored protein SclD

YP_002745683.1

313

Streptococcus equi subspecies equi 4047

24
(3rd hit)

ILYNYWD

Collagen-like cell surfaceanchored protein SclD

YP_002122604.1

336

Streptococcus equi subspecies zooepidemicus
MGCS10565

24
(4th hit)

ILYNYWD

Collagen-like protein D

ABA41494.1

258

Streptococcus equi subspecies Equi

24
(5th hit)

A+LY YWDK

Hypothetical protein
Btr_0321

YP_001608779.1

711

Bartonella tribocorum CIP 105476

41
(6th hit)

AILYNYW

Complement component
c3

NP_990736.1

1652

Gallus gallus

41
(7th hit)

NEALIALLR

Plastin-2

Q6P698.1

624

Danio rerio

0.79
(1st hit)

NEALIALLR

Plastin-2

P13796.5

627

Homo sapiens

0.79
(2nd hit)

NEALIALLR

Plastin-2

Q61233.4

627

Mus musculus

0.79
(3rd hit)

NEALIALL

Plastin-1
A6H742.1

630

NEALIALLR

Bos taurus
8.3
(4th hit)

NEALIALL

Plastin-1

Q14651.2

629

Homo sapiens

8.3
(5th hit)

NEALIALL

Plastin-1

Q3V0K9.1

630

Mus musculus

8.3
(6th hit)

NEALIALL

Plastin-1

P19179.1

630

Gallus gallus

8.3
(7th hit)

NEALIAL LR

Metal-dependent
hydrolase

Q6KZZ9.1

220

Picrophilus torridus

20
(8th hit)
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Table A.2. Proteins identified at single peptide level using BLAST. De novo sequenced peptides obtained from gel digest were
searched using BLAST with a limited taxonomy, containing birds (taxid:8782), crocodiles (taxid:8493), turtles (taxid:8459), tuataras
(taxid:8508) and squamates (taxid:8509) using the SwissProt database. The top three E-values are reported.
Band
Number
B4

B4

B4

B1

m/z

Charge

De Novo Sequence

1060.6

+2

EINLSPDSTSAVVSGLMVATK

536.3

701.3

613.9

+2

+2

+2

Protein

Accession Number

Protein Length

Organism

E-Value

EINLSPDSTSAVVSGLMVATK

Fibronectin

P11722

1256

Gallus gallus

2e-13
(1st hit)

NLSP+S SA

Endoribonuclease Dicer

Q25BN1

1921

Gallus gallus

2.2
(2nd hit)

NL P TS VSGL

Protein sidekick-1

Q8AV58

2169

Gallus gallus

4.0
(3rd hit)

YEVSVYALK

Fibronectin

P11722

1256

Gallus gallus

0.003
(1st hit)

Y+++VYA+K

Collagen α-1(XII)

P13944

3124

Gallus gallus

3.7
(2nd hit)

Y VSVYA

Tyrosine-protein kinase
BTK

Q8JH64

657

Gallus gallus

12
(3rd hit)

YQINQ ER

Solute carrier family 41
member 2

Q5ZHX6

573

Gallus gallus

2.1
(1st hit)

INQQW

Thrombin-like enzyme

Q072L7

258

Lachesis stenophrys

INQQW

Serine α-fibrinogenase

Q8JH85

258

Macrovipera lebetina

2.8
(2nd hit)
2.8
(3rd hit)

INQQW

Serine β-fibrinogenase

Q8JH62

257

Macrovipera lebetina

2.8
(4th hit)

QQWER

Zyxin

Q04584

542

Gallus gallus

2.8
(5th hit)

YQ + QQWE

Structural maintenance of
chromosomes protein 2

Q90988

1189

Gallus gallus

5.0
(6th hit)

IA LLEVLS

Adenylate cyclase type 9

Q9DGG6

1334

Gallus gallus

2.3
(1st hit)

LLEVL+Q

Exportin-7

Q5ZLT0

1087

Gallus gallus

4.1
(2nd hit)

LI +LE +LSQK

E3 ubiquitin-protein ligase
MIB2

Q5ZIJ9

954

Gallus gallus

5.5
(3rd hit)

YEVSVYALK

YQINQQWER

LIALLEVLSQK

182
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Cell division
cycle-associated protein 1

Q76I90

469

Gallus gallus

5.5
(4th hit)

Q5F3X4

972

Gallus gallus

6.7
(1st hit)

VYGPG

116 kDa U5 small nuclear
ribonucleoprotein
component
Homeobox protein Hox-C8

Q9YH13

242

Gallus gallus

29
(2nd hit)

YGP VE

Protein sidekick-2

Q8AV57

2177

Gallus gallus

39
(3rd hit)

AQQVSQGLDLLTAK

Vinculin

P12003

1135

Gallus gallus

5e-07
(1st hit)

L+LLTAK

NADH-ubiquinone
oxidoreductase chain 3

O47874

115

Alligator mississippiensis

5.4
(2nd hit)

LDLLT K

Probable ATP-dependent
RNA helicase DDX10

Q5ZJF6

875

Gallus gallus

9.8
(3rd hit)

LGQMTDQ+ADLR

Vinculin

P12003

1135

Gallus gallus

6e-05
(1st hit)

Q+TDQVA LR

COUP transcription factor 2

Q90733

410

Gallus gallus

2.3
(2nd hit)

MLGQM

Importin-13

Q5ZIC8

958

Gallus gallus

5.5
(3rd hit)

TVTAMDVVYALK

Histone H4

P70081

103

Gallus gallus

5e-06
(1st hit)

TVTAMDVVYALK

Histone H4

P62800

103

Cairina moschata

5e-06
(2nd hit)

Rho guanine nucleotide
exchange factor 6

Q5ZLR6

764

Gallus gallus

1.7
(3rd hit)

UPF0636 protein C4orf41
homolog

Q5ZI89

1132

Gallus gallus

5.5
(4th hit)

LITKAVSASK

Histone H1.03

P08285

224

Gallus gallus

0.005
(1st hit)

LITKAVSASK

Histone H1.10

P08286

220

Gallus gallus

0.005
(2nd hit)

LITKAVSASK

Histone H1.11L

P08287

225

Gallus gallus

0.005
(3rd hit)

AL EV+SQK
B1

487.3

+2

VYGPGVEPR
VYGP VE

B2

B2

B2

736.4

739.4

655.9

+2

+2

+2

AQQVSQGLDLLTAK

MLGQMTDQVADLR

TVTAMDVVYALK

TVT

+D VYALK

T+T +DVVY
B2

628.7

+2

LITKAVSASK
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B6

B6

B2

833.9

751.4

510.8

+2

+2

+2

LITKAVSASK

Histone H1.01

P08284

219

Gallus gallus

0.005
(4th hit)

LITKAVSASK

Histone H1

P09987

218

Gallus gallus

0.005
(5th hit)

LITKAVSASK

Histone H1.11R

P08288

219

Gallus gallus

0.005
(6th hit)

LITKAV+ASK

Histone H1

P09426

218

Anas platyrhynchos

0.028
(7th hit)

L+TKAV A

Neurochondrin

Q5ZIG0

702

Gallus gallus

18
(8th hit)

FSG GSG +FT

Large fibroblast
proteoglycan

Q90953

3562

Gallus gallus

1.7
(1st hit)

S SG GT FTF+ R

Docking protein 3

A3R064

426

Gallus gallus

5.4
(2nd hit)

SG+GSG+ TF

Protein PRRC1

Q5F3I0

442

Gallus gallus

13
(3rd hit)

TVLGQP

Transmembrane protein
184C

Q5ZMP3

445

Gallus gallus

5.4
(1st hit)

GT LTVL Q K

Integrator complex subunit
2

Q5ZKU4

1192

Gallus gallus

13
(2nd hit)

VFG +KLT

Protein HIRA

P79987

1019

Gallus gallus

18
(3rd hit)

P02131

146

Caiman crocodilus

0.003
(1st hit)
0.003
(2nd hit)
0.015
(3rd hit)

FSGSGSGTDFTFTISR

VFGGGTKLTVLGQPK

VLASFGEAVK
VLASFGEAVK

Hemoglobin subunit β

VLASFGEAVK

Hemoglobin subunit β

P02130

146

Alligator mississippiensis

VL+SFGEAVK

Hemoglobin subunit
epsilon

P02128

147

Gallus gallus

VL+SFGEAVK

Hemoglobin ρ chain

P02127

147

Gallus gallus

0.015
(4th hit)

VLASFGEAV

Hemoglobin β chain

P02129

146

Crocodylus niloticus

0.021
(5th hit)

VL SFGEAVK

Hemoglobin β chain

P13274

146

Chrysemys picta bellii

0.021
(6th hit)

VL SFGEAVK

Hemoglobin β chain

P83133

146

Dipsochelys dussumieri

0.021
(7th hit)

VL SFGEAVK

Hemoglobin β chain

P02125

146

Ciconia ciconia

0.021
(8th hit)
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B2

500.8

+2

VL SFGEAVK

Hemoglobin β chain

P14524

146

Turdus merula

0.021
(9th hit)

VL SFGEAVK

Hemoglobin β chain

P08851

146

Accipiter gentilis

0.021
(10th hit)

VL SFGEAVK

Hemoglobin β chain

P02116

146

Ara ararauna

0.021
(11th hit)

VL SFGEAVK

Hemoglobin β chain

P07411

146

Vultur gryphus

0.021
(12th hit)

VL SFGEAVK

Hemoglobin β chain

P15165

146

Apus apus

0.021
(13th hit)

VL SFGEAVK

Hemoglobin β/β' chain

P08261

146

Larus ridibundus

0.021
(14th hit)

VL SFGEAVK

Hemoglobin β chain

P21668

146

Psittacula krameri

0.021
(15th hit)

VL SFGEAVK

Hemoglobin β chain

P02120

146

Anseranas semipalmata

0.021
(16th hit)

VL SFGEAVK

Hemoglobin β chain

P10782

146

Phalacrocorax carbo

0.021
(17th hit)

VL SFGEAVK

Hemoglobin β chain

P07406

146

Passer montanus

0.021
(18th hit)

VL SFGEAVK

Hemoglobin β chain

P68061

146

Aegypius monachus

0.021
(19th hit)

VL SFGEAVK

Hemoglobin β chain

P02122

146

Aquila chrysaetos

0.021
(20th hit)

VL SFGEAVK

Hemoglobin β chain

P02121

146

Phoenicopters ruber ruber

0.021
(21st hit)

VL SFGEAVK

Hemoglobin β chain

Q98905

147

Geochelone carbonaria

0.021
(22nd hit)

VL SFGEAVK

Hemoglobin β chain

P82113

146

Stercorarius maccormicki

0.021
(23rd hit)

LSSP ISG+P

Hemoglobin subunit β

P07036

146

Chloephaga melanoptera

PISGDP

Myosin-binding protein C

Q90688

1272

Gallus gallus

2.3
(1st hit)
4.1
(2nd hit)

LSSP I G+PK

Hemoglobin subunit ε

P14261

147

Cairina moschata

13
(3rd hit)

LSSP I G+PK

Hemoglobin ρ chain

P02127

147

Gallus gallus

13

LSSPISGDPK
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B6

B5

B1

522.8

506.2

683.9

(4th hit)

+2

+3

+2

LSSP I+G+P

Hemoglobin β/β' chain

P08261

146

Larus ridibundus

13
(5th hit)

LSSP I+G+P

Hemoglobin β-1 chain

P18993

146

Varanus exanthematicus
albigularis

13
(6th hit)

IMSIVDPNR

α-actinin-1

P05094

893

Gallus gallus

0.001
(1st hit)

IMS+VDPN

α-actinin-2

P20111

897

Gallus gallus

0.15
(2nd hit)

IMS+VDPN

α-actinin-4

Q90734

904

Gallus gallus

0.15
(3rd hit)

SIVDP NR

PRELI domain-containing
protein 1, mitochondrial

Q90673

215

Gallus gallus

5.0
(4th hit)

QEYDESGPSIVHR

γ-actin

Q5ZMQ2

375

Gallus gallus

3e-07
(1st hit)

QEYDESGPSIVHR

γ-actin

P63256

375

Anser anser

3e-07
(2nd hit)

QEYDESGPSIVHR

β-actin

P60706

375

Gallus gallus

3e-07
(3rd hit)

QEYDESGPSIVHR

Actin, cytoplasmic type 5

P53478

376

Gallus gallus

3e-07
(4th hit)

QEYDE+GPSIVHR

Actin, alpha cardiac muscle
1

P68034

377

Gallus gallus

2e-06
(5th hit)

QEYDE+GPSIVHR

α-actin

P08023

377

Gallus gallus

2e-06
(6th hit)

QEYDE+GPSIVHR

α-actin-1

P68139

377

Gallus gallus

2e-06
(7th hit)

QEYDE+GPSIVHR

α-actin-1

Q90X97

377

Atractaspis microlepidota

2e-06
(8th hit)

EYDE+GPSIVHR

Γ-2-actin

P63270

376

Gallus gallus

2e-05
(9th hit)

STDYGILQINSR

Lysozyme C

P84492

130

Chelonia mydas

5e-06
(1st hit)

STDYGILQINSR

Lysozyme C

Q7LZI3

129

Tragopan satyra

5e-06
(2nd hit)

IMSIVDPNR

QEYDESGPSIVHR

STDYGILQINSR

186
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STDYGILQINSR

Lysozyme C

Q7LZQ1

131

Pelodiscus sinensis

5e-06
(3rd hit)

STDYGILQINSR

Lysozyme C

P24364

129

Lophura leucomelanos

5e-06
(4th hit)

STDYGILQINSR

Lysozyme C

P81711

129

Syrmaticus soemmerringii

5e-06
(5th hit)

STDYGILQINSR

Lysozyme C

P00702

147

Phasianus colchicus
colchicus

5e-06
(6th hit)

STDYGILQINSR

Lysozyme C

P00703

147

Meleagris gallopavo

5e-06
(7th hit)

STDYGILQINSR

Lysozyme C

Q7LZP9

129

Lophophorus impejanus

5e-06
(8th hit)

STDYGILQINSR

Lysozyme C

P49663

130

Phasianus versicolor

5e-06
(9th hit)

STDYGILQINSR

Lysozyme C

P00698

147

Gallus gallus

5e-06
(10th hit)

STDYGILQINSR

Lysozyme C-1

P00705

147

Anas platyrhynchos

5e-06
(11th hit)

STDYGILQINSR

Lysozyme C

P19849

129

Pavo cristatus

5e-06
(12th hit)

STDYGILQINSR

Lysozyme C

P00701

147
Coturnix japonica

5e-06
(13th hit)

STDYGILQINSR

Lysozyme C

Q7LZQ3

129

Crax fasciolata

5e-06
(14th hit)

STDYGILQINSR

Lysozyme C

P24533

129

Syrmaticus reevesii

5e-06
(15th hit)

STDYGILQINSR

Lysozyme C

Q7LZT2

129

Tragopan temminckii

5e-06
(16th hit)

STDYGILQINSR

Lysozyme C

P00707

129

Ortalis vetula

5e-06
(17th hit)

STDYGILQINSR

Lysozyme C

P22910

129

Chrysolophus amherstiae

5e-06
(18th hit)

STDYG+LQINSR

Lysozyme C

P00704

129

Numida meleagris

3e-05 (19th
hit)
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B1

B4

B1

503.3

509.8

565.3

+2

+2

+2

STDYG+LQINSR

Lysozyme C

P00699

129

Callipepla californica

3e-05
(20th hit)

STDYG+LQINSR

Lysozyme C

P00700

129

Colinus virginianus

3e-05
(21st hit)

STDYGIL+INSR

Lysozyme C-3

P00706

129

Anas platyrhynchos

4e-05 (22nd
hit)

STDYGIL+INSR

Lysozyme C

Q7LZQ2

129

Aix sponsa

4e-05
(23rd hit)

WDAW+ALK

Acyl-coenzyme A binding
protein

Q9PRL8

86

Gallus gallus

0.017
(1st hit)

WDAW AL

Acyl-CoA-binding domaincontaining protein 5

Q5ZHQ6

492

Gallus gallus

0.76
(2nd hit)

W+ WDA

β-crystallin B3

P55165

211

Gallus gallus

11
(3rd hit)

WDAW

β-crystallin A3

P10042

215

Gallus gallus

11
(4th hit)

W+AW+ LK

Acyl-CoA-binding protein

P45882

103

Anas platyrhynchos

11
(5th hit)

MLPMQK

Myeloid protein-1

P08940

326

Gallus gallus

0.35
(1st hit)

TMLPM

Brachyury protein

P79777

433

Gallus gallus

3.7
(2nd hit)

ML MQK

Eukaryotic translation
initiation factor 3 subunit

Q5F428

564

Gallus gallus

12
(3rd hit)

TM LPMQ

Paired box protein Pax-6

P47237

216

Gallus gallus

12
(4th hit)

TM LPMQ

Paired box protein Pax-6

P47238

416

Coturnix japonica

12
(5th hit)

LVTDVQEAVR

Saposin-A

O13035

518

Gallus gallus

8e-04
(1st hit)

VTDV EA

Cadherin-4

P24503

913

Gallus gallus

13
(2nd hit)

LVT+VQ EA

Prolactin-2

P55752

199

Gallus gallus

13
(3rd hit)

WDAWDALK

IGTMLPMQK

LVTDVQEAVR
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B2

B2

B2

646.9

772.0

525.8

+2

+2

+2

LVT+VQ EA

Prolactin-1

P55751

199

Alligator mississippiensis

13
(4th hit)

VTD VQEA

Cystatin

P08935

111

Bitis arietans

13
(5th hit)

LVT+VQ EA

Prolactin-2

P55754

199

Crocodylus novaeguineae

13
(6th hit)

LVT+VQ EA

Prolactin-1

P55753

199

Crocodylus novaeguineae

13
(7th hit)

VTDVQ+

Fibronectin

P11722

1256

Gallus gallus

18
(8th hit)

SMPDF

Myosin-Ig

Q5ZMC2

1007

Gallus gallus

7.4
(1st hit)

DFDL+L

Zinc finger FYVE domaincontaining protein 27

Q5ZL36

406

Gallus gallus

18
(2nd hit)

M D+DL LK

Uncharacterized protein
C17orf85 homolog

Q5ZM19

604

Gallus gallus

24
(3rd hit)

IS+PDF

Collagen α-3(VI) chain

P15989

3137

Gallus gallus

24
(4th hit)

AVASAAAALVLK

Talin-1

P54939

2541

Gallus gallus

2e-04
(1st hit)

VASAAAA

Insulin-like growth factor 2
mRNA-binding protein
3

Q5ZLP8

584

Gallus gallus

5.5
(2nd hit)

V +AA+ALVL

NADH-ubiquinone
oxidoreductase chain 2

O21398

346

Struthio camelus

7.3
(3rd hit)

LGTFL N EK

α-type phospholipase A2
inhibitor anMIP

A1XRN2

166

Atropoides nummifer

2.1
(1st hit)

LGTFL N

α-phospholipase A2
inhibitor clone 09

B1A4R4

166

Lachesis muta muta

6.7
(2nd hit)

LGTFL N

α-phospholipase A2
inhibitor

B1A4R0

166

Lachesis muta muta

6.7
(3rd hit)

LGTFL N

Phospholipase A2
myotoxin inhibitor protein

Q8AYA2

166

Bothrops moojeni

6.7
(4th hit)

LGTF LEN

Cannabinoid receptor 1

P56971

473

Taeniopygia guttata

8.9
(5th hit)

ISMPDFDLNLK

AVASAAAALVLK

LGTFLENEK
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B4

B6

B5

B6

821.9

587.3

506.8

583.8

+2

+2

+2

+2

VIQQQADDAEER
VIQ QQ+D+ EE

Tenascin

P10039

1808

Gallus gallus

0.29
(1st hit)

I+Q+ADD EE

Transcription factor SOX11

P48435

396

Gallus gallus

0.70
(2nd hit)

QQ DDAEER

Myosin heavy chain

P29616

1102

Gallus gallus

0.70
(3rd hit)

+Q +AD DAEER

Myosin-3

P02565

1940

Gallus gallus

1.7
(4th hit)

+Q +AD DAEER

Myosin heavy chain

P13538

1939

Gallus gallus

1.7
(5th hit)

+PPKPPA

G2/mitotic-specific cyclinB2

P29332

399

Gallus gallus

1.7
(1st hit)

PPKP P RAA

Venom protease inhibitor 2

B7S4N9

88

Oxyuranus scutellatus

5.5
(2nd hit)

PP+PPAR

Eukaryotic translation
initiation factor 3 subunit H

Q5ZLE6

348

Gallus gallus

5.5
(3rd hit)

PPKP A+AA

Transcription factor SOX11

P48435

396

Gallus gallus

5.5
(4th hit)

PP PPAR AR

Histone H3-like
centromeric protein A

Q6XXM1

131

Gallus gallus

7.4
(5th hit)

PARAAR

SCO-spondin

Q2PC93

5255

Gallus gallus

7.4
(6th hit)

IP LPSGV

Coatomer subunit ∆

Q5ZL57

510

Gallus gallus

13
(1st hit)

LPS VDK

116 kDa U5 small nuclear
ribonucleoprotein
component

Q5F3X4

972

Gallus gallus

18
(2nd hit)

LPSG+D

Neural cell adhesion
molecule 1

P13590

1091

Gallus gallus

32
(3rd hit)

IP+LP+G

Hepatocyte nuclear factor
1-α

Q90867

634

Gallus gallus

32
(4th hit)

Jumonji
domain-containing protein

Q5ZHV5

425

Gallus gallus

24
(1st hit)

IPPKPPARAAR

IPSLPSGVDK

AAGEIIAIPRR
AGEI+ IP
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IAIPR

4
Lysine-specific
demethylase 3A

Q5ZIX8

1325

Gallus gallus

24
(2nd hit)

IIAIP

Cytochrome
c oxidase polypeptide I

079548

533

Gallus gallus

24
(3rd hit)

IIAIP

Cytochrome c oxidase
subunit 1

Q94WR7

516

Buteo buteo

24
(4th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O21399

516

Struthio camelus

24
(5th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03546

337

Rhea americana

24
(6th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03539

337

Nothoprocta perdicaria

24
(7th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03521

337

Casuarius bennetti

24
(8th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03515

337

Apteryx australis

24
(9th hit)

IIAIP

Cytochrome c oxidase
subunit 1

P18943

515

Gallus gallus

24
(10th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03524

337

Dromaius novaehollandiae

24
(11th hit)

IIAIP

Cytochrome c oxidase
subunit 1

P24984

516

Coturnix japonica

24
(12th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O03554

337

Tinamus major

24
(13th hit)

IIAIP

Cytochrome c oxidase
subunit 1

O79672

514

Pelomedusa subrufa

24
(14th hit)

AGEII

MBD1-containing
chromatin-associated
factor 1

Q5ZIE8

1085

Gallus gallus

43
(15th hit)

I IPRR

Tenascin

P10039

1808

Gallus gallus

43
(16th hit)

EIIA RR

Protein sidekick-1

Q8AV58

472

Gallus gallus

58
(17th hit)

AAG IIAI

Alcohol dehydrogenase 1

P49645

375

Gallus gallus

58
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B1

B5

831.4

684.9

+2

+2

(18th hit)

AAG IIAI

Alcohol dehydrogenase 1

P19631

375

Coturnix japonica

58
(19th hit)

GEI IPR

Lysozyme C

Q91159

145

Opisthocomus hoazin

58
(20th hit)

GEI IPR

DNA damage-binding
protein 1

Q805F9

1140

Gallus gallus

NSWGT WG GY

Cathepsin K

Q90686

334

Gallus gallus

0.008
(1st hit)

NSWG WG+ GY

Cathepsin L1

P09648

218

Gallus gallus

0.12
(2nd hit)

NSW T WG G+F

Cathepsin B

P43233

340

Gallus gallus

0.29
(3rd hit)

TML+DS+

Talin-1

P54939

2541

Gallus gallus

7.3
(1st hit)

MLQD+I

Hsp90 co-chaperone Cdc37

O57476

393

Gallus gallus

7.3
(2nd hit)

78 kDa glucose-regulated
protein

Q90593

652

Gallus gallus

7.3
(3rd hit)

MLQDS

5,6-dihydroxyindole-2carboxylic acid oxidase

O57405

535

Gallus gallus

13
(4th hit)

LQ+SIR

Coiled-coil domaincontaining protein 132

Q5ZKV9

949

Gallus gallus

18
(5th hit)

TTML+ +I

Filensin

Q06637

657

Gallus gallus

18
(6th hit)

LPPEQG

Basic protease inhibitor

P00993

110

Caretta caretta

3.0
(1st hit)

LPPE G+ SS

Muscle-specific
regulatory factor 4

Q01795

242

Gallus gallus

13
(2nd hit)

LPPEQ

Abhydrolase domaincontaining protein
FAM108C1

Q5ZJX1

310

Gallus gallus

18
(3rd hit)

NSWGTSWGEDGYFR

FRTTMLQDSIR

FR+TM

B6

586.8

+2

58
(21st hit)

L+DS

LPPEQGTTSSR
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B6

B6

593.3

506.8

+2

+2

LPPEQ

α-actinin-2

P20111

897

Gallus gallus

18
(4th hit)

PEQG TS

Dihydropyrimidinaserelated protein 2

Q90635

572

Gallus gallus

18
5th hit)

LPPEQ

α-actinin-4

Q90734

904

Gallus gallus

18
6th hit)

AILYNY

Complement C3

Q01833

1651

Naja naja

0.85
(1st hit)

LYNYW

Ectonucleoside triphosphate
diphosphohydrolase

P79784

495

Gallus gallus

1.1
(2nd hit)

LY+YW

Fatty acyl-CoA reductase 1

Q5ZM72

515

Gallus gallus

12
(3rd hit)

LY NYW+

Monocarboxylate
transporter 9

Q5ZJU0

507

Gallus gallus

12
(4th hit)

NEALIALL

Plastin-1

P19179

630

Gallus gallus

0.081
(1st hit)

NEA+IA LL

tRNA (cytosine-)methyltransferase NSUN2

Q5ZLV4

796

Gallus gallus

21
(2nd hit)

NE+LI L R

Ubiquitin carboxyl-terminal
hydrolase 28

Q5ZID5

1047

Gallus gallus

21
(3rd hit)

EALI+L

CCR4-NOT transcription
complex subunit 10

Q5ZIW2

744

Gallus gallus

39
(4th hit)

AILYNYWDK

NEALIALLR
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APPENDIX B. LECTIN SEQUENCE

Protein sequencing with MS/MS and de novo sequencing yielded almost full coverage of an alligator
lectin. The sequence was compared to lectins from other vertebrates using DIALIGN software to
investigate sequence homology (Chapter 6, Section 6.4.4).
Figure 1. Alligator mississippiensis lectin sequence aligned with Homo sapiens and Mus musculus
intelectin-2.
Human
Mouse
Alligator

MLSMLRTMTRLCFLLFFSVATSGCSAAAASSLEMLSREFETCAFSFSSLPRSCKEIKERC 60
-------MTQLGFLLFIMIATRVCSAAEEN----LDTNRWGNSF-FSSLPRSCKEIKQED 48
-------NNQLALKLAATGGSTNXLPALALQN--LLNTWEDTSCCSQTSPGQQSWPRD-- 49
.:* : *
.:
.*
*
:
.: * . . ::

Human
Mouse
Alligator

HSAGDGLYFLRTKNGVVYQTFCDMTSGGGGWTLVASVHENDMRGKCTVGDRWSSQQGNKA 120
TKAQDGLYFLRTENGVIYQTFCDMTTAGGGWTLVASVHENNLRGRCTVGDRWSSQQGNRA 108
-GAQDGLYTLSTADGEIYQTFCDMSTHGGGWTLVASVHENNAHGKCTVGDRWSSQQGNSP 108
* **** * * :* :*******:: *************: :*:************* .

Human
Mouse
Alligator

DYPEGDGNWANYNTFGSAEAATSDDYKNPGYYDIQAKDLGIWHVPNKSPM--QHWRNSAL 178
DYPEGDGNWANYNTFGSAEGATSDDYKNPGYFDIQAENLGIWHVPNNSPL--HTWRNSSL 166
LYPEGDGNWANNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWHVPDRAPLRKEMIESSVL 168
********** * **** .:**********:*:** :*.:****:.:*: . ..* *

Human
Mouse
Alligator

LRYRTNTGFLQRLGHNLFGIYQKYPVKYRSGKCWNDNGPAIPVVYDFGDAKKTASYYSPY 238
LRYRTFTGFLQRLGHNLFGLYQKYPVKYGEGKCWTDNGPAFPVVYDFGDAQKTASYYSPS 226
LFYR--TGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPS 226
* ** ****. * **: :*:****** *.* *****.*:*****.*:***:****

Human
Mouse
Alligator

GQREFVAGFVQFRVFNNERAANALCAGIKVTGCNTEHHCIGGGGFFPQGKPRQCGDFSAF 298
GRNEFTAGYVQFRVFNNERAASALCAGVRVTGCNTEHHCIGGGGFFPEFDPEECGDFAAF 286
GRGEFTAGFVQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAF 286
*: **.**:*********:*. ***:*::******************: .*.:****.**

Human
Mouse
Alligator

DWDGYGTHVKSSCSREITEAAVLLFYR 325
DANGYGTHIRYSNSREITEAAVLLFYR 313
DWDGYGTHQSWSTSREMIESSVLLFYR 313
* :*****
* ***: *::******
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Figure 2. Alligator mississippiensis lectin sequence aligned with Homo sapiens ficolin-α and ficolinβ.
Ficolin-1
Alligator

-MELSGATMARGLAVLLVLFLHIKNLPAQAADT-CPEVKVVGLEGSDKLTILRGCPGLPG 58
NNQLALKLAATGGSTNSLPALALQNLLNTWEDTSCCSQTSPGQQSWPRDGAQDGLYTLST 60
:*:
* * :. : * ::**
** * . . * :. :
*
*.

Ficolin-1
Alligator

APGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRGEKGDAGQSQSCATGPRNC 118
ADG-----EIYQTFCDMSTHGGGWTLVASVHENNAHGKCTVGDRWSSQQG-NSPLYPEGD 114
* *
:
: . *. . .
:.:
*
*:: .: *. ... *..

Ficolin-1
Alligator

KDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDGGGWTVFQRRMDGSVDFYRDWAAYKQG 178
GNWANNNIFGSAMG----STSDDYKNPGYYDLQAGDLSVWH--VPDRAPLRKEMIESSVL 168
: :.. * *.
. .
.
* :.*. :*:: : . . : ::
.

Ficolin-1
Alligator

FGSQLGEFWLGNDNIHALTAQGSSELRVDLVDFEGNHQFAKYKSFKVADEAEKYKLVLG- 237
LFYRTGFLSSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPSGR 228
: : * :
..*: * : . : .. ..:.. ..
.* *::: *
*

Ficolin-1
Alligator

-AFVGGSAGNSLTGHNNNFFSTKDQDNDVSSSNCAEKFQGAWWYADCHASNLNGLYLMGP 296
GEFTAGFVQFRVFNNEKAPMALCSG-LKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAFD 287
*..* .
: .::: :: .
.*:..* .: *. :
.. * :

Ficolin-1
Alligator

HESYANGINWSAAKGYKYSYKVSEMKVRPA 326
WDGYGTHQSWSTSREMIESSVLLFYR---- 313
:.*.. .**:::
* :
:

Ficolin-2
Alligator

-MELDRAVGVLGAATLLLSFLGMAWALQAAD--TCPEVKMVGLEGSDKLTILRGCPGLPG 57
NNQLALKLAATGGSTNSLPALALQNLLNTWEDTSCCSQTSPGQQSWPRDGAQDGLYTLST 60
:*
:.. *.:* *. *.:
*:: : :* . . * :. :
*
*.

Ficolin-2
Alligator

APGPKGE--AGTNGKRGERGPPGPPGKAGPPGPNGAPGEPQPCLTGPRTCKDLLDRGHFL 115
ADGEIYQTFCDMSTHGGGWTLVASVHENNAHG-KCTVGDRWSSQQGNSPLYPEGD-GNWA 118
* *
: .. . : *
.. : .. * : : *: .. * .
* *::

Ficolin-2
Alligator

SG--WHTIYLPDCRPLTVLCDMDTDGGGWTVFQRRVDGSVDFYRDWATYKQGFGSRLGEF 173
NNNIFGSAMGSTSDDYKNPGYYDLQAGDLSVWH--VPDRAPLRKEMIESSVLLFYRTGFL 176
.. : :
. .
.
* :.*. :*:: * . . : ::
. : * * :

Ficolin-2
Alligator

WLGNDNIHALTAQGTSELRVDLVDFEDNYQFAKYRSFKVADEAEKYNLVLG--AFVEGSA 231
SSEGGNLLRLYEKYPVKYGAGSCKVDNGPAVPIVYDFGSAEKTAAYYSPSGRGEFTAG-F 235
..*: * : . : .. ..::. ..
.* *::: *
*
*. *

Ficolin-2
Alligator

GDSLTFHNNQSFSTKDQDNDLNTGNCAVMFQGAWWYKNCHVSNLNGRYLRGTHGSFANGI 291
VQFRVFNNEKAPMALCSGLKVTGCNTEHHCIGGGGFFPEGNPRQCGDFPAFDWDGYGTHQ 295
: .*:*::: : .. .:. *
*. :
.. * :
..:..

Ficolin-2
Alligator

NWKSGKGYNYSYKVSEMKVRPA 313
SWSTSREMIESSVLLFYR---- 313
.*.:.:
* :
:
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